# APPENDIX C

# APPENDIX C

*Curricula Vitae of Independent Experts*

# ROBERT H. ECKEL, M.D.

**University of Colorado Health Sciences Center**
Division of Endocrinology, Metabolism and Diabetes
4200 East Ninth Avenue, B-151
Denver, Colorado 80262

(Phone)(303) 315-4059
(FAX)(303) 315-0770
(E-mail) Robert.eckel@uchsc.edu

## EDUCATION

**1969** Bachelor of Sciences, Bacteriology, University of Cincinnati, Cincinnati, Ohio

**1973** Doctor of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio

## POSTGRADUATE TRAINING

**1973-74** Internship in Medicine, University of Wisconsin Hospitals, Madison, Wisconsin

**1974-76** Medical Residency, University of Wisconsin Hospitals, Madison, Wisconsin

**1976-79** Senior Fellowship in Metabolism and Endocrinology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington

## LICENSURE TO PRACTICE

Wisconsin, July 10, 1974, License No. 18866
Washington, July 10, 1976, Certificate No. 25209
Colorado, July 10, 1979, License No. 22425

## APPOINTMENTS

**1979-85** Assistant Professor of Medicine,
University of Colorado Health Sciences Center, Denver, Colorado

**1981-93** Associate Program Director, Adult General Clinical Research Center,
University of Colorado Health Sciences Center, Denver, Colorado

**1983-1985** Acting Chairman, Division of Endocrinology,
University of Colorado Health Sciences Center, Denver, Colorado

**1984-present** Graduate Faculty Appointment,
University of Colorado Health Sciences Center, Denver, Colorado

**1985-1989** Associate Professor of Medicine,
University of Colorado Health Sciences Center, Denver, Colorado

**1989-90** Faculty Affiliate, Department of Food Science and Human Nutrition,
Colorado State University, Fort Collins, Colorado

**1989-present** Professor of Medicine,
University of Colorado Health Sciences Center, Denver, Colorado

**1989-95** Professor of Biochemistry, Biophysics and Genetics,
University of Colorado Health Sciences Center, Denver, Colorado

**1990-present** Graduate Faculty Appointment, Department of Food Science and Human Nutrition,
Colorado State University, Fort Collins, Colorado

**1991-1997** Co-Director, Center for Human Nutrition,
University of Colorado Health Sciences Center, Denver, Colorado

| | |
|---|---|
| **1993-present** | Program Director, Adult General Clinical Research Center, University of Colorado Health Sciences Center, Denver, Colorado |
| **1995-present** | Professor of Physiology and Biophysics, University of Colorado Health Sciences Center, Denver, Colorado |
| **1997-present** | Co-Director, Clinical Nutrition Research Unit, University of Colorado Health Sciences Center, Denver, Colorado |
| **1997-present** | Associate Director, Center for Human Nutrition, University of Colorado Health Sciences Center, Denver, Colorado |
| **1998-present** | Vice-Chairman, Research Affairs, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado |
| **2000-present** | Charles A. Boettcher Endowed Chair in Atherosclerosis, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado |
| **2002-present** | Professor of Medicine, Division of Cardiology University of Colorado Health Sciences Center, Denver, Colorado |

## BOARDS

Diplomate, National Board of Medical Examiners, July 1974
Diplomate, American Board of Internal Medicine, June 16, 1976
Diplomate, American Board of Endocrinology and Metabolism, June 19, 1979
Diplomate, Board of the Denver Metro Division of the American Heart Association Desert/Mountain Affiliate

## HONORS

| | |
|---|---|
| **1969** | Bachelor of Sciences Cum Laude in Bacteriology, University of Cincinnati, Cincinnati, Ohio |
| **1973** | Alpha Omega Alpha, University of Cincinnati College of Medicine, Cincinnati, Ohio |
| **1987** | American Society for Clinical Investigation |
| **1987-88** | Full-Time Faculty Housestaff Teaching Award, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado |
| **1990** | Moses Barron Award, American Diabetes Association, Minnesota Affiliate |
| **1991** | Award of Excellence, Colorado Dietetic Association |
| **1994-99, 2001** | Best (Top) Doctors in America Recognition |
| **1997** | Association of American Physicians |
| **1998** | Excellence in Teaching, Medical Student Council |
| **1999** | Outstanding Teaching Award, Clinical Science Program, University of Colorado Health Sciences Center |
| **2000** | Charles A. Boettcher Endowed Chair in Atherosclerosis, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado |
| **2000** | Robert H. Williams-Rachmiel Levine Award, Western Metabolism Club |
| **2001** | Robert W. Schrier Award of Excellence, Department of Medicine, University of Colorado School of Medicine |

**2002** The Alexander Marble Lecturer at the Elliott P. Joslin Research Laboratory, Harvard Medical School

**AWARDS**

**7/77-6/79** Juvenile Diabetes Foundation Research Fellowship. Cultured fibroblasts as a cellular model of diabetes mellitus and its complications.

**4/79-3/80** University of Colorado Research Assistance, Grant: BRS699. Hormonal control of adipose tissue lipoprotein lipase.

**12/79-11/82** National Institute of Arthritis, Diabetes, Digestive, and Kidney Diseases, Grant: DK26356. Hormonal control of adipose tissue lipoprotein lipase.

**9/80-8/82** Juvenile Diabetes Foundation Research, Grant, 80R055. Pathophysiology of adipose tissue lipoprotein regulation in diabetes: Use of cultured human preadipocytes.

**7/82-6/84** Cambridge Quest Foundation. Adipose tissue lipoprotein lipase regulation after weight reduction in obese humans.

**12/82-11/85** National Institute of Arthritis, Diabetes, Digestive, and Kidney Diseases, Grant: DK26356. Hormonal control of adipose tissue lipoprotein lipase.

**11/84-10/86** Mead Johnson, Nutritional Division. Regulation of adipose tissue lipoprotein lipase before and after weight loss in obese subjects. Response to variable fatty acid chain length formula diets.

**12/85-11/90** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: AM26356. Hormonal control of adipose tissue lipoprotein lipase.

**4/86-3/89** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: AM30747. Diabetes mellitus in the San Luis Valley, Colorado. (Prinipal Investigator): Richard F. Hamman, MD

**2/87-1/90** National Institute of Child Health and Human Development, Grant: HD19547. Physiological factors affecting human lactation. PI: Margaret C. Neville, PhD.

**3/89-2/90** Proctor and Gamble Co. Effect of medium chain triglycerides on glucose and lipid metabolism in type II diabetes mellitus.

**12/89-11/92** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: DK42266. Nutrition, lipoprotein lipase and body weight regulation.

**12/90-11/94** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: AM26356. Tissue-specific regulation of lipoprotein lipase.

**9/92-8/94** United States Department of Agriculture, Grant: 92-37200-7522. Transcriptional control of lipoprotein lipase by cytokines.

**7/94-6/99** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: DK46881. Diet, lipoprotein lipase, insulin action and weight gain.

**1/95-12/05** National Institute of Diabetes, Digestive, and Kidney Diseases Clinical Nutrition Research Unit, Metabolic Core Director.

**4/95-4/02** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: DK42266. Nutrition, lipoprotein lipase and body weight regulation.

**6/96-5/00** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: DK26356. Tissue-specific regulation of lipoprotein lipase.

**7/97-6/98** Amgen, The effect of leptin on postprandial lipid metabolism.

**3/98-2/04** Slim-Fast Nutrition Institute, Effects of weight loss with reduced-weight maintenance and subsequent high-carbohydrate vs. high-fat macronutrient feeding on neck morphology, whole-body energy metabolism, sleep dynamics, pulmonary function, and insulin sensitivity in severely obese humans.

**7/99-6/04** National Heart, Lung, and Blood Institute. Grant: K30. Advanced Training for Clinical Investigators.

**7/00-7/04** American Diabetes Association Grant 30K Mentor Based Postdoctoral Fellowship

**8/01-6/05** National Institute of Diabetes, Digestive, and Kidney Diseases, Grant: R01 DK26356-21A2. Tissue-specific regulation of lipoprotein lipase.

**12/01-7/03** Merck -Impact of HMG Inhibitors

**2002 & 2003** America's Top Doctors American Registry Recognition

## TRAINEES

### Past Trainees

| Name | Pre/Post Doctorate | Dates in Lab | Degree | Current Position |
|---|---|---|---|---|
| Craig Sadur | Post | 07/01/80-06/30/82 | MD | Private practice |
| Phil Kern | Post | 07/01/81-06/30/85 | MD | Prof of Medicine, Univ. of Arkansas, Little Rock, Arkansas |
| Mary O'Shea | Post | 07/01/84-06/30/85 | MD | Private practice |
| Tammi Gregg | Pre | 1988-1989 | BS | Dietitian, Madison, Wisconsin |
| Paul Rudolf | Post | 07/01/85-06/30/87 | MD | Private practice |
| Daniel Rule | Post | 09/01/86-07/30/87 | PhD | Assoc Prof, Animal Sciences Univ. of WY, Laramie, Wyoming |
| Daniel Bessesen | Post | 07/01/87-12/30/90 | MD | Assoc. Prof of Medicine, Div. of Endocrinology, Metab & Diabetes UCHSC, Denver, CO |
| Mary Kay Rozmyslovicz | Post | 07/01/88-06/30/90 | MD | Private Practice |
| Mary Raynolds | Post | 05/01/88-07/01/92 | PhD | Asst. Prof., Division of Cardiology, UCHSC, Denver, CO |
| Jamie Erskine | Pre | 09/01/90-09/01/92 | PhD | Asst. Prof, Human Nutrition Univ of Northern Colorado Greeley, CO |
| Jackie Berning | Pre | 09/01/90-12/30/94 | PhD | Asst Prof, Kinesiology Univ. of Colorado, Denver, CO |
| Sharon Travers | Post | 07/01/92-07/01/94 | MD | Asst Prof, Division of Endocrinology, Dept of Pediatrics UCHSC, Denver, CO |

| | | | | |
|---|---|---|---|---|
| Hong Liu | Pre | 09/01/92-06/01/94 | Ph.D. | Graduate Student, Dept. Nutrition Univ. of Texas, Austin, Texas |
| Carrie Ganong | Post | 07/01/94-1997 | MD | Asst. Prof, Pediatrics Ohio State Univ., Columbus, OH |
| Cathy Morin | Post | 09/01/92-06/01/98 | PhD | Asst Prof, Preventive Medicine, UCHSC, Denver, CO |
| Angie McGinnis | Pre | 07/01/96-06/30/98 | BS | Predoc |
| Patricia Uelmen Huey | Post | 09/15/96-9-1-99 | PhD | Assistant Professor of Medicine Emory University, Atlanta, GA |
| Paul Poirier | Post | 02/01/98-12-1-99 | MD | Scientific Director, Cardiovascular Rehabilitation Program Quebec Heart Institute/Laval Hospital Quebec, Canada |
| Luis Ferreira | Post | 11/01/98 – 10/31/01 | Ph.D | Instructor of Medicine University of Perth, Perth, Australia |

**Current Trainees**

| | | | | |
|---|---|---|---|---|
| Lisa Kosmiski | Post | 07/01/93-present | MD | Asst. Professor of Medicine, UCHSC, Denver, Colorado |
| William Troy Donahoo | Post | 07/01/95-present | MD | Asst. Prof of Medicine, UCHSC, Denver, Colorado |
| Bakary J. Sonko | Post | 11/14/2000-present | PhD | Postdoc |
| Warren H. Capell | Post | 7/01/01-present | MD | Postdoc |
| Alison M. Morris | Post | 9/01/01-present | PhD | Postdoc |
| Dean J. Calsbeek | Post | 07/01/02-present | PhD | Postdoc |
| Linda Barbour | Post | 09/01/02-present | MD | Assoc. Professor of Medicine, OB/GYN, UCHSC |
| Leigh Perreault | Post | 11/14/2000 - present | MD | Assistant Professor of Medicine Boulder GCRC |
| Paul Wischmeyer | Post | 11/14/200 - present | MD | Assistant Professor of Anesthesiology |

## PROFESSIONAL ORGANIZATIONS

American College of Physicians, Fellow
American Diabetes Association
American Federation for Clinical Research
American Heart Association,
    Council on Arteriosclerosis, Thrombosis, and Vascular Biology
    Council on Nutrition, Physical Activity, and Metabolism
American Society for Clinical Investigation
American Society for Clinical Nutrition
American Society for Nutritional Sciences
Association of American Physicians
Association for Patient-Oriented Research, Board of Directors,
Endocrine Society
North American Association for the Study of Obesity
Western Association of Physicians

Western Society for Clinical Investigation

## COMMITTEES - LOCAL

1. Animal Care Control Committee
   University of Colorado Health Sciences Center, Denver, Colorado 1980-1983
2. Intern Selection Committee, Department of Medicine
   University of Colorado Health Sciences Center, Denver, Colorado 1980-present
3. American Diabetes Association, Colorado Affiliate, Organizational Committee, 1980-1985
4. Juvenile Diabetes Foundation, Denver, Colorado Denver Medical Advisory Board, 1980-1981
5. Attending Physician, Gordon Meiklejohn Service, Department of Medicine
   University of Colorado, Denver, Colorado 1980-1993; Ward Darley Service, 1993-present.
6. Scientific Advisory Committee, Adult General Clinical Research Center
   University of Colorado Health Sciences Center, 1981-1984, 1986-present
7. Grant Review Committee, Colorado Heart Association, 1983-1987
8. Dean's Subcommittee on "Centers of Excellence" in Cardiovascular Disease
   University of Colorado Health Sciences Center, Denver, Colorado 1984
9. Faculty Senate
   University of Colorado Health Sciences Center, Denver, Colorado 1985-1987, 1989-present
10. Research and Development Committee, Veterans Administration Medical Center, Denver, Colorado, Dean's Committee Representative, 1985-1988
11. Curriculum Review Committee
    University of Colorado Health Sciences Center, Denver, Colorado 1986-1994.
12. Inter-Departmental Steering Committee on Nutrition, 1987-1990.
13. University of Colorado/Colorado State University Consortium for Human Nutrition
    Board Member, 1988-present
14. Nutrition Support Subcommittee
    University of Colorado Hospital, Department of Medicine Representative, 1990-1992.
15. Search Committee, Executive Director, Barbara Davis Childhood Diabetes Center, 1991-1992.
16. Metabolic Regulation of Fetal Growth Center Grant: Internal Advisory Committee, 1991-1997.
17. Faculty Communications Committee
    University of Colorado Health Sciences Center, Denver, Colorado 1991-1993.
18. University of Colorado School of Medicine Faculty Council Representative, University of Colorado Health Sciences Center, Denver, Colorado 1992-1994.
19. Clinical Trials Office Committee
    University of Colorado Health Sciences Center, Denver, Colorado 1995-1997.
20. Graduate School Governance Committee
    University of Colorado Health Sciences Center, Denver, Colorado 1996-present.
21. Doctor of Philosophy in Biology, Clinical Investigation Track Curriculum Committee
    University of Colorado Health Sciences Center, Denver , Colorado 1997-present.
22. The Robert W. Schrier Award of Excellence Committee, 1997.
23. University of Colorado Health Sciences Center Committee on Planning and Fiscal Policy, 1997-1999.
24. Denver Metro Physicians Advisory Council, American Heart Association, Colorado Affiliate, 1997-1998.
25. American Heart Association of Colorado, Public Affairs Committee, 1998-present.
26. Electives Committee, University of Colorado School of Medicine, 1999-present
27. Clinical/Translational Research Committee, University of Colorado School of Medicine, Co-Chair, 2001
28. Veterinarian Pathologist Search Committee, 2002.
29. University Hospital Research Committee, 2002-present
30. Keystone Symposia Scientific Advisory Board, 2003-2006

## COMMITTEES – NATIONAL/INTERNATIONAL

1. National Eye Institute, Diabetes Retinopathy Study II, Medical Therapy Committee, 1977-1978.
2. Councilor, American Federation for Clinical Research (Western Section), 1982-1984.
3. National Councilor, American Federation for Clinical Research, 1984-1988.
4. Secretary-Treasurer, American Federation for Clinical Research (Western Section), 1985-1988.

5. Councilor, North American Association for the Study of Obesity, 1987-1990.
6. Technical Advisory Board, Institute for Creation Research, El Cajon, California, 1988-present.
7. Program Committee, Council on Nutritional Sciences and Metabolism, American Diabetes Association, 1989-1991.
8. Education Committee, North American Association for the Study of Obesity, 1991-1992.
9. Chairman, Publications Committee, North American Association for the Study of Obesity, 1991-1994.
10. External Advisory Committee, Nutrition Training Grant:
    University of California, Davis, 1990-1995.
11. Vice-President, North American Association for the Study of Obesity, 1993-1994.
12. Program Committee, International Association for the Study of Obesity, Toronto, August 1994.
13. President, North American Association for the Study of Obesity, 1995-1996.
14. Executive Committee, General Clinical Research Center Program Directors, 1995-present.
15. Nutrition Committee, American Heart Association, 1996-present; Vice-Chairman 1997-1998, Chairman July 1998-present.
16. Co-Chairman, Annual Meeting of the North American Association for the Study of Obesity, 1996.
17. Program Committee, International Association for the Study of Obesity, October 1996.
18. President's Committee, North American Association for the Study of Obesity, 1996-present.
19. Long Range Planning Committee, North American Association for the Study of Obesity, 1996-present.
20. President, Western Society for Clinical Investigation, 1997-1998.
21. Co-Chairman, Planning Committee, General Clinical Research Program Directors Meeting, 1998.
22. Chairman, Nutrition Committee, American Heart Association, July 1998-present.
23. Executive Board, Kern Aspen Lipid Conference, 1997-present.
24. Boston Obesity Nutrition Research Center, Scientific Advisory Committee, 1998-2001.
25. Board of Directors, Association for Patient-Oriented Research, 1998-present.
31. Co-Chairman, Program Committee, Association for Patient-Oriented Research, 1999-2001.
32. Vice-Chairman, Council on Nutrition, Physical Activity and Metabolism, American Heart Association, 2000-2002.
33. Secretary-Treasurer, Association of Patient-Oriented Research, 2001-2003.
34. Chair, Prevention VII: Obesity, A Worldwide Epidemic Related to Heart Disease and Stroke, American Heart Association, Honolulu, Hawaii, April 26-27, 2002
35. Chairman, Council on Nutrition, Physical Activity and Metabolism, American Heart Association, 2002-2004.
36. Chair, Kern Aspen Lipid Conference, Fatty Acid Transport and Metabolism: Impact on Insulin Action/Secretion and Body Weight Regulation, 2002
37. Member, Science Advisory and Coordinating Committee, American Heart Association, 2002-present.
38. University of Alabama, Guest Lecturer, 2002-present.
39. University of North Carolina Chapel Hill, Member of External Advisory Committee for Mentored Clinical Research Scholar Program, NIH K-12 Award RR-02-001.
39. CNRU NIDDK sponsored "National Task Force on Prevention and Treatment of Obesity," 2003-present.
40. NIDDK Advisory Council, 2003-2007.
41. American Board of Internal Medicine Endocrinology Subspecialty Writing Committee 2003.
42. Chairman, Nutrition, Physical Activity and Metabolism Council, American Heart Association, 2002-present.

**JOURNAL REVIEWS**

Acta Endocrinologica
American Journal of Clinical Nutrition, Editorial Board, 1997-1999
American Journal of Medicine, Editorial Board, 1998-present
American Journal of Physiology
- Applied Physiology
- Anthropology
- Endocrinology and Metabolism
- Heart and Circulatory
- Regulatory Integrative Comparative

Annals of Epidemiology
Annals of Internal Medicine

Archives of Biochemistry and Biophysics
Arteriosclerosis, Thrombosis and Vascular Biology, Editorial Board, 2001-present
Arthritis and Rheumatology
Atherosclerosis
Biochimica Biophysica Acta
Chemical Reviews
Circulation
Cleveland Clinic Journal
Clinical Chemistry
Clinical Endocrinology
Clinical Science
Diabetes, Editorial Board, 1988-1992
Diabetes Care
Diabetes, Obesity and Metabolism
Diabetes/Metabolism Research and Reviews
Diabetologia
Endocrine
Endocrinology
European Journal of Clinical Investigation
Gene
Hepatology
Hormone and Metabolic Research
Hypertension
In Vitro
International Journal of Obesity, Editorial Board, 1989-present
Journal of the American Society of Nephrology
Journal of Biological Chemistry
Journal of Cardiopulmonary Rehabilitation
Journal of Cardiovascular Research
Journal of Cellular Physiology
Journal of Clinical Endocrinology and Metabolism, 2003-present
Journal of Clinical Investigation
Journal of Gerontology
Journal of Hepatology
Journal of Investigative Dermatology
Journal of Laboratory and Clinical Medicine
Journal of Lipid Research
Journal of Nutritional Biochemistry
Journal of Obesity and Weight Regulation, Editorial Board, 1984-present
Journal of Pediatric Gastroenterology
Journal of Pediatrics
Mayo Clinic Proceedings
Mechanisms of Ageing and Development
Metabolism
Metabolic Syndrome and Related Disorders, Editorial Board
Neuroendocrinology
New England Journal of Medicine
Nutrition
Obesity Research, Section Editor, 1992-present
Obstetrics and Gynecology
Proceedings of the National Academy of Sciences
Proceedings of the Society for Experimental Biology and Medicine
The Online Journal of Current Clinical Trials

**INVITED PARTICIPANT**

1. Adipose Tissue Development and Metabolism Satellite Symposium to the Third International Congress on Obesity; Gothenburg, Sweden; October 4-6, 1980.
2. First International Symposium on Acarbose; Montreux, Switzerland; October 8-10, 1981.
3. National Institutes of Health Workshop on the Classification of Obesity; Poughkeepsie, New York, October 17-19, 1982.
4. American Diabetes Research Symposium; Denver, Colorado; January 10-12, 1983.
5. National Institutes of Health Special Study Section; Bethesda, Maryland; August 9, 1983.
6. National Institutes of Health Site Visit; East Carolina University; July 23-25, 1985.
7. Joint Conference on Obesity and Non-Insulin Dependent Diabetes Mellitus; Toronto, Ontario, Canada; October 30 - November 1, 1985.
8. National Institutes of Health Reverse Site Visit; Bethesda, Maryland; October 8-10, 1986.
9. General Clinical Research Center Site Visit; Stanford University; December 3-4, 1986.
10. Council on Nutritional Sciences and Metabolism of the American Diabetes Association: Program on Obesity and Exercise in Type II Diabetes; Indianapolis, Indiana; June 6, 1987.
11. American Diabetes Association, Northern Illinois Affiliate, Thirtieth Professional Symposium; Chicago, Illinois; October 14, 1987.
12. Seminars in Medicine, Beth Israel Hospital, Harvard Medical School; Boston, Massachusetts; December 15, 1987.
13. The Endocrine Society National Meeting, Symposium on Hormonal Control of the Adipose Cell; New Orleans, Louisiana; June 9, 1988.
14. American Diabetes Association Symposium on Current Issues in Nutrition and Metabolism; San Francisco, California; October 7, 1988.
15. National Institutes of Health Nutrition Study Section, Special Reviewer; Bethesda, Maryland; October 6-17, 1988.
16. General Clinical Research Center Site Visit; University of Cincinnati; December 1-2, 1988.
17. National Institutes of Health Metabolism Study Section, Special Reviewer; Bethesda, Maryland; December 15, 1988..
18. National Institutes of Health Nutrition Study Section; July 1, 1989 - June 30, 1993;. Chairman; July 1, 1991 - June 30, 1993.
19. General Clinical Research Center Site Visit; Brown University; April 5-6, 1989.
20. American Society for Clinical Nutrition Postgraduate Course; Washington, D.C.; April 27-28, 1989.
21. American Diabetes Association National Meeting. Symposium: Issues in the Nutritional Management of Patients with Diabetes; Detroit, Michigan; June 6, 1989.
22. FASEB Summer Conference on the Regulation of Energy Balance; Vermont Academy; July 31 - August 4, 1989.
23. National Institutes of Health Workshop on Basic and Clinical Aspects of Regional Fat Distribution; Bethesda, Maryland; September 9-11, 1989.
24. International Symposium on Lipoprotein Metabolism and Lipid Lowering Agents; Netherlands; February 27 - March 2, 1990.
25. National Institutes of Health, Genetics of Obesity; Phoenix, Arizona; March 26-27, 1990.
26. General Clinical Research Center Site Visit; University of Florida; April 10-11, 1990.
27. The Endocrine Society National Meeting. Symposium on Control of Regional Fat Distribution; Atlanta, Georgia; June 21, 1990.
28. The Aspen Bile Acid/Cholesterol Conference. Hepatic Cholesterol and Postprandial Lipoproteins; August 18-21, 1990.
29. International Symposium on Obesity and Diabetes Mellitus; Nagoya, Japan; October 18-19, 1990.
30. North American Association for the Study of Obesity Symposium on the Treatment of the Patient with Medically Significant Obesity; Atlanta, Georgia; December 1, 1990.
31. Keystone Symposia. The Adipose Cell: A Model for Integration of Hormone Signaling in the Regulation of Cellular Function; Park City, Utah; January 18-24, 1991.
32. The Science of Food Regulation Symposium. Pennington Biomedical Research Center; Louisiana State University; Baton Rouge, Louisiana; March 14-15, 1991.
33. North American Association for the Study of Obesity/Society for the Study of Ingestive Behavior National Meeting; Sacramento, California;' October 20-28, 1991.

34. FASEB Summer Conference on Regulation of Energy Balance: From Organism to Gene; Copper Mountain, Colorado; August 2-7, 1992.
35. North American Association for the Study of Obesity Symposium Obesity Update: Pathophysiology, Clinical Consequences and Therapeutic Options; Atlanta, Georgia; August 31-September 2, 1992.
36. American Heart Association Scientific Conference on Central Obesity/Insulin Resistance Syndrome and Coronary Artery Disease; Washington, DC; April 22-23, 1993.
37. International Symposium on Insulin Resistance as a Risk Factor for Cardiovascular Disease; Ste-Adèle, Québec, June 22-24, 1993.
38. North American Association for the Study of Obesity. National Meeting; Milwaukee, Wisconsin; October 17-20, 1993.
39. International Symposium on Atherosclerosis; Montreal, Ontario; October 9-12, 1994.
40. Master Clinical Dieticians; Key Biscayne; January 14, 1995.
41. NIDDK Program Project on Body Composition Site Visit, St. Luke's-Roosevelt Hospital, Columbia University; New York, New York; April 5-7, 1995.
42. North American Association for the Study of Obesity. National Meeting; Baton Rouge, Louisiana; October 14-17, 1995.
43. NIDDK Program Project on Body Composition, Columbia University; Reverse Site Visit, Washington, D.C.; March 24-25, 1996.
44. NIDDK Symposium on Transgenic Animals in Nutrition Research, FASEB Meeting; Washington, D.C.; April 14, 1996.
45. NIDDK Metabolism Study Section, Special Reviewer; Bethesda, Maryland; July 2,3, 1996.
46. The Endocrine Society Clinical Endocrinology Update; Chicago, Illinois; October 9, 1996.
47. General Clinical Research Center Site Visit, University of Alabama; Birmingham, Alabama; December 17-18, 1996.
48. Kern Aspen Lipid Conference; Aspen, Colorado; August 15-18, 1997.
49. Satellite Symposium of the 11th Annual International Symposium on Atherosclerosis; St. Malo, France; October 3-5, 1997
50. American Heart Association Annual Sessions, Plenary speaker; Orlando, Florida; November10-13, 1997
51. Pennington Biomedical Research Symposium on Obesity; Baton Rouge, Louisiana; March 1-3, 1998
52. American Heart Association, Obesity: Impact on Cardiovascular;, Amelia Island, Florida; May 22-24, 1998
53. American College of Sports Medicine; Orlando, Florida; June 3-6, 1998
54. American Diabetes Meeting; Chicago; June 13-16, 1998
55. FASEB Summer Conference on Behavioral and Metabolic Sub-phenotypes in Obesities, Genetic and Molecular Aspects, Pathophysiology and Therapeutic Implications; Snowmass, Colorado; June 20-25, 1998
56. NIDDK Metabolism Study Section, Special Reviewer; July1-2, 1998
57. General Clinical Research Center Site Visit, Beth Israel Deaconess, Harvard Medical School; July 13-15, 1998
58. NIDDK Diabetes Complications Special Study Section, Chairman; July 30-31, 1998
59. 8th International Congress on Obesity, Plenary speaker; Paris, France; Aug 29-Sept 3, 1998
60. American Association of Cardiovascular and Pulmonary Rehabilitation Annual Meeting; Denver, CO; Oct 15, 1998
61. Joslin Diabetes Center 100th Anniversary; Boston, Mass; Oct 22-24, 1998.
62. FASEB, 50th Anniversary of NIDDK, San Diego Convention Center, April 17, 2000.
63. NIDDK Special Study Section on Lipids and Lipoproteins, Chair, June 18, 19, 2000
64. North American Association for the Study of Obesity, Women's Health and Obesity Across the Life Span Symposium speaker, Oct 31, 2000
65. American Heart Association Annual Sessions, Cardiovascular Seminar on Secondary Prevention in the Elderly, Nov 13, 2000
66. American Heart Association Annual Sessions, Special Session on It's Time to Treat Obesity, Nov 15, 2000
67. American Heart Association Prevention VI on Cardiovascular Disease and Diabetes Mellitus, Orlando, Jan 18-20, 2001
68. NIDDK Special Study Section on Lipids and Lipoproteins, Chair, Feb 21, 2001

69. NHLBI-NIDDK Working Group on The Pathophysiology of Obesity-Associated Cardiovascular Disease, Chair, May 23, 24, 2001.
70. NIDDK Special Study Section on Lipids and Lipoproteins, Chair, June 18, 2001.
71. The Endocrine Society Annual Meeting, Meet the Professor on Hyperlipidemia, June 20, 2001.
72. The American Dietetics Annual Meeting, 'Beyond the AHA Guidelines', St. Louis, Oct 22, 2001
73. American Diabetes Association Meeting on Insulin Resistance. Tempe, Arizona, Dec 6-8, 2001.
74. American Heart Association Prevention VII: Obesity, a Worldwide Epidemic Related to Heart Disease and Stroke, Honolulu, April 26-28, 2002, Chair.
75. The Kern Aspen Lipid Conference, 'Fatty Acid Transport and Metabolism: Impact on Insulin Action/Secretion and Body Weight Regulation', Aspen, Aug 17-20, 2002, Co-Chair.
76. MSDM (Multiclinical Study for Diabetic Macrovascular Complication) Tokyo, Japan October 11-12, 2002
77. U.S.-Japan Panel on Nutrition and Metabolism Tokyo, Japan October 13, 2002.
78. American Heart Association Scientific Sessions 2002, November 17, 2002, Moderator "Emerging Epidemics, Obesity, Diabetes Mellitus, Sedentary Lifestyle "and talk "Curbing the Diabetic Epidemic".
79. American Heart Association scientific Sessions 2002 November 18, 2002,Plenary Session "Metabolic Syndrome: Pathogenesis of CVD in Metabolic Syndrome and Diabetes".
80. American Heart Association scientific Sessions 2002 November 18, 2002, "Role of Diet in the Statin Era".
81. Keystone Symposia's Role in Translational Medicine, January 14, 2003.
82. 2005 Keystone Symposia Planning Committee, January 15, 2003.
83. Metabolic Syndrome Clinical Conference, Washington, DC. "Obesity and its Metabolic Complications'.

## BIBLIOGRAPHY

### PUBLICATIONS


1. **Eckel RH**, Crowell EB Jr, Waterhouse BE, Bozdech MJ. Platelet inhibiting drugs in thrombotic thrombocytopenic purpura. *Arch Int Med* 37:735-737, 1977.
2. **Eckel RH**, Fujimoto WY, Brunzell JD. Development of lipoprotein lipase in cultured 3t3-l1 cells. *Biochem Biophys Res Comm*; 78:288-293, 1977.
3. **Eckel RH**, Fujimoto WY, Brunzell JD. Insulin regulation of lipoprotein lipase in cultured 3t3-l1 cells. *Biochem Biophys Res Comm*; 84:1069-1075, 1978.
4. **Eckel RH**, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide (gip) enhanced lipoprotein lipase activity in cultured preadipocytes. *Diabetes*; 28:1141-1142, 1979.
5. **Eckel RH**, Green WL. Postpartum thyrotoxicosis in a patient with graves' disease. association with low radioactive iodine uptake. *J Am Med Assoc*; 243:1454-1456, 1980.
6. **Eckel RH**, Albers JJ, Cheung MC, Wahl PW, Lindgren FT, Bierman EL. High density lipoprotein composition in insulin-dependent diabetes mellitus. *Diabetes*; 30:132-138, 1981.
7. **Eckel RH**, Fujimoto WY. Insulin stimulated glucose uptake, leucine incorporation into protein and uridine incorporation into RNA in skin fibroblast cultures from patients with diabetes mellitus. *Diabetologia*; 20:186-189, 1981.
8. **Eckel RH**, Albers JJ, Cheung MC, McLean EG, Bierman EL Plasma lipids and microangiopathy in insulin-dependent diabetes mellitus. *Diabetes Care*; 4:447-493, 1981.
9. **Eckel RH**, Fujimoto WY. Quantification of cell death in human fibroblast by measuring the loss of [14$^{c}$] thymadine from prelabeled cell monolayers. *Anal Biochem*;114:118-124, 1981.
10. **Eckel RH**, Fujimoto WY, Brunzell JD. Effect of *in vitro* lifespan of 3t3-l1 cells on hormonal responsiveness of lipoprotein lipase activity. *Int J Obesity*; 5:571-578, 1981.
11. Brunzell JD, Schwartz RS, **Eckel RH**, Goldberg AP. Insulin and adipose tissue lipoprotein lipase activity in humans. *Int J Obesity*; 5:685-694, 1981
12. Sadur CN, **Eckel RH**. Insulin stimulation of adipose tissue lipoprotein lipase: use of the euglycemic clamp technique. *J Clin Invest*; 69:1119-1125, 1982.

13. Kern PA, Knedler; **Eckel RH**. Insulin regulation of lipoprotein lipase in cultured isolated rat adipocytes. *J Clin Invest,* 71:1822-1829, 1983.
14. Sadur CN, **Eckel RH**. Insulin-mediated increases in the HDL cholesterol/cholesterol ratio in adipocytes. *J Clin Invest*; 71:1822-1829, 1983. humans. *Arteriosclerosis*; 3:339-343, 1983.
15. **Eckel RH**, Prasad JE, Kern PA, Marshall S: Insulin regulation of lipoprotein lipase in cultured isolated rat adipocytes. *Endocrinology*; 114:1665-1671, 1984.
16. Kern PA, **Eckel RH**. Absence of lipoprotein lipase in cultured human adipose stromal cells. *Arteriosclerosis,* 4:232-237, 1984.
17. Sadur CN, Yost TJ, **Eckel RH**. Fat feeding decreases insulin responsiveness of adipose tissue lipoprotein lipase. *Metabolism*; 33:1043-1047, 1984.
18. **Eckel RH**, Robbins RJ: Lipoprotein lipase is produced, regulated and functional in rat brain. *Proc Natl Acad Sci USA*; 81:7604-7607, 1984.
19. Sadur CN, Yost TJ, **Eckel RH**. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. *J Clin Endocr Metab*; 59:1176-1182, 1984.
20. Kern PA, Marshall S, **Eckel RH**. Regulation of lipoprotein lipase in primary cultures of isolated human adipocytes. *J Clin Invest*; 75:199-208, 1985.
21. Berr F, **Eckel RH**, Kern F Jr. Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting men. *J Lipid Res*; 26:852-859, 1985.
22. Berr F, **Eckel RH**, Kern F Jr. Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. *J Lipid Res*; 27:645-651, 1986.
23. Garvey WT, Grundy SM, **Eckel RH**. Xanthogranulomatosis in an adult: lipid analysis of xanthomata and plasma. *J Am Acad Derm*; 16:183-187, 24, 1987.
24. Baron AD, **Eckel RH**, Schmeiser L, Kolterman OG. The effect of short term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II diabetics. *Metabolism*; 36:409-415, 1987.
25. Kern PA, Mandic A, **Eckel RH**. Regulation of lipoprotein lipase by glucose in primary cultures of isolated human adipocytes: relevance to the hypertriglyceridemia of diabetes. *Diabetes*; 36:1238-1245, 1987.
26. **Eckel RH**, Yost TJ. Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women. *J Clin Invest,* 80:992-997, 1987.
27. **Eckel RH**, Goldberg IJ, Steiner L, Yost TJ, Paterniti JR ,Jr. Plasma lipolytic activity: relationship to postheparin lipolytic activity and evidence for metabolic regulation. *Diabetes*; 37:610-615, 1988.
28. **Eckel** RH, Sadur CN, Yost TJ. Deficiency of the insulin/glucose-mediated decrease in serum triglycerides in normolipidemic obese subjects. *Int J Obesity*; 12:369-376, 1988.
29. Yost TJ, **Eckel RH**. Fat calories may be preferentially stored in reduced-obese women: a permissive pathway for resumption of the obese state. *J Clin Endocr Metab*; 67:259-264, 1988.
30. Draznin B, Sussman KE, **Eckel RH**, Kao M, Yost TJ, Sherman N. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. *J Clin Invest.*; 82:1848-1852, 1988.
31. Yost TJ, **Eckel RH**. Hypocaloric feeding in obese women: metabolic effects of medium-chain triglyceride substitution. *Am J Clin Nutr*; 49:326-330, 1989.
32. **Eckel RH**, Yost TJ. HDL subfractions and adipose tissue metabolism in the reduced-obese state. *Am J Phys.* 256:E740-746, 1989.
33. Kern PA, Svoboda ME, Graves D, **Eckel RH**, Van Wyk JJ. Insulin-like growth factor action and production in adipocytes and endothelial cells from human adipose tissue. *Diabetes,* 38:710-717, 1989.

34. **Eckel RH**. Lipoprotein lipase: A multifunctional enzyme relevant to common metabolic diseases. *N Engl J Med*; 320:1060-1068, 1989.
35. Samuels MH, **Eckel RH**: Massive insulin. overdosage: Detailed studies of free insulin levels and glucose requirements. *Clin Tox J Tox*; 26:157-168, 1989.
36. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser PM, Perry BG, Klecker RW, Flexner C, **Eckel RH**, Bartlett JG, Leitman PS. Dextran sulfate is poorly absorbed after oral administration. *Ann Int Med*; 111:561-566, 1989.
37. Brass EP, Tserng K-Y, **Eckel RH**. Urinary organic acid excretion during feeding of medium-chain or long-chain triglyceride diets in patients with non-insulin dependent diabetes mellitus. *Am J Clin Nutr*; 52:923-926, 1990.
38. **Eckel RH**, Raynolds MV, Bessesen DH, Farese RV Jr, Ohtake A, Yost TJ. Lipoprotein lipase: hormonal and nutritional regulation. *J Drug Devel*; 3 Suppl 1:91-94, 1990.
39. Raynolds MV, Awald PD, Gordon DF, Gutierrez-Hartmann A, Rule DC, Wood WM, **Eckel RH**. Lipoprotein lipase gene expression in rat adipocytes is regulated by isoproterenol and insulin through different mechanisms. *Mol Endocr*; 4:1416-1422, 1990.
40. Farese RV Jr, Yost TJ, **Eckel RH**. Tissue-specific regulation of lipoprotein lipase activity by insulin in normal weight humans. *Metabolism*; 40:214-216, 1991.
41. Neville MC, Waxman LJ, Jensen DR, **Eckel RH**. Lipoprotein lipase in human milk:compartmentalization and effect of fasting, insulin and glucose. *J Lipid Res*; 32:251-257, 1991.
42. Jensen DR, Bessesen DH, Etienne J, **Eckel RH**, Neville MC. Distribution and source of lipoprotein lipase in mouse mammary glands. *J Lipid Res*; 32:733-742, 1991.
43. Regensteiner JG, Mayer EF, Shetterly SM, **Eckel RH**, Haskell WL, Marshall JA, Baxter J, Hamman RF. Relationship between habitual physical activity and hyperinsulinemia among non-diabetic men and women: The San Luis Valley Diabetes Study. *Diabetes Care*; 14:1066-1074, 1991.
44. Bessesen DH, Robertson AD, **Eckel RH**. Weight reduction increases adipose but decreases cardiac LPL in reduced-obese Zucker rats. *Am J Phys*; 261:E246-E251, 1991.
45. Mayer EJ, Burchfiel CM, **Eckel RH**, Marshall JA, Haskell WL, Hamman RF. The role of insulin and body fat in associations of physical activity with lipids and lipoproteins in a bi-ethnic population: The San Luis Valley Diabetes Study. *Arteriosclerosis and Thrombosis*; 11:973-984, 1991.
46. Yost TJ, **Eckel RH**. Regional similarities in the metabolic regulation of adipose tissue lipoprotein lipase. *Metabolism*; 41:33-36, 1992.
47. Sniderman A, Cianflone K , **Eckel RH**. Levels of acylation stimulating protein in obese women before and after moderate weight loss. *Int J Obesity*; 15:327-332, 1991.
48. Barchiesi BJ, **Eckel RH**, Ellis PP. The cornea and disorders of lipid metabolism. *Surv Ophthalmol,* 36:1-22, 1991.
49. Glaser DS, Yost TJ, **Eckel RH**. Preheparin lipoprotein lipolytic activities: Relationship to plasma lipoproteins and postheparin lipolytic activities. *J Lipid Res*; 33:209-214, 1992.
50. **Eckel RH**, Hanson AS, Chen AY, Berman JN, Yost TJ, Brass EP. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in non-insulin dependent diabetics. *Diabetes*; 41:641-647, 1992.
51. Fulton-Kehoe DL, **Eckel RH**, Shetterly S, Hamman RF. Determinations of total HDL and HDL subfraction cholesterol levels among Hispanic and non-Hispanic white subjects with normal glucose tolerance. The San Luis Valley Diabetic Study. *J Clin Epidemiol*; 45:1191-1200, 1992.
52. Currie RA, **Eckel RH**. Characterization of a high affinity octamer transcription factor binding site in the human lipoprotein lipase promoter. *Arch Biochem Biophys*; 298:630-639, 1992.
53. Yost TJ, Jensen DR, **Eckel RH**. Tissue-specific lipoprotein lipase: Relationship to body composition and body fat distribution in normal weight humans. *Obesity Res*; 1:1-4, 1993.

54. **Eckel RH**. Insulin Resistance: An adaptation for weight maintenance. *Lancet*; 340:1452-1453, 1992.
55. Bessesen DH, Richards CL, Etienne J, Goers JW, **Eckel RH**. The spinal cord is the most abundant source of lipoprotein lipase in the central nervous system. *J Lipid Res*; 34:229-238, 1993.
56. Yost TJ, Rodgers CM, **Eckel RH**. Suction lipectomy: Outcome relates to region-specific lipoprotein lipase activity and interval weight change. *Plastic Reconstr Surg*; 92:1101-1108, 1993.
57. Ferraro RT, **Eckel RH**, Larson DE, Fontvieille A-M, Rising R, Jensen DR, Ravussin E. Relationship between skeletal muscle lipoprotein lipase activity and 24-hr macronutrient oxidation. *J Clin Invest*; 92:441-445, 1993.
58. Jensen DR, Gavigan S, Sawicki V, Witsell DL, **Eckel RH**, Neville MC. Regulation of lipoprotein lipase activity and MRNA in the mammary gland of the lactating mouse. *Biochem J*; 98:321-327, 1994.
59. Erskine JM, Jensen DR, **Eckel RH**. Macronutrient regulation of lipoprotein lipase is posttranslational. *J Nutrition*; 124:500-507, 1994.
60. Yost TJ, Erskine JM, Gregg TS, Podlecki DL, Brass EP, **Eckel RH**. Dietary substitution of medium chain triglycerides (mct) in non-insulin dependent diabetes mellitus in an ambulatory setting: impact on control and insulin-mediated glucose metabolism. *J Am Col Nutrition*; 13:615-622, 1994.
61. Bagdade JD, Dunn FL, **Eckel RH**, Ritter MC. Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activity in insulin-dependent diabetes mellitus. *Arterioscler Thromb*; 14:1933-1939, 1994.
62. Yost TJ, Froyd KK, Jensen DR, **Eckel RH**. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. *Metabolism*; 44:786-790, 1995.
63. Travers SH, Jeffers BW, Bloch CA, Hill JO, **Eckel RH**. Gender and Tanner Stage differences in body composition and insulin sensitivity in early pubertal children. *J Clin Endocr Metab*; 80:172-178, 1995.
64. **Eckel RH**, Yost T, Jensen DR. Sustained weight reduction in moderately obese women results in decreased activity of skeletal muscle lipoprotein lipase. *Eur J Clin Invest*; 25:396-402, 1995.
65. Bessesen DH, Rupp CL, **Eckel RH**. Trafficking of dietary fat in lean rats. *Obesity Res*; 3:191-204, 1995.
66. Bessesen DH, Rupp CL, **Eckel RH**. Dietary fat is shunted away from oxidation towards storage in obese Zucker rats. *Obesity Res*; 3:179-190, 1995.
67. Morin CL, Schlaepfer IR, **Eckel RH**. Tumor necrosis-α eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. *J Clin Invest*; 95:1684-1689, 1995.
68. Regensteiner JG, Shetterly SM, Mayer EJ, **Eckel RH**, Haskell WR, Baxter J, Hamman RF. Relationship between habitual physical activity and insulin area among persons with impaired glucose tolerance: The San Luis Valley Diabetes Study *Diabetes Care*; 18:490-497, 1995.
69. Yost TJ, Sadur CN, **Eckel RH**. Glycohemoglobin levels relate to the response of adipose tissue lipoprotein lipase to insulin/glucose in obese non-insulin-dependent diabetes mellitus. *Metabolism*; 44:1475-1480, 1995.
70. Yost TJ, Jensen DR, **Eckel RH**. Weight regain following sustained weight reduction is predicted by relative insulin sensitivity. *Obesity Res*; 3:583-587, 1995.
71. Coppack SW, Yost TJ, Fisher RM, **Eckel RH**, Miles JM. Periprandial and regional lipase activity in normal men. *Am J Physiol*; 270:E718-E722, 1996.

72. Gnudi L, Jensen DR, Tozzo E, **Eckel RH**, Kahn BB. Adipose specific overexpression of the GLUT4 glucose transporter in transgenic mice alters lipoprotein lipase activity in muscle and adipose tissue: Implications for regulation of nutrient partitioning. *Am J Physiol*; 270 (Regulatory Integrative Comp. Physiol.39):R785-R792, 1996.
73. **Eckel RH**, Jensen DR, Schlaepfer IR, Yost TJ. Tissue-specific regulation of lipoprotein lipase by isoproterenol in normal weight humans. *Am J Physiol*; (Regulatory Integrative Comp. Physiol. 40):R1280-R1286, 1996.
74. Bagdade, JD, Kelley DE, Henry RR, **Eckel RH**, Ritter MC. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in non-insulin-dependent diabetes mellitus. *Diabetes*; 46:414-420, 1997.
75. Mehler PS, Lezotte, D, **Eckel RH**. Lipid levels in anorexia nervosa. *Int J Eating Dis*; 24:217-221,1998.
76. Morin CL, Pagliassotti MJ, Windmiller D, **Eckel RH**. Adipose tissue-derived tumor necrosis factor-α is elevated in older rats. *J Gerontol*; 52:B190-B195, 1997.
77. Jensen DR, Schlaepfer IR, Morin CL, Pennington DS, Marcell T, Ammon SM, Gutierrez-Hartmann A, **Eckel RH**. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. *Am J Physiol,* (Regulatory Integrative Comp. Physiol 42.).273:R683-R689, 1997.
78. Morin CL, **Eckel RH**, Marcel T, Pagliassotti MJ. High fat diets elevate adipose tissue-derived tumor necrosis factor-α activity. *Endocrinology*; 138:4665-4671, 1997.
79. Morin CL, **Eckel RH**. Transgenic and knockout animals: Novel mechanisms of body weight regulation. *J Nutr Biochem*; 8:702-706, 1997.
80. Donahoo WT, Jensen DR, Yost T, **Eckel RH**. Isoproterenol and somatostatin decrease plasma leptin in humans: A novel mechanism regulating leptin secretion. *J Clin Endocrinol Metab*; 82:4139-4143, 1997.
81. **Eckel RH**. The Nutrition Committee of the American Heart Association. Obesity and Heart Disease. *Circulation*; 3248-3250, 1997.
82. Travers SH, Labarta JI, Gargosksy SE, Rosenfeld RG, Jeffers BW, **Eckel RH**. Insulin-like growth factor binding protein-1 (IGFBP-1) levels are strongly associated with insulin sensitivity and obesity in early pubertal children. *J Clin Endocrinol Metab*; 83:1935-1939, 1998.
83. Bagdade JD, Teuscher A, Ritter MC, **Eckel RH**, Robertson RP. Alterations in cholesterol ester transfer, lipoprotein lipase, and lipoprotein composition following combined pancreas-kidney transplantation. *Diabetes*; 47:113-8, 1998.
84. Yost TJ, Jensen DR, Haugen B, **Eckel RH**. Effect of dietary macronutrient composition on tissue-specific lipoprotein lipase activity and insulin action in normal-weight subjects. *Am J Clin Nutr*; 68:296-302, 1998.
85. Regensteiner JG, Bauer TA, Reusch J EB, Brandenburg SL, Sippel JT, Vogelsong AM, Smith S, Wolfel EE, **Eckel RH**, Hiatt WR. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. *J Applied Physiol*; 85;1, 310-7, 1998.
86. Huey PU, Marcell T, Owens GC, Etienne J, **Eckel RH**. Lipoprotein lipase is expressed in cultured Schwann cells and functions in lipid synthesis and utilization. *J Lipid Res*; 39 2135- 2142, 1998.
87. Donahoo WT, **Eckel RH**. Lipid management post-myocardial infarction: Outcomes and cost. *Primary Care Case Reviews*; 1:4, 158-167, 1998.
88. Schlaepfer IR, **Eckel RH**. Plasma triglyceride reduction in mice following direct injections of muscle-specific lipoprotein lipase DNA. *Diabetes*; 48:223-227, 1999.
89. Ginzinger DG, Clee SM, Dallongeville J, Lewis ME, Henderson HE, Bauje E, Togers QR, Jensen DR, **Eckel RH**, Dyer R, Innis S, Jones B, Fruchart JC, Hayden MR. Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. *Eur J Clin Invest*; 29; 1: 17-26, 1999.

90. Grundy SM, Benjamin IJ, Burke GL, Chait A, **Eckel RH,** Howard BV, Mitch W, Smith SC, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the council on arteriosclerosis, thrombosis and vascular biology of the American Heart Association. *Diabetes Care*; 22, C21-24, 1999.

91. Yost TJ, Jensen DR, Blotner S, Zhi J, Guerciolini R, Pace D, **Eckel RH**. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal weight male volunteers. *Int J Obesity Relat Metab Disord*; (2):187-94, 2000.

92. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow, B, Sanan DA, Raber J, **Eckel RH**, Farese, Jr. RV. Obesity Resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. *Nature Genetics,* 25:87-90, 2000.

93. Poirier P, Marcell T, Uelmen Huey P, Schlaepfer IR, Owens GC, Jensen DR, **Eckel RH**. Increased Intracellular Triglyceride in C2C12 Muscle Cells Transfected with Human Lipoprotein Lipase. *Biochem Biophys Res*, 270:997-1001, 2000.

94. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, **Eckel RH**, Krezel W, Chambon P and Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXRγ deficient mouse. *J Clin Invest*, 106:73-79, 2000.

95. Donahoo WT, Jensen DR, Shepard TY, **Eckel RH**. Seasonal variation in lipoprotein lipase and plasma lipids in physically active normal weight humans. *J Clin Endo Metab*, 85:9: 3065-3068,2000.

96. Shepard TY, Weil KM, Sharp TA, Grunwald GK, Bell ML, Hill JO, **Eckel RH**. Occasional physical inactivity combined with a high-fat diet may be important in the development and maintenance of obesity in human subjects. *Am J Clin Nutr,* 73:703-708, 2001.

97. Backus RC, Ginzinger DG, Ashbourne Excoffon KJD, Clee SM, Hayden MR, **Eckel RH**, Hickman A, Rogers QA. Maternal expression of functional lipoprotein lipase and effects on body fat mass and condition scores of mature cats with lipoprotein lipase deficiency. *Am J Vet Res,* 62:264-269, 2001.

98. Jensen DR, Gayles EC, Ammon S, Phillips R, **Eckel RH**. A Self-Correcting Indirect Calorimeter System for the Measurement of Energy Balance in Small Animals *J App Phys,* 90:912-918, 2001.

99. Krauss RM, **Eckel RH**, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW, Kris-Etherton P, Goldberg I, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St. Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines Revision 2000: A statement for Healthcare Professionals From the Nutrition Committee of the American Heart Association. *Circulation,* 102:18; 2284-2299, 2000.

100. Davies PJ, Berry SA, Shipley GL, **Eckel RH**, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. *Mol Pharmacol,* Feb;59(2):170-6, 2001.

101. Ferreira LDMC-B, Pulawa LK, Jensen DR, **Eckel RH.** Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. *Diabetes*, 50:1064-1068, 2001.

102. Eckel RH. Familial combined hyperlipidemia and insulin resistance : distant relatives linked by intra-abdominal fat? *Arterioscler Throm Vasc Biol*, April 21, 4:469-470, 2001.

103. Kris-Etherton P, **Eckel RH**, Howard BV, St. Jeor S, Bazzarre T. The Lyon Heart Study: Benefits of a Mediterranean style NCEP/AHA Step 1 dietary pattern for cardiovascular disease. *Circulation*, 103:13;1823-1825, 2001.

104. Monks J, Huey PC, Hanson L, **Eckel RH**, Neville MC, Gavigan S. Cholesterol-depleted, low density lipoprotein-sized particles are present in the milk of lactating mice. *J Lipid Research*, 42:686-696, 2001.

105. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, **Eckel RH**. Fat Distribution and Metabolic Changes are Strongly Correlated and Energy Expenditure is Increased in the HIV Lipodystrophy Syndrome. *AIDS,* 15:1993-2000, 2001.

106. Kris-Etherton P, Daniels SR, **Eckel RH**, Engler M, Howard BV, Krauss RM, Lichtenstein AH, Sacks F, St. Jeor S, Stampfer M, Grundy SM, Appel LJ, Byers T, Campos H, Cooney G, Denke MA, Kennedy E, Marckmann P, Pearson TA, Riccardi G, Rudel LL, Rudrum M, Stein DT, Tracy RP, Ursin V, Vogel RA, Zock PL, Bazzarre TL, Clark J. AHA scientific statement: summary of the Scientific Conference on Dietary Fatty Acids and Cardiovascular Health. Conference summary from the Nutrition Committee of the American Heart Association. *J Nutr,* 131:4;1322-6, 2001.

107. St. Jeor S, Howard BV, Prewitt, TE, Bovee V, Bazzarre T, **Eckel RH**. Dietary Protein and Weight Reduction. *Circulation,* 104:1869-1874, 2001.

108. Huey PU, Waugh KC, Etienne J, **Eckel RH**. Lipoprotein lipase is expressed in rat sciatic nerve and regulated in response to crush injury. *J. Lipid Research*, 43:19-26, 2002.

109. Ferreira LDMC-B, Huey PU, Pulford BE, Ishii DN and **Eckel RH.** Sciatic nerve lipoprotein lipase is reduced in streptozotocin-induced diabetes and corrected by insulin. *Endocrinology*, 143(4): 1213-1217, 2002.

110. Hokanson JE, Cheng S, Snell-Bergeon JK, Grow MA, Hung C, Erlich HA, Ehrlich J, **Eckel RH,** Rewers M. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in Type 1 Diabetes. *Diabetes*, Apr. 51:4; 1208-1213, 2002.

111. Francis CC and **Eckel RH.** Assessing dietary fat intake in cardiac rehabilitation. *J Cardiopulm Rehab,* 22:3; 168-169, 2002.

112. Pulawa LK and **Eckel RH.** Overexpression of muscle lipoprotein lipase and insulin sensitivity. *Curr Opin Clin Nutr Metab Care,* 5:569-574, 2002.

113. **Eckel RH**, Ershow AG, and Barouch WW. Report of the NHLBI-NIDDK Working Group on the Pathophysiology of Obesity-Associated Cardiovascular Disease. *Circulation,* 105:2923-2928, 2002.

114. Chen HC, Smith SJ, Ladha Z, Jensen DR, Ferreira LD, Pulawa LK McGuire JG, Pitas RE, **Eckel RH,** and Farese RV Jr. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase. *J Clin Invest.* 109(8):1049-55, 2002.

115. Travers SH, Jeffers BW, and **Eckel RH**. Insulin Resistance During Puberty and Future Fat Accumulation. *J Clin Endo and Metab*, 87:8;3814-3818, 2002.

116. **Eckel RH**, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, and Vlassara H. Prevention Conference VI Diabetes and Cardiovascular Disease Writing Group II: Pathogenesis of Atherosclerosis in Diabetes. *Circulation,* 105:e138-e143, 2002.

117. Grundy SM, Smith S Jr., **Eckel RH**, Redberg R, and Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. *Circulation,* 105:2231-9, 2002.

118. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM and **Eckel RH**. Simvastatin lowers C-reactive protein within fourteen days: An effect independent of LDL cholesterol reduction. *Circulation,* Sept 17, 106:12; 12,1447-1452, 2002.

119. Pearson TA, Blair SN, Daniels SR, **Eckel RH,** Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Houston-Miller N, Lauer RM, Ockene IS, Sacco R, Sallis, Jr, JF, Smith SC, Jr, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation,* July 16, 106:3; 388-391, 2002.

120. Perri M, Theriaque D, Hutson A, **Eckel RH,** Stacpoole P, Duncan GE. Exercise Training, Without Weight Loss, Increases Insulin Sensitivity and Postheparin Plasma Lipase Activity in Previously Sedentary Adults *Diabetes Care*, 2002 In Press.

121. Kosmiski L, Kuritzkes D, Lichtenstein K, **Eckel RH**. Adipocyte-Derived Hormone Levels in HIV Lipodystrophy *Antiviral Therapy,* 2002 In Press.
122. Poirier P and **Eckel RH.** Obesity and cardiovascular disease. *Curr. Atheroscler Rep* 4:6;448-453, 2002.
123. Merkel M, **Eckel RH**, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake and regulation. *J Lipid Res,* 43:12: 1997-2006, 2002.
124. Capell WH, **Eckel RH.** Vascular dysfunction in hypertriglyceridemia. *Arterioscler Throm Vasc Bio*, In Press.
125. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, **Eckel RH** and Hill JO. Energy Expenditure in HIV Lipodystrophy. *Metabolism,* In Press.
126. Snell-Bergeon J, Hokanson J, Jensen L, MacKenzie T, Kinney G, Dabelea D, **Eckel RH**, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: The importance of glycemic control. *Diabetes Care.* In Press, 2003.
127. Chen HC, Jensen DR, Myers HM, **Eckel RH,** and Farese RV., Jr. Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. *J Clin Invest* 111:1715-1722, 2003.
128. Schlaepfer IR, Pulawa LK, Ferreira LDM C-B, James DE, Capell WH, and **Eckel RH.** Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistance. *J Lipid Res*, 44: 1174-1181, 2003.
129. Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J, **Eckel RH**. Fat distribution is altered in HIV-infected men without clinical evidence of HIV lipodystrophy syndrome. *HIV Med.* Jul;4(3):235-40, 2003.
130. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, **Eckel RH**, Hill JO. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. *Metabolism.* May;52(5):620-5, 2003.
131. Kosmiski L, Kurtizkes D, Lichtenstein K, **Eckel RH**. Adipocyte-derived hormone levels in HIV lipodystrophy. *Antivir Ther.* Feb;8(1):9-15, 2003.
132. Poirier P, Hernandez TL, Weil KM, Shepard TJ and **Eckel RH**. The impact of diet-induced weight loss on cardiac autonomic nervous system and arrhythmias in subjects with severe obesity. *Obesity Research.* 11(9); 1040-1047, 2003.
133. **Eckel RH** The Effect of Type 1 Diabetes on the Gender Difference in Coronary Artery Calcification: A Role for Insulin Resistance? *Diabetes,* In Press, 2003.

## LETTERS AND EDITORIALS

1. **Eckel RH**, Sadur CN, Yost TJ. Smoking, weight change and lipoprotein lipase (Correspondence). *New Engl J Med*; 311:259-260, 1984.
2. **Eckel RH** Very low Calorie Diets. *Diabetes Spectrum*; 1:33-34, 1987.
3. **Eckel RH** and Kim SK. Workshop on nutrition, immunity, and infection: Introduction. *J Nutr Immunol,* 2:71-72, 1994.
4. **Eckel RH**. Insulin resistance in atherosclerosis. *Am J Clin Nutr*; 65:164-165, 1997.
6. Krauss RM, **Eckel RH**. Obesity. *New Engl J Med*; 338:1156, 1998.
7. **Eckel RH**, Krauss RM. For the Nutrition Committee of the American Heart Association. American Heart Association Call to Action: Obesity as a major risk factor for coronary artery disease. *Circulation,* 7:2099-2100, 1998.
8. **Eckel RH**. The five-to-ten percent weight loss: Long-term changes in lipids and lipoproteins and some unanswered questions. *Obesity Res,* 7;227-228, 1999.
9. **Eckel RH.** Natural history of macrovascular disease and classic risk factors for atherosclerosis session summary. *Diabetes Care,* 22: C21-C24, 1999.

10. **Eckel RH.** Advanced glycation end products and coronary heart disease in type 2 diabetes. *Diabetes Care,* 23:1441-2, 2000.
11. **Eckel RH**. Perspectives on Vascular Biology and Diabetes. *J Invest Med*; 49:100-103, 2001.
12. **Eckel RH.** Familial combined hyperlipidemia and insulin resistance: Distant relatives linked by intra-abdominal fat? *Arterio Thromb Vasc Biol,* 21:469-471, 2001.
13. **Eckel RH.** ApoA-I Mutant Increases Atherosclerosis. *Arterio Thromb Vasc Biol*, 21:1977-1983, 2001.
14. Francis CC, **Eckel RH.** Assessing dietary fat intake in cardiac rehabilitation. *J Cardiopulm Rehabil,* May-June ;22(3):168-9, 2002.
15. **Eckel RH**. A new look at dietary protein in diabetes. *Am J Clin Nutr*; In Press, 2003.

**CHAPTERS AND BOOKS, REVIEWS**

1. **Eckel RH,** Hofeldt FD. Endocrinology and metabolism in the aged. IN: C*linical Internal Medicine in the Aged.* Schrier RW, ed. New York, NY:WB Saunders; 222-255, 1982.
2. **Eckel RH.** Diabetes and hyperlipidemia. IN*: Clinical Guide to Diabetes Mellitus* Sussman KE, Draznin B, James WE, eds. New York, NY Alan R. Liss, Inc.; 209-222, 1987.
3. **Eckel RH**, Kern PA, Sadur CN, Yost TJ. Methods for studying lipoprotein lipase in human adipose tissue. IN: *Methods in Diabetes Research* SL Pohl, Clarke WL, Larner J, eds. Poughkeepsie, New York John Wiley and Sons, Inc.: 259-273, 1986.
4. **Eckel RH**. Adipose tissue lipoprotein lipase. IN: *Lipoprotein Lipase* Borensztajn J, ed. Chicago, IL, Evener Publishing, Inc., 79-132, 1987.
5. Sadur CN, **Eckel RH**. Diabetes mellitus and hyperlipidemia. IN: *Current Medical Therapy*. Schrier RW, ed. New York , NY: Raven Press, 486-509, 1989.
6. **Eckel RH**, Bessesen DH, Yost TJ. Molecular regulation of lipoprotein lipase in obesity and diabetes mellitus. IN: *New Directions in Research and Clinical Works for Obesity and Diabetes Mellitus*. Sakamoto N, Angel A, Hatta H, eds. Elsevier-Science, Amsterdam: 71-75, 1991.
7. **Eckel RH**, Bessesen DH, Raynolds MV, Jensen DR, Fox D, Yost TJ. Lipoprotein lipase and nutrient partitioning. IN: *The Science of Food Regulation, Food Intake, Taste, Nutrient Partitioning, and Energy Expenditure* Bray GH, Ryan DH, eds. Baton Rouge, LA LSU Press: 187-192, 1992.
8. **Eckel RH**. Lipoprotein lipases and diabetes mellitus. IN: *Diabetes and Atherosclerosis* Draznin B, Eckel RH, eds. New York, NY; Elsevier-Science: 77-102, 1993.
9. **Eckel RH**, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. *Intern J Obesity* 19:S16-S21; Supplement 1, 1995:.
10. Estacio R, **Eckel RH**. Abnormalities of lipids. IN: *Primary Care Secrets* Mladenovic J, ed. Philadelphia, PA Hanley and Belfus, Inc. 134-140, 1995.
11. Morin CL, **Eckel RH**. Transcriptional regulation of the lipoprotein lipase gene. *Atherosclerosis*; X:231-235, 1995.
12. **Eckel RH**, Ailhaud G, Astrup A, Flatt J-P, Hauner H, Levine AS, Prentice AM, Ricquier D, Steffens AB, Woods SC. What are the metabolic and physiological mechanisms associated with the regulation of body weight? IN: *Regulation of Body Weight: Biological and Behavioral Mechanisms* Bray GA, Bouchard C, eds. Dahlem Workshop Report LS 57. Chichester: John Wiley & Sons Ltd., 1996.
13. Donahoo WT, **Eckel RH**. Adipocyte metabolism in obesity. IN: *Current Opinions in Endocrinology and Diabetes*; 3:501-508, 1996.
14. Kosmiski L, **Eckel RH**. Dyslipidemia, atherosclerosis and non-insulin dependent diabetes mellitus. IN: *Clinical Research in Diabetes Mellitus and Obesity* Volume II. Draznin B,. Rizza R, eds. Humana Press, 159-185, 1997
15. Kosmiski L, **Eckel RH**. The use of anorectic agents in non-insulin dependent diabetes mellitus. IN: *Current Opinions in Endocrinology and Diabetes* 1998 In Press.

16. Arner P, **Eckel RH**. Adipose tissue as a storage organ. IN: *Handbook of Obesity*. Bray CA, Bouchard C, James WPT, eds. Marcel Dekker, Inc. 379-396, 1998.
17. Donahoo WT, Kosmiski LA, **Eckel RH**. Drugs causing dyslipoproteinemia. IN. Endocrinology Clinics of North America J Hoeg, ed, WB Saunders, Inc.; 27: 677-698, 1998.
18. Poirier P, **Eckel RH**, Adipose tissue metabolism and obesity IN Physical Activity and Obesity Bouchard C, ed. Human Kinetics publisher, Chapter 9, p.181-200, 2000.
19. **Eckel RH**. Substrate trafficking and the regulation of adipose mass. IN: *Progress in Obesity Research* B Guy-Grand and G Ailhaud, eds, John Libbey & Company, Ltd.;50:415-422, 1999.
20. **Eckel RH.** Late breaking advances in the biological understanding of obesity and its sequelae IN: *Obesity: Impact on Cardiovascular Disease* Fletcher GF MD, ed. Armonk, NY, Futura Publishing,: 205-218, 1999.
21. Poirier P, **Eckel RH**. The Heart in Obesity IN: *HURST'S THE HEART*. NY, NY McGraw-Hill: 2289-2303, 2001.
22. Poirier P, **Eckel RH.** Management of Diabetes and Heart Disease. *Cardiology Special Edition* 7:17-21, 2001.
23. Poirier P, **Eckel RH.** The Heart and Obesity. IN: *Hurst's The Heart: Manual of Cardiology*. McGraw-Hill, NY: 733-749, 2001.
24. Donahoo WT, Stephens E, **Eckel RH.** The Evaluation of Dyslipidemia and Obesity, in The Handbook of Diagnostic Endocrinology. Humana Press, 2002 In Press.
25. Donahoo WT and **Eckel RH**. Leptin. McGraw Hill Yearbook of Science, 2002.
26. Ludwig DS and **Eckel RH.** The Glycemic Index at 20 y [1-3] *Am J Clin Nutr* 76(suppl):264S-265-S, 2002.
27. Wolfert AL and **Eckel RH.** Abnormalities of Lipids. *Primary Care Secrets*, 2002, In Press.
28. Pulawa LK and **Eckel RH.** Overexpression of Muscle Lipoprotein Lipase and Insulin Sensitivity. *Current Opinion in Clinical Nutrition and Metabolic Care*, 5; 569-574 2002.
29. Cooke PS, Naaz A, Heine PA, Zakroczymski MA, Saunders PTK, Taylor JA, **Eckel RH,** Jensen DR, Helferich WG, and Lubahn DB. Chapter 179 Effects of Estrogen and phytoestrogen signaling through estrogen receptor α {ER α} and ERβ on adipose tissue in males and females. IN: *Progress in Obesity Research*. In Press, 2003.

**ABSTRACTS** (*-Presented; **-at both regional and national meetings)

1. **Eckel RH**, Waterhouse BE, Bozdech MJ, Crowell EB, Jr. Antiplatelet drugs in thrombotic thrombocytopenic purpura (TTP). *American Society of Hematology Annual Meeting* Dallas, Texas, December, 192, 1975.
2. **Eckel RH**, Fujimoto WY, Brunzell JD. The development of lipoprotein lipase (LPL) in cultured 3T3-L1 cells. *Clin Res*; 25:495A, 1977.
3. **Eckel RH**, Fujimoto WY, Brunzell JD. The development of lipoprotein lipase (LPL) in cell culture. *Diabetes*; 26; Suppl.1:373, 1977.*
4. **Eckel RH**, Albers JJ, Wahl PW, Bierman EL. Alterations of high density lipoprotein cholesterol in juvenile onset diabetes. *Clin Res*; 26:560A, 1978.
5. **Eckel RH**, Fujimoto WY, Brunzell JD. Insulin regulation of lipoprotein lipase in culture. *Clin Res* 26:413A, 1978.*
6. **Eckel RH** and Fujimoto WY. Quantitation of cell death in the proliferative pool of cultured cells. Annual Meeting of the Tissue Culture Association Abstracts, 189,1979.*
7. **Eckel RH**, Albers JJ, McLean EB, Wahl PW and Bierman EL. High density lipoprotein cholesterol and microangiopathy in juvenile onset diabetes mellitus. *Diabetes*; 27(Suppl.2):67, 1978.
8. **Eckel RH**, Fujimoto WY. Abnormalities in insulin stimulated leucine incorporation into protein and uridine incorporation into RNA in diabetic fibroblasts. *Clin Res*; 27:85A, 1979.

9. **Eckel RH**, Albers JJ, Cheung MC, Wahl PW, Bierman EL. Antiatherogenic high density lipoprotein composition in juvenile onset diabetes mellitus. *Clin Res*; 27:44A, 1979.
10. **Eckel RH**, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured cells. *Clin Res*; 27:354A, 1979.*
11. **Eckel RH**, Albers JJ, Cheung MC, Wahl PW, Bierman EL. Antiatherogenic high density lipoprotein composition in juvenile onset diabetes mellitus. *Diabetes*; 28 (Suppl.2:94), 1979.*
12. **Eckel RH,** Fujimoto WY. The decreased growth capacity of fibroblasts from diabetes donors is not attributable to enhanced cell death. *Clin Res*; 28:48A, 1980.*
13. Sadur CN, **Eckel RH**. Insulin-induced alterations in lipoprotein lipase activity: Use of the euglycemic clamp technique. *Clin Res;*29:59A, 1981.*
14. Sadur CN, **Eckel RH.** Insulin stimulation of adipose tissue lipoprotein lipase activity in man: a definite, but delayed effect. *Clin Res*; 29:421A, 1981.*
15. **Eckel RH,** Gwinner DA. Variability in lipoprotein lipase regulation in cultured preadipocytes also occurs in primary cultures. *Clin Res*;29:404A, 1981.
16. **Eckel RH,** Gwinner DA. primary cultures of rat adipocytes also demonstrate variability in lipoprotein lipase regulation. *The Endocrine Society Abstracts;*108:370, 1981.
17. Sadur CN, **Eckel RH**. Insulin-mediated decreases in plasma cholesterol in man: use of the euglycemic clamp technique. *Diabetes*; 30; (Suppl.2):189, 1981.*
18. Sadur CN, **Eckel RH**. Alterations in insulin stimulation of adipose tissue lipoprotein lipase in obesity. *Clin Res*; 30:64A, 1982.*
19. Sadur CN, **Eckel RH**. Insulin stimulation of adipose tissue lipoprotein lipase in obesity: A deviation from insulin resistance. *Clin Res*; 30:403A, 1982.
20. **Eckel RH**, Kern PA, Prasad JE, Marshall S. Adipose tissue lipoprotein lipase regulation by insulin in the cultured rat adipocyte: A selective protein synthesis dependent effect. *Clin Res*; 30:390A, 1982.
21. Sadur CN, **Eckel RH**, Insulin-mediated lipoprotein metabolism in obesity. *Diabetes*; 31, (Suppl.2):596, 1982.
22. Kern PA, **Eckel RH**. Lipoprotein lipase activity is measurable in cultured isolated human adipocytes. *Diabetes;* 31 Suppl.2 :228, 1982.*
23. Kern PA, Knedler A, **Eckel RH**. The isolation and culture of human microvascular endothelium. *Circulation*; 66:II:204, 1982.*
24. **Eckel RH**, Steiner L, Kern PA, Paterniti JR, Jr. Plasma lipolytic activity in humans: evidence for hormone regulation. *Circulation*; 66:II:282, 1982.*
25. Sadur CN, Yost TJ, **Eckel RH**. Fat feeding decreases insulin responsiveness of adipose tissue lipoprotein lipase. *Clin Res*; 31:60A and 244A3, 1983.**
26. **Eckel RH**, Prasad JE, Kern PA, Marshall S. Cultured isolated rat adipocytes. a novel system for investigation of lipoprotein lipase regulation by insulin. *Clin Res*; 31:54A, 1983.*
27. Kern PA, Marshall S, **Eckel RH**. Regulation of lipoprotein lipase in cultured isolated human adipocytes. *Diabetes*; 32, Suppl.1:55, 1982.*
28. Clark RAF, Folkvord JM, Kern PA, **Eckel RH**. Human endothelial cells from both large and small blood vessels demonstrate fibronectin dependent inherence. *J Cell Biol*; 97;327A, 1983.**
29. Kern PA, **Eckel RH**. Glucose is a more important regulator of lipoprotein lipase than insulin in cultured isolated human adipocytes. *Clin Res*; 32:49A and 400A, 1984.**
30. **Eckel RH**, Robbins RJ. Lipoprotein lipase is produced and regulated in the brain. *Clin Res*; 32:74A and 394A, 1984.*
31. Sadur CN, Yost TJ, **Eckel RH**. Glucose is the major determinant of the early response of adipose tissue lipoprotein lipase activity to insulin. *Clin Res;* 32:86A and 407A, 1984.*

32. Berr F, **Eckel RH,** Kern F, Jr. Plasma disappearance of retinol palmitate labeled chylomicrons is independent of enhanced plasma lipolytic activity. *Clin Res*; 32:45A, 1984.*
33. Berr F, **Eckel RH,** Kern F, Jr. Plasma clearance of retinol palmitate labeled chylomicrons is not affected by enhanced plasma lipolytic activity. *Gastroenterology* 1984.
resistance: Elevated fasting (basal), yet diminished sensitivity of response. *Clin Res*1986; 34:543A, 1986.*
34. **Eckel RH**, Awald PD, O'Shea AM, Edwards DP. Heparin treatment of cultured rat adipocytes results in a quantitative and highly purified preparation of lipoprotein lipase. *Clin Res*; 34:543A, 1986.*
35. Kern PA, **Eckel RH**. Effect of glucose on lipoprotein lipase and lipolysis in cultured human adipocytes: Relevance to diabetes. *Clin Res*; 34:547A, 1986.*
36. **Eckel RH,** Yost TJ. Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women: A potential mechanism for resumption of the obese state. *Diabetes*; 35:10A,
37. Sadur CN, Yost TJ, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase is deficient in type II diabetics. *Diabetes,* 33 (Suppl.1):, 623, 1984.
38. Kern PA, Graves D, Baskin J, **Eckel RH**, Van Wyk JJ. Somatomedin-C may be a local regulator of lipoprotein lipase in human adipose tissue. *Clin Res*; 33:62A and 434A, 1985.**
39. **Eckel RH.** Glucose and protein synthesis dependency of the insulin effect on lipoprotein lipase in cultured isolated rat adipocytes. *Clin Res*; 33:102A and 429A, 1985.**
40. **Eckel RH**, Sadur CN, Yost TJ. Deficiency of the insulin, glucose mediated increase in the HDL cholesterol/cholesterol ratio in normolipidemic obese subjects. *Clin Res*; 33:429A, 1985.
41. **Eckel RH**, Sadur CN, Yost TJ. The increase in adipose tissue lipoprotein lipase activity in obese women is luteal phase-dependent. *Int J Obesity* 9:A27, 1985;.*
42. **Eckel RH.** Prasad JM. Impairment of tubulin polymerization increases intracellular lipoprotein lipase activity in cultured rat adipocytes. *Int J Obesity*; 9:A281985.*
43. **Eckel RH**, Sadur CN, Yost TJ. Low-dose insulin increases adipose tissue lipoprotein lipase in normal weight but not obese women. *Clin Res*; 34:58A, 1986.*
44. **Eckel RH**, Awald PD, O'Shea AM, Edwards DP. Lipoprotein lipase is the major protein released by heparin from cultured rat adipocytes. *Clin Res*; 34:57A, 1986.*
45. **Eckel RH**, Sadur CN, Yost TJ. Adipose tissue lipoprotein lipase in obese women, a paradox of insulin. *Clin Res*, 1987.
46. Yost TJ, **Eckel RH**. Fat calories may be preferentially stored in reduced-obese women: A permissive pathway for resumption of the obese state. *Clin Res*; 35:160A and 520A, 1987.*
47. Rule DC, Cook C, Ridgway EC, **Eckel RH**. Lipoprotein lipase may play a role in the regulation of pituitary hormone secretion. *Clin Res*; 35:516A,1987.*
48. Rudolf PM, Horwitz KB, **Eckel RH**. The metabolic effects of progesterone on parametrial adipose tissue must be indirect. *Clin Res*; 35:401A, 1987.
49. Draznin B, Sussman KE, **Eckel RH**. Role of cytosolic free calcium concentration in mediating insulin resistance of obesity and hyperinsulinemia. *Diabetes*; 36:573, 1987.
50. **Eckel RH,** Yost TJ. Increasing pounds off may predict increasing pounds on: Weight loss-dependent adipose tissue lipoprotein lipase responsiveness in reduced-obese women. *Diabetes*; 36:691, 1987.
51. Lewis D, Kao M, Yost TJ, **Eckel RH**, Leitner JW, Sherman N, Sussman KE, Draznin B. Mechanism of glucose- and insulin-induced insulin resistance in human and rat adipocytes. *Clin Res*; 36:155A, 1988.*
52. Berman JN, Yost TJ, **Eckel RH**. Dietary substitution of medium chain triglycerides for long chain triglycerides enhances insulin action. *Clin Res*; 36:148A, 1988.*

53. Coleman-Smith A, Steiner Z, Tonnensen M, Viders D, Moo-Young GA, Chase P, Peters JH, Clark RAF, **Eckel RH**. Dermal capillary basement membrane thickness is increased in Type I diabetics and correlated with the duration of diabetes and diabetic retinopathy. *Clin Res*; 36:491A, 1988.*
54. Awald PD, Gordon DF, Wood WM, Rule DC, Gutierrez-Hartmann A, **Eckel RH**. Insulin-mediated increases in lipoprotein lipase specific mRNA precede increases in lipoprotein lipase activity in cultured rat adipocytes. *Clin Res*; 36:477A, 1988.*
55. Viders D, Tonnensen MG, Steiner Z, Couchman JR, Smith AC, **Eckel RH,** Clark RAF. Thickened blood vessel walls in patients with type I diabetes mellitus consist of glycoproteins conjugated with n-linked mannose-type oligosaccharides. *Clin Res*; 36:380A, 1988.*
56. Christiansen C, **Eckel RH**. Is "sliding scale" insulin the optimal approach to the management of hospitalized diabetics? *Diabetes*; 37:682, 1988.
57. **Eckel RH**. Insulin regulation of lipoprotein lipase in adipose cells: relevance to common metabolic disease states. *The Endocrine Society Abstracts*; 115:12, 1988.*
58. Hanson AS, Chen AY, Berman JN, Yost TJ, Brass EP, **Eckel RH**. Medium chain triglycerides: Implications for their use in the treatment of non-insulin dependent diabetes mellitus. *Clin Res*; 37:526A, 1989.*
59. Farese RV, Yost TJ, Awald PD, **Eckel RH**. The regulation of lipoprotein lipase activity and mRNA by insulin is tissue-specific *Clin Res*; 37:570A, 1989.*
60. Lang CA, Pearson JR, **Eckel RH,** Byyny RL. The effectiveness of cholesterol screening. *Clin Res*; 37:318A, 1989.
61. Bessesen DH, **Eckel RH**. Maintenance of reduced obesity increases adipose tissue but decreases cardiac muscle lipoprotein lipase in the obese Zucker rat. *Int J Obesity*; 13:545, 1989.*
62. Schneider DJ, Arend WP, **Eckel RH**. Gamma interferon decreases human monocyte-derived macrophage lipoprotein lipase activity and mRNA: An effect distinct from that of lipopolysaccharide. *Arteriosclerosis*; 9:762A, 1989.
63. Raynolds MV, Awald PD, **Eckel RH.** Lipoprotein lipase gene expression in cultured adipocytes is regulated by insulin and isoproterenol through different mechanisms. *Circulation* 1989; 80:II-78.*
64. **Eckel RH**. Regional regulation of adipose tissue lipoprotein lipase activity. *The Endocrine Society Abstracts*; 8, 1990.*
65. Regensteiner JG, Mayer EJ, Shetterly SM, **Eckel RH**, Haskell WL, Marshall JA, Baxter J, Hamman RF. Relationship between physical activity and hyperinsulinemia among non-diabetic men and women: The San Luis Valley Study. *Soc for Epid Res Abstracts* 1990.*
66. Mayer EJ, Burchfiel CM, **Eckel RH**, Marshall JA, Hamman RF. The role of insulin in the association of physical activity with HDL cholesterol (HDL-c) and HDL subfractions: The San Luis Valley Diabetes Study. *Soc for Epid Res Abstracts* 1990.*
67. Currie RA, **Eckel RH**. Transcription control of lipoprotein lipase by octamer transcription factor-1. *Arteriosclerosis*; 10:781A, 1990.*
68. Raynolds MV, **Eckel RH.** Isoproterenol-induced decreases in lipoprotein lipase in adipocytes may be mediated by inhibitory effects of cyclic amp on lipoprotein lipase gene expression. *The Endocrine Society Abstracts*; 171,1991.*
69. Neville MC, Jensen DR, Witsell DC, **Eckel RH**. Metabolic Regulation of Mammary Lipoprotein Lipase. *FASEB,* 1991.*
70. Yost TJ, **Eckel RH**. Adipose tissue lipoprotein lipase in two subcutaneous regions: Similarities in enzyme regulation by insulin may mean more metabolically than basal differences. *Clin Res*; 39:277A, 1991.*
71. Bessesen DH, Fox D, Erskine J, **Eckel RH**. In obesity, the metabolism of chylomicron triglyceride fatty acids factors storage over oxidation. *Clin Res*; 39:277A, 1991.*

72. Bessesen DH, Etienne J, Goers J, **Eckel RH**. Lipoprotein lipase mRNA and protein in the brain: discrepancies in colocalization predict a novel regulation. *Clin Res*; 39:330A, 1991.*
73. Currie RA, **Eckel RH** (SPON: Wood WM). Transcriptional Control of Human Lipoprotein Lipase During Differentiation. *The Endocrine Society Abstracts*; 33, 1991.*
74. Raynolds MV, Jensen DR, **Eckel RH**. C2 Skeletal Myoblasts: A New Model for Studying Regulation of Muscle Specific Lipoprotein Lipase Gene Expression. *The Endocrine Society Abstracts*; 475, 1991.*
75. **Eckel RH**, Bessesen DH, Raynolds MV. Tissue-specific Regulation of Lipoprotein Lipase in Adipose Tissue and Muscle. *J Cell Biochem*; 15B:9, 1991.*
76. Raynolds MV, **Eckel RH**. Tissue-specific Regulation of Lipoprotein Lipase Gene Expression by cAMP. *J Cell Biochem*; 15B:32, 1991.*
77. **Eckel RH,** Currie RA. Transcriptional regulation of human lipoprotein lipase: Regulation by octamer transcription Factor-1 and TATA box factor interactions. *Gene Expression During Liver Differentiation and Disease*; 104, 1991.*
78. Raynolds MV, Jensen DR, **Eckel RH**. Divergent effects of cAMP on lipoprotein lipase gene transcription in adipocytes and myocytes. *Arteriosclerosis*; 11:1392a, 1991.*
79. Slaughter JL, **Eckel RH,** Currie RA. Transcriptional regulation of human lipoprotein lipase during differentiation. Cancer cells: Regulation of eucaryotic mRNA transcription.; 191, 1991.*
80. Yost TJ, Rodgers CM, **Eckel RH**. Results of suction lipectomy relate to region-specific changes in adipose tissue lipoprotein lipase. *Clin Res*; 39:104A, 1992.*
81. Erskine JM, Jensen DR, Raynolds MV, **Eckel RH**. Responses of lipoprotein lipase mRNA and activity to high carbohydrate and high fat diets are tissue-specific. *FASEB Journal*; 6:A1938, 1992.*
82. Bagdade J, Ritter M, **Eckel RH**, Rodby R, Thistlewaite R, Fellner S, Dunn F Jr. Insulin therapy pathologically alters cholesteryl ester transfer (CET) in insulin-dependent diabetes mellitus (IDDM). *Clin Res*; 40:208A, 1992. *
83. Raynolds MV, **Eckel RH**. Identification and localization of a muscle-specific CAMP response element in the human lipoprotein lipase promoter. *The Endocrine Society Abstracts*; 572, 1992.*
84. Ferraro RT, Jensen DA, **Eckel RH,** Ravussin E. Relationship between skeletal muscle lipoprotein lipase activity and 24-hr regulatory quotient. *Diabetes*; 41:188A, 1992.*
85. Dunn FL, Thompson MJ, **Eckel RH**, Howard BV. Intraperitoneal insulin therapy in IDDM normalizes very low density lipoprotein composition independent of improved glycemic control. *Diabetes*; 41:26A, 1992.*
86. Raynolds MV, **Eckel RH.** Cyclic AMP-mediated induction of lipoprotein lipase gene transcription in myocytes may be transduced by the nuclear factor cyclic AMP response element binding protein. *Circulation* 86:291, 1992.*
87. Ferraro RT, Jensen DR, **Eckel RH,** Ravussin E. Relationship between skeletal muscle/adipose tissue LPL activity and whole-body substrate oxidation. *Obesity Res*; 1:059, 1993.*
88. Jensen DR, **Eckel RH.** Differences in the regulation of muscle and adipose tissue lipoprotein lipase by short and long-term isoproterenol infusions. *Obesity Res*; 1:075, 1993. *
89. Bessesen DH, Richards CL, **Eckel RH**. Uptake of dietary fat by the central nervous system and pituitary of lean, obese and reduced-obese rats. *Obesity Res*; 1:016, 1993.*
90. Yost TJ, Jensen DR, **Eckel RH**. Divergent responses of skeletal muscle lipoprotein lipase to insulin in obese and lean women: relationship to insulin resistance. *Clin Res*; 41:391A, 1993.
91. Morin CL, Schlaepfer IR, **Eckel RH.** Transcriptional control of lipoprotein lipase in 3T3-L1 adipocytes by tumor necrosis factor-α is mediated by DNA:protein interactions at the proximal promoter. *Circulation* 1993.*

92. Yost TJ, Jensen DR, **Eckel RH**. Sustained weight reduction in obese women decreases skeletal muscle lipoprotein lipase: another metabolic predictor of subsequent weight gain. *Obesity Res*; 1; Suppl 2:77S, 1993.*
93. **Eckel RH**. Tissue specific regulation of lipoprotein lipase: relationship to obesity and insulin resistance. *Obesity Res*; 1 Suppl 2: 66S, 1993.*
94. **Eckel RH**. Lipoprotein lipase and dyslipidemia. *Obesity Res,* 3 Suppl 3:322S, 1995.*
95. Jensen DR, Kosmiski L, Lowell BB, Flier JS, **Eckel RH**. Divergent and altered lipoprotein lipase and hormone-sensitive lipase activities in brown adipose-deficient transgenic mice. *Int J Obesity*; 18; Suppl 2: 4, 1994.*
96. Gnudi L, Jensen DR, Tozzo E, Bliss JL, **Eckel RH**, Kahn BB. Regulation of adipose mass in transgenic mice overexpressing GLUT-4 selectively in adipocytes. *Int J Obesity*; 18; Suppl 2: 81, 1994.*
97. **Eckel RH**. Tissue specific regulation of lipoprotein lipase and nutrient partitioning. *Int J Obesity*; 8; Suppl 2: 41, 1994.*
98. Travers SH, Bloch CA, Hill JO, **Eckel RH**. Gender differences in the relationship between insulin sensitivity and body composition in early pubertal children *Int J Obesity*; 18 Suppl 2: 34, 1994.*
99. Morin CL, Schlaepfer IR, **Eckel, RH**. Tumor necrosis factor-α eliminates binding of NF-Y and an octamer binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. *J Clin Invest*; 95:1684, 1995.*
100. Berning JR, Ratliff KA, Leenders NL, Clem KL, Troup JP, **Eckel RH**. The effects of ingested medium chain triglycerides on muscle glycogen preservation during exercise. *Med Sci Sports Exerc,* 1995.*
101. Morin CL, Sundquist KO, **Eckel RH,** Pagliassotti MJ. A high fat diet (HF) elevates adipose tissue-derived tumor necrosis factor-α (AT-TNF) activity. *Diabetes*; 44; Suppl 1:203A, 1995.*
102. Jensen DR, Morin CL, Schlaepfer IR, Pennington DS, Marcell T, Gutierrez-Hartmann A, **Eckel RH**. Transgenic mice with overexpression of skeletal muscle lipoprotein lipase: divergent effects of differential overexpression on body lipid. *Obesity Res*; 3:361S, 1995.*
103. Travers SH, Labarta JI, Gargosky SE, Rosenfeld RG, **Eckel RH**. Insulin-like growth factor binding protein-1 (IGFBP-1) levels are strongly associated with insulin sensitivity and obesity in early pubertal children. *Obesity Res*; 3; Suppl 3: 403S, 1995.*
104. Yost TJ, Jensen DR, **Eckel RH**. Weight regain following sustained weight reduction is predicted by relative insulin sensitivity. *Obesity Res*; 3; Suppl 3: 367S, 1995.*
105. Jensen DR, Morin CL, Schlaepfer IR, Pennington DS, Marcell T, **Eckel RH**. Transgenic mice with overexpression of skeletal muscle lipoprotein lipase: Divergent effects of differential overexpression of body lipid. *Obesity Res*; 4; Suppl 1: 2S, 1996.*
106. Donahoo WT, Jensen DR, Yost TJ, **Eckel RH**. Tissue specific seasonal variation in lipoprotein lipase in fasted, normal weight humans. *Obesity Res*; 4; Suppl 1: 29S, 1996.*
107. Donahoo WT, Jensen DR, Yost TJ, **Eckel RH**. Isoproterenol and somatostatin decrease plasma leptin in humans. *Obesity Res;* 4; Suppl 1: 39S, 1996.*
108. Schlaepfer IR, Jensen DR, Kosmiski LA, Makovsky NJ, **Eckel RH**. Tissue specific overexpression of hormone sensitive lipase (HSL) in adipose tissue using a cationic liposome-mediated gene transfer: A promising approach for changing body weight and composition. *Obesity Res;* 4; Suppl 1: 50S6, 1996.*
109. Jensen DR, Schlaepfer IR, Pennington DS, Marcell T, Morin CL, Gutierrez-Hartmann A, **Eckel RH.** High fat feeding induced obesity is prevented by skeletal muscle overexpression of lipoprotein lipase in transgenic mice. *Circulation;* 94; Suppl 1:266, 1996.*

110. Donahoo WT, Berg CL, Marcell T, **Eckel RH**. The effect of macronutrient composition and a meal on serum leptin in humans. *J Invest Med*; 45,1:152A, 1997.*
111. Ganong CA, Schlaepfer IR, Marcell T, Jensen DR, **Eckel RH.** Cellular localization of hormone sensitive lipase mRNA in rat cardiac and skeletal muscle. *J Invest Med;* 45;1:106A, 1997.*
112. Makovsky NJ, Schlaepfer IR, **Eckel RH**. Tissue specific overexpression of hormone sensitive lipase in adipose tissue mediated by gene therapy. *J Invest Med*; 45(1):141A, 1997.*
113. Yost TJ, Jensen DR, **Eckel RH**. The effect of dietary macronutrient composition on skeletal muscle lipoprotein lipase activity reflects the oxidative fuel mix. *J Invest Med*; 45(1):105A, 1997.*
114. Regensteiner JG, Bauer TA, Brandenburg SL, Sippel J, Wolfel EE, **Eckel RH**, Reusch JEB, Vogelsong AM, Hiatt WR. Slowed oxygen uptake kinetic responses in women with non-insulin dependent diabetes (NIDDM). *J Invest Med*; 45:215A, 1997.*
115. Davy BM, Seagle HM, Kealey EH, Yost TJ, **Eckel RH,** Hill JO. A comparison of three prediction equations for estimating energy requirements. *J Am Dietetic Assn*; 97 Suppl 9 :A-18, 1997.
116. Morin C, **Eckel RH,** Pagliassotti MJ. Adipose tissue-derived tumor necrosis factor (AT-TNF) activity is related to cell size and glucose uptake. *Diabetes*; 46: Supp 1; 965-965, 1997.*
117. Trouillot TE, **Eckel RH**, McKinley CL, Showalter RB, Yost TJ, Everson GT. The link between., weight loss, gallstones and insulin action: A pathophysiologic study in humans *Hepatology,* 1997.*
118. Trouillot TE, **Eckel RH**, McKinley CL, Showalter RB, Yost TJ, Everson GT. Hepatic and total body insulin sensitivities are disassociated in obese subjects after diet-induced weight loss followed by isocaloric weight maintenance. *Hepatology,* 1997.*
119. McGinnis AR, Jensen DR, Ammon SM, Pennington DS, Schlaepfer IR, **Eckel RH**. Diet and age induced increases in body weight prevented by overexpression of skeletal muscle lipoprotein lipase. *Obesity Res*; 5; Supp l, 25S, 1997.*
120. Yost TJ, Jensen DR, Hill JO, **Eckel RH.** The effects of dietary macronutrient composition on fuel substrate utilization and balance in normal weight humans. *J Invest Med* In Press.*
121. Schlaepfer IR, McGinnis AR, Marcell T, **Eckel RH**. Human lipoprotein lipase (hLPL) is overexpressed in mouse skeletal muscle following direct injection of naked plasmid DNA. *Obesity Res*; 5, Supp 1; 78S, 1997. *
122. Yost TJ, Jensen DR, Hill JO, **Eckel RH**. The effects of dietary macronutrient composition on fuel substrate utilization and balance in normal weight human subjects. *Obesity Res,* 1999; 5, Supp 1; 87S.*
123. Rewers M, Ehrlich J, Jensen L, Seigel R, Barriga K, Garg S, Janowitz W, **Eckel RH**. High prevalence of asymptomatic coronary atherosclerosis detected by electron beam computed tomography in young adults with IDDM. *Diabetes*; 47; Suppl 1: A12, 1998.*
124. Ferreira LDMC-B, Huey PU, Waugh KC, **Eckel RH.** The effect of acute stretozotocin-induced diabetes on rat sciatic nerve lipoprotein lipase expression. *Diabetes*; 48 Suppl 1: A2, 1999.*
125. Poirier P, Marcell T, Schlaepfer I, Owens GC, Waugh KC, **Eckel RH.** A new *in vitro* model for the study of the role of lipoprotein lipase in skeletal muscle metabolism and substrate partitioning. *Circulation,* 1999.
126. Capell WH, Poirier P, DeSouza CA, **Eckel RH**. Lowering triglycerides with fenofibrate improves vascular reactivity; impact of free fatty acids. *Circulation,* 1999.
127. Weil, KM, Shepard TY, **Eckel RH.** A diet high in fat versus carbohydrate increases insulin sensitivity in weight-maintained, reduced severely obese subjects. *Obesity Res,* 7:(1),32S, 1999;.*
128. Kosmiski L, Kuritzkes D, Lichenstein K, Greenberg K, Ehrlich J, **Eckel RH**. An increase in abdominal girth on protease inhibitor therapy is associated with visceral obesity and metabolic disturbances that closely resemble syndrome X. *Obesity Res*;7:(1),126S, 1999.*

129. Smith SJ, Jensen DR, Ammon S, Cases S, **Eckel RH,** Farese RV. Increases in metabolic rate explain the protection from obesity in high fat fed DGAT Knockout mice. *Obesity Res*; 7:(1),128S, 1999.*

130. Donahoo WT, Rothman R, Ammon S, Grunwald G, Davis J, Levin N, **Eckel RH.** Chronic leptin administration alters postprandial lipid metabolism by decreasing postprandial triglyceride excursion and increasing skeletal muscle lipoprotein lipase. *Obesity Res* ,7:(1),28S, 1999.*
131. Ferreira LDMC-B, Jensen DR, Schlaepfer I, Ammon S, **Eckel RH.** Evidence for glucose intolerance in mice overexpressing lipoprotein lipase in skeletal muscle. *Obesity Res*; 7:(1),80S, 1999.*
132. Smith, SJ Cases S, Sande E, Tow B, Yu T, Newland D, Sanan D, Jensen DR, Ammon S, **Eckel RH**, Farese, RV Jr. DGAT Knockout Mice: Resistance and evidence for an alternative tricylglycerol synthesis pathway. AHA Scientific Sessions *Circulation,* Vol 100; 18, I609,1999.
133. Huey PJU, Waugh KC, Marcell T, Ferreira LDMC-B, Schaller K, **Eckel, RH**. The effect of crush injury on lipoprotein lipase expression in rat sciatic nerve. *Soc Neurosci* 1999;25:(Part1),1001.
134. Schlaepfer IR, Jensen DR, **Eckel RH**. Potential Mechanisms for Increased Substrate Oxidation in White Skeletal Muscle of Mice Overexpressing Human Lipoprotein Lipase. *Obesity Res* 8:1;130S,(NAASO) 2000.*
135. Ferreira LDMC-B, Pulawa LK, Schlaepfer IR, Jensen DR and **Eckel RH**. Muscle Specific Overexpression of Lipoprotein Lipase Protects Diabetic Transgenic Mice from Hypertriglyceridemia. *Obesity Res* 8:1; 130S (NAASO) 2000.*
136. Pulawa LK, Ferreira LDMC-B, Jensen DR and **Eckel RH**. The Overexpression of Human Lipoprotein Lipase in Murine Skeletal Muscle Results in Insulin Resistance Obesity Res 8:1 130S (NAASO) 2000.*
137. Sharma V, Jensen DR, Chambon P, **Eckel RH**, Haugen BR. RXR(Gamma) Deficient Mice Have Lower Body Fat , Lower Serum Triglyceride Levels and Increased Skeletal Muscle Lipoprotein Lipase Activity. Endocrine Society Meeting 2001.*
138. Chen HC, Jensen DR, Ferreira LDMC-B, Pulawa L, **Eckel RH**, Farese RV, Farese RV, Jr. Increased Insulin Sensitivity in DGAT-Deficient Mice. Endocrine Society Meeting 2001.*
139. Heine PA, Jensen DR, Tayor JA, Eckel RH, Lubahn DB, Cooke PS. Estrogen Receptor Alpha (ER'a) Regulates the Effect of Estrogen on Metabolic Rate (MR). Endocrine Society Meeting 2001.*
140. Capell WH, Poirier P, Desouza CA, Weil KM, Stauffer BL, **Eckel RH**. Effect of Triglyceride Lowering on Endothelial Dysfunction in Patients with Hypertriglyceridemia. Clinical Research 2001.*
141. Schlaepfer IR, Ramanathan M, James DE and **Eckel RH.** Skeletal Muscle Lipoprotein Lipase-Mediated Resistance to Obesity and Insulin Action Results in Increased Expression of Munc 18c. 2001 The American Diabetes Association 61st Scientific Sessions.*
142. Ferreira LDMCB, Pulawa LK, Schlaepfer IR, Jensen DR and **Eckel RH**. Overexpression of Lipoprotein Lipase in Skeletal Muscle Protects Transgenic Mice from Diabetes-Related Hypertriglyceridemia., The American Diabetes Association 61st Scientific Sessions, 2001.*
143. Snell Bergeon J, Hokanson JE, Ehrlich J, Garg S, Quaife R, **Eckel RH** and Rewers MJ. Coronary Atherosclerosis Progression in Type 1 Diabetes: Importance of Age, Increasing Total and LDL Cholesterol and Pre-existing Disease., The American Diabetes Association 61st Scientific Sessions, 2001.*
144. Hokanson JE, Cheng S, Snell-Bergeon JK, Grow MA, Hung C, Erlich HA, Ehrlich J, **Eckel RH** and Rewers M. The Hepatic Lipase Gene Promoter Polymorphism is associated with Coronary Artery Classification in Type 1 Diabetes, The American Diabetes Association 61st Scientific Sessions, 2001.*

145. Hokanson JE, Kamboh MI, **Eckel RH** and Hamman RF. The hepatic lipase promoter polymorphism is associated with genetic susceptibility to coronary heart disease. 2001
146. Donahoo WT, Melanson EL, Pistone B, Hamilton J and **Eckel RH**. Exercise Following Weight Loss Helps Prevent the Fall in Skeletal Muscle Lipoprotein Lipase: A Potential Mechanism for Maintenance of the Reduced Obese State. NAASO, 2001.*
147. Jensen DR, Pulawa LK, Lerman I, and **Eckel RH**. Transgenic Mice Overexpressing Skeletal Muscle Lipoprotein Lipase Have Reduced Exercise Performance. NAASO, 2001.*
148. Weil KW, Shepard TY, Bell ML, Grunwald GK, Sharp TA, Hill JO, and **Eckel RH.** Carbohydrate balance on a high carbohydrate diet predicts fat gain over 4 years. NAASO, 2001.*
149. Weil KW, Shepard TY, Scherzinger AL, Stamm ER, Ballard R and **Eckel RH**. Modest weight loss in the severely obese improves the upper airway as well as sleep efficiency and oxygenation. NAASO, 2001.*
150. Chen HC, Jensen DR, Ferreira L, Pulawa LK, Standaert ML, Kanoh Y, Sajan MJ, **Eckel RH**, Farese RV and Farese, Jr. RV. Increased Insulin Sensitivity in DGAT-Deficient Mice. Endo 2001.*
151. Sharma V, Jensen DR, Krezel W, Chambon P, **Eckel RH** and Haugen BR. RXR (Gamma) Deficient Mice Have Lower Body Fat, Lower Serum Triglyceride Levels and Increased Skeletal Muscle Lipoprotein Lipase Activity. Endo 2001.*
152. Heine PA, Jensen DR, Taylor JA, Lubahn DB, **Eckel RH** and Cooke PS. Estrogen Receptor Alpha (ERα) Regulates The Effect Of Estrogen On Metabolic Rate (MR). Endo 2001.*
153. Hokanson JE, Snell-Bergeon JK, Dabelea D, **Eckel RH,** Ehrlich J, Rewers M. Visceral Adiposity is Associated with the Presence of Coronary Artery Calcium in Type I Diabetes and Non-Diabetic Subjects. Endo 2001.
154. Morris AM, Donahoo WT and **Eckel RH.** Plasma Adiponectin Concentrations Are Not Acutely Affected By Diet Composition. AHA Scientific Sessions 2002. Submitted.
155. Hernandez TL, Weil KM, Shepard TY, Bell ML, Grunwald GK, Francis CC, Sharp TA, Hill JO, and **Eckel RH.** The Response to High Carbohydrate Feeding May Predict Obesity *Circulation*, 106;19, Supp. II, 468. AHA Scientific Sessions 2002.*
156. Jensen DR, Sharma V, Pulawa LK, Morris AM, Krezel W, Chambon P, **Eckel RH,** and Haugen B. RXRγ Deficient Mice Have Lower Body Fat and Higher Skeletal Muscle Lipoprotein Lipase Activity When Fed A High Fat Diet. 106:19 Supp. II, 122. AHA Scientific Sessions.*
157. Pulawa LK, Schlaepfer IR, Ferreira LDMC-B, and **Eckel RH**. Effects of diabetes and lipoprotein lipase on munc18c gene expression in skeletal muscle. AHA Scientific Sessions. Submitted.
158. Emily L, Laposky A, Horton T, Easton A, Jensen DR, **Eckel RH**, Olson S, Turek F, Bass J. Diet Induced Obesity in Clock Mutant Mice: Circadian Regulation of Sleep, Food Intake and Metabolism. Keystone Symposia 2002. Submitted.
159. Snell-Bergeon J, Hokanson, JE, **Eckel RH**, Ehrlich J, Ogden LG, Rewers M. Abdominal Fat by CT Is Not Superior to Anthropometric Measures As A Predictor Of Subclinical Atherosclerosis. American Heart Association Epidemiology Meetings 2002. Submitted.
160. Jensen DR, Sharma V, Pulawa LK, Morris AM, Krezel W, Chambon P, **Eckel RH** and Haugen BR. RXRγ Deficient Mice Have Lower Body Fat and Higher Skeletal Muscle Lipoprotein Lipase Activity When Fed a High Fat Diet. American Heart Association Scientific Sessions 2002.*
159. Hokanson, JE, Cheng S, Snell-Bergeon JK, Erlich HA, Ehrlich J, **Eckel RH**, and Rewers M. The Heptic Lipase Promoter Polymorphism Predicts Progression of Coronary Calcium Type 1 Diabetes American Diabetes Association, Submitted.
160. Chen MY, Bhola R, Snell-Bergeon JK, Kinney GL, Fisher AD, **Eckel RH**, Ehrlich J, Rewers M and Quaife RA. Myocardial Perfusion Reserve in Patients with Longstanding Type 1 Diabetes Mellitus and Coronary Artery Calcification. American Diabetes Association, Submitted.

161. Poirier, P, Hernandez TL, Weil KM, Shepard TJ and **Eckel RH**. The Impact of Diet-Induced Weight Loss on Cardiac Autonomic Nervous System and Arrythmias in Subjects with Severe Obesity. American Diabetes Association, Submitted.
162. Hernandez TL, Weil KM, Shepard TY, Bell, ML, Grunwald GK, Francis CC, Sharp TA, Hill JO, and **Eckel RH**. The Response to High Carbohydrate Feeding During Short-Term Inactivity Predicts Changes in Fat Mass. Baltimore Clinical Research, 2003, Submitted.
163. Dietary and Endogenous Fat Oxidations are Similar for Mixed Meal High-Fat and Low-Fat Maintenance Treatments: A Potential Recipe for Long-Term Obesity Development NAASO
164. Carbohydrate overfeeding decreases endogenous but not ingested fat oxidation

Revised 09-03 rc.

# CURRICULUM VITAE

| | | |
|---|---|---|
| **Name:** | Ernst John Schaefer, M.D. | 11/21/03 |
| **Date of Birth:** | November 18, 1945 | |
| **Citizenship:** | United States | |
| **Marital Status:** | Married, three children | |
| **Current Positions:** | Professor of Medicine<br>Tufts University School of Medicine<br>Professor of Nutrition<br>Tufts University School of Nutrition Science and Policy<br>Chief, Lipid Metabolism Laboratory, and Senior Scientist,<br>Jean Mayer USDA Human Nutrition Research Center<br>on Aging at Tufts University<br>Director, Lipid and Heart Disease Prevention Clinic<br>New England Medical Center<br>Boston, MA | |
| **Present Address:** | Lipid Metabolism Laboratory<br>Jean Mayer USDA Human Nutrition Research Center<br>on Aging at Tufts University<br>711 Washington Street<br>Boston, MA 02111<br>(617) 556-3100 - phone; email: eschaefer@hnrc.tufts.edu<br>(617) 556-3103 - fax; 781-258-1454 (cell) | |
| **Education:** | 1968 - B.A., Harvard University, Cambridge, MA, (biology)<br>1970 - B.M.S., Dartmouth Medical School, Hanover, NH.<br>1972 - M.D., Mount Sinai School of Medicine, New York, NY. | |
| **Board Certification:** | American Board of Medicine<br>American Board of Internal Medicine | |

**Brief Summary:** Dr. Schaefer received his B.A. from Harvard University, his B.M.S. from Dartmouth Medical School, and his M.D. from Mt. Sinai School of Medicine; he did his medical residency at Mt. Sinai Hospital, New York, and an endocrinology fellowship at the National Institutes of Health, where he also was a senior investigator. Since 1982 he has been at Tufts University where he is currently a Professor of Medicine at Tufts University School of Medicine, Director of the Lipid and Heart Disease Prevention Program at New England Medical Center, and Senior Scientist and Chief of the Lipid Metabolism Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He was the recipient of the J.D. Lane Award of the U.S. Public Health Service (1981), the Irvine H. Page Arteriosclerosis Research Award from the American Heart Association (1981), the Saul Horowitz Jr. Research Award, Mt. Sinai School of Medicine (1989), the Oliver Smith Award of New England Medical Center for Patient Care (1999,2001), the E.V. McCollum Research Award of the American Society for Clinical Nutrition (2000), and a Distinguished Faculty Award from Tufts University (2001). Since 1997 he has been a member of Who's Who in America. He is an author or co-author of over 400 publications and served on the first and second adult treatment panels of the National Cholesterol Education Program of the National Institutes of Health, on the Nutrition and Metabolism Study Section of the NIH, and the Nutrition Committee of the American Heart Association. Dr. Schaefer is the U.S. editor of the journal Atherosclerosis. His research focuses on the nutritional and genetic regulation of plasma lipoproteins, and their relationship to coronary heart disease risk, and on the dietary and drug treatment of lipid disorders, as well as on optimal diets for the prevention of heart disease in the elderly.

| | |
|---|---|
| **Employment:** 1971 | Research Rotation on Lipoproteins, Albert Einstein College of Medicine,<br>(Drs. Paul Roheim, Howard Eder). |
| 1972-1975 | The Mount Sinai Hospital, New York, New York, Medical Internship,<br>First and Second Year Medical Residency (Dr. Solomon Berson, Dr. Fenton Schaffner, Dr. Richard Gorlin) |
| 11/74-4/75 | Guest Investigator, Rockefeller University, New York, New York;<br>(on elective time from Mt. Sinai); (Dr. Paul Schreibman). |
| 1975-1978 | Staff Associate, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; (Dr. Robert Levy, Dr. Bryan Brewer). |

| | |
|---|---|
| 1978-1980 | Endocrinology Fellow, National Institutes of Health, Bethesda, MD. (Dr. Bruce Weintraub). |
| 1980-1982 | Senior Investigator, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. (Dr. Bryan Brewer). |
| 1982- | Chief, Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA. (Drs. Hamish Munro, Harold Sandstead, Irwin Rosenberg, Robert Russell). |
| 1982- | Director, Lipid Clinic and Lipid Division, New England Medical Center, Boston, MA |
| 1982-1989 | Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA |
| 1982-1989 | Associate Professor of Nutrition, School of Nutrition, Tufts University, Medford, MA |
| 1989- | Professor of Nutrition, School of Nutrition Science and Policy, Tufts University Medford, MA |
| 1989- | Professor of Medicine, Tufts University School of Medicine, Boston, MA |

**Military Service**:1975-82: Surgeon, Commissioned Corps, U.S. Public Health Service.

**Societies**:
Fellow, American Heart Association, Council on Arteriosclerosis
Fellow, American Federation of Clinical Research
Fellow, American Society of Clinical Investigation
Fellow, American Institute of Nutrition
Fellow, American College of Physicians
Member, American Association for the Advancement of Science

**Honors:**
B.A., cum laude, Harvard University, 1968.
Mosby Book Award for Excellence in Clinical Medicine, Mount Sinai School of Medicine, Class of 1972.
J. D. Lane Investigator Award, U.S. Public Health Service Professional Association (shared with D.W. Anderson, Ph.D. and H. Bryan Brewer, Jr., M.D.), 1981.
Irvine H. Page Arteriosclerosis Research Award for Young Investigators, American Heart Association Council on Arteriosclerosis, 1981.
Saul Horowitz Jr. Memorial Research Award, Mt. Sinai School of Medicine, NY, 1989.
Outstanding Publication of the Year, 1992, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (shared with J.S. Cohn).
Oliver Smith Award for excellence, compassion, and service to patients at New England Medical Center, 1999, 2001.
E.V. McCollum Award, American Society for Clinical Nutrition, 2000.
Distinguished Faculty Award, Tufts University, 2001.

**Special Scientific Recognition, Professional Activities**:
USA-USSR First Lipoprotein Symposium and Scientific Exchange, Leningrad, 1981.
David Rubinstein Lecture, Canadian Lipoprotein Club, Quebec, 1982.
Seminar in Medicine, Beth Israel Hospital, Boston, 1983.
Reviewer, NHLBI Program Projects, 1982-present.
Member, American Heart Association, Council on Arteriosclerosis, Credentials Committee, 1984-1986.
Member, American Heart Association, Lipoprotein Metabolism Grant Review Committee, 1983-1987.
Member, American Heart Association, Council on Arteriosclerosis, Program Committee, 1985-1987.
Member, Parent Committee for Evaluation of Specialized Centers of Research on Arteriosclerosis, National Heart, Lung, and Blood Institute, 1985-1986.
Member, Parent Committee for Evaluation of National Demonstration and Education Programs in Arteriosclerosis, NHLBI, 1986.
Member, Editorial Board, Circulation, 1983-1986.
Member, Editorial Board, Metabolism, 1985-1992.
Member, Editorial Board, Journal of Nutrition, 1987-1992.
Member, National Cholesterol Education Program, Expert Panel on Adult Detection and Treatment (ATP I), National Heart, Lung and Blood Institute, National Institutes of Health, 1986-1987.
Member, Nutrition Study Section, National Institutes of Health, 1986-1990.
USA-USSR Second Lipoprotein Symposium and Scientific Exchange, Bethesda, MD, 1986.
Member, Policy Board, Atherosclerosis Risk in Communities, National Heart, Lung and Blood Institute, 1986-present.
Member, Cholesterol Education Program, American Heart Association, Massachusetts Affiliate, 1988-1996; Chairman 1990-1991.
Member, American Heart Association Nutrition Committee, 1989-1992;

Chairman, Program Committee 1989-1991.
Member, National Cholesterol Education Program, Second Expert Panel on Adult Detection and Treatment (ATP II), National Heart Lung and Blood Institute, National Institutes of Health, 1991-1992.
Member, Metabolism Study Section, National Institutes of Health, 1995-2000; Chairman 1998-2000.
U.S. Editor and Reviews Editor, *Atherosclerosis*, 1997 - present.
Member, US-Italy Scientific Exchange, 2002.

**Major Current Research Support**:

1. Tufts University Contract with the U.S. Department of Agriculture at the Human Nutrition Research Center on Aging at Tufts University, Lipoproteins, Nutrition, and Aging Contract 53-3K06-5-10 (10/82-present; E.J. Schaefer, M.D., Principal Investigator).
2. National Institutes of Health, Caloric Density, Obesity, and Cardiovascular Risk Grant R01HL-57981; (8/1/99 - 7/30/04, E.J. Schaefer, M.D., Principal Investigator).
3. National Institutes of Health, Human Metabolic and Genetic Core Laboratory, Tufts-New England Medical Center, Boston Obesity Nutrition Research Center, Center Grant with Boston University, Harvard School of Public Health, and Beth Israel Deaconess Medical Center, Harvard Medical School, (7/1/08 – 6/30/08; E.J. Schaefer, M.D., Core Laboratory Director, B. Corkey, Principal Investigator).
4. Veterans Affairs Contract Central Laboratory for Diabetes Intervention Study, (9/1/01 – 8/30/07, E.J. Schaefer, Principal Investigator).
5. National Institutes of Health, HDL Subspecies and Coronary Heart Disease, (4/1/00 – 4/30/03, B.F. Asztalos, Ph.D., Principal Investigator).
6. National Institutes of Health, Hormone Replacement, Inflammation, and Coronary Artery Disease, (11/1/03 – 10/30/06, S. Lamon-Fava, M.D., Ph.D., Principal Investigator).
7. National Institutes of Health R01HL-54727, Dietary Fat, Plasma Lipids and other CHD Risk Factors (5/96- present, A.H. Lichtenstein, D.Sc., Principal Investigator).
8. National Institutes of Health R01HL-54776, Gene/diet effects on plasma lipoprotein levels (10/96-present, J.M. Ordovas, Ph.D., Principal Investigator).
9. National Institutes of Health, Markers of Cholesterol Metabolism and Heart Disease, (11/1/03 – 10/30/06, A.H. Lichtenstein, D.Sc., Principal Investigator).

**Research Interests**:

The nutritional and genetic regulation of plasma lipoproteins, the relationship of lipoproteins to atherosclerosis, and the dietary and drug treatment of lipid disorders, and the development of optimal diets for the prevention of heart disease in the elderly.

**Significant Original Research Accomplishments**

1. Documentation of transfer of chylomicron apoA-I and apoA-II to plasma HDL and its recirculation in vivo and in vitro (references 4, 38, 322).
2. Documentation of metabolic and genetic defect studies in Tangier disease, a form of genetic HDL deficiency (references 6,15 19, 24, 36, 54, 66, 221, 348, 364, 381, 369).
3. Description of first kindred in which plasma apoA-I was lacking, associated with marked HDL deficiency and premature atherosclerosis and delineation of molecular defect (references 30, 66, 79, 137).
4. Description of first kindred in which plasma apoE was lacking, associated with marked accumulation of chylomicron remnants and atherosclerosis, delineation of molecular defect (references 28, 82, 90).
5. Documentation that apoA-I fractional catabolism is a major determinant of HDL cholesterol and apoA-I plasma levels, and that apoA-I catabolism is enhanced in the setting of hypertriglyceridemia (references 6, 33, 42, 86, 332).
6. Documentation that females produce more apoA-I than do males, and that estrogen administration increases apoA-I production (references 33, 52, 293).
7. Documentation that restriction fragment length polymorphisms within or adjacent to the apoA-I, C-III, A-IV, apoB and apoA-II genes are not useful markers for coronary heart disease risk (references 83, 119, 120, 152, 161, 179).
8. Documentation that an intestinal cell line ($CaCo_2$) synthesizes apolipoproteins and lipoproteins and can be utilized for studies on nutritional effects of lipoprotein production in vitro (references 94, 109, 197).
9. Development of methodology to carry out population studies (with the Framingham Heart Study) to assess normal ranges and the utility of apolipoproteins, lipoproteins and their isoforms and genotypes, fatty acids, and lipoprotein subspecies as biochemical markers of premature coronary artery disease (references 95, 96, 101, 102, 195, 212, 213, 214, 216, 219, 220, 224, 227, 229, 233, 238, 240, 252, 259-265, 267, 268, 270, 272, 273, 274, 275, 281, 286, 287, 290, 297).
10. Precise studies documenting postprandial alterations in plasma lipoproteins and fat soluble vitamins in the young and the elderly (references 112, 115, 123, 131, 135, 144, 146, 149, 202, 394).
11. Documentation that cells can make HDL following apoA-I gene transfection (reference 97).
12. Research on the diagnosis and management of lipid disorders (references 10, 13, 15, 17-19, 24, 26, 27, 53, 58, 64, 65, 67, 69, 74, 77, 84, 85, 89, 91-93, 99, 106, 108, 124, 126, 140-143, 154, 156, 168, 169, 175, 189, 190, 194, 199, 204, 244, 250, 251, 252, 253, 255, 270, 271, 280, 304, 307).
13. Development of stable istope methods to study the effects of diet and aging on cholesterol and apolipoprotein kinetics in the constantly fed state (references 144, 155, 180, 186, 217, 218, 249, 278, 279, 283, 284, 293, 295, 299, 302).
14. Delineation of lipoprotein abnormalities and familial lipoprotein disorders and other disorders associated with premature coronary artery disease (references 62, 63, 65, 66, 71, 75, 83, 91, 92, 113, 114, 117, 118, 154, 162, 163, 171, 173, 178, 184, 190, 198, 209, 213, 214, 219, 220, 224, 235, 237, 238, 244, 264, 307).
15. Effects of estrogen replacement on plasma lipoproteins in elderly women (references 116, 127, 139, 153, 175, 188).
16. Definitive studies on factors (mainly triglyceride levels) affecting LDL particle size and documentation that LDL size is not an independent risk factor for coronary heart disease (references 103, 110, 127, 138, 165, 178 191, 192, 265).
17. Documentation of the effects of dietary fat saturation and dietary cholesterol as well as antioxidants and lovastatin on plasma lipoprotein metabolism and hepatic and intestinal apolipoprotein and LDL receptor mRNA levels and diet-induced aortic foam cell formation in monkeys and hamsters (references 147, 174, 182, 218, 222, 231, 241, 242, 243, 247, 256, 291, 298).
18. Documentation of the effects of dietary fats and cholesterol on plasma lipoprotein composition, metabolism, and immune status in humans (references 17, 26, 112, 115, 128, 144, 165, 181, 193, 196, 210, 211, 217, 218, 223, 228-230, 234, 256, 258, 259, 276, 282, 285, 288, 294, 301, 305, 306, 402).
19. Documentation that specific common mutations within the apoE gene and the apoA-IV gene affect the LDL cholesterol lowering response to dietary saturated fat and cholesterol restriction and HMG CoA reductase inhibitors. (references 223, 229, 244, 255, 276, 294, 389).
20. Documentation of the efficacy of various National Cholesterol Education Program Step 2 diets and variability in response in LDL cholesterol lowering (references 201, 247, 250, 251, 256, 257, 258, 276).
21. Documentation that ad libitum diets restricted in fat (15% of calories) promote weight loss and LDL cholesterol lowering (230, 252).
22. Development and evaluation of methods to directly measure serum Lp(a), LDL, and remnant lipoprotein cholesterol levels (216, 241, 297, 405).
23. Documentation of the effect of fat feeding on human intestinal apoB mRNA levels and editing (234).

**BIBLIOGRAPHY** * invited reviews


1. Levy RI, Blum CB, Schaefer EJ: The composition, structure and metabolism of high density lipoproteins. In Greten, H. (ed.),

*Lipoprotein Metabolism,* Berlin, Springer-Verlag, p. 56-64, 1976.*

2. Schaefer EJ, Hughes JR: Socioeconomic factors and maternal and child health care. *Medical Care*, 14:535-543, 1976.

3. Gordon M, Schaefer EJ, Finkel M: Treatment of protein losing gastropathy with atropine. *Am J Gastroenterol.* 66:535-539, 1976.

4. Schaefer EJ, Jenkins LL, Brewer HB Jr: Human chylomicron apolipoprotein metabolism. *Biochem. Biophys. Res. Commun.* 80:405-412, 1978.

5. Schaefer EJ, Eisenberg S, Levy RI: Lipoprotein apolipoprotein metabolism. *J. Lipid Res.* 19:667-687, 1978.*

6. Schaefer EJ, Blum CB, Levy RI, Jenkins LL, Alaupovic P, Foster DM, Brewer HB Jr: Metabolism of high density lipoprotein apolipoproteins in Tangier disease. *N. Eng. J. Med.* 299:905-910, 1978.

7. Schaefer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC: Plasma-triglycerides in regulation of HDL-cholesterol levels. *Lancet* 2:391-393, 1978.

8. Schaefer EJ, Foster DM, Jenkins LL, Lindgren FT, Berman M, Levy RI, Brewer HB Jr: The composition and metabolism of high density lipoprotein subfractions. *Lipids* 14:511-521, 1979.

9. Schaefer EJ, Levy RI: Composition and metabolism of high density lipoproteins. In *Lipoprotein Metabolism*, Eisenberg, S. (ed.), Prog. Biochem. Pharmacology. S. Karger, Basel. Vol. 15, pp. 186-201, 1979.*

10. Chu FC, Kuwabara T, Cogan PG, Schaefer EJ, Brewer HB Jr: Ocular manifestations of familial high density lipoprotein deficiency (Tangier disease). *Arch. Opthalmol.* 97:1926-1928, 1979.

11. Brewer HB Jr, Schaefer EJ, Osborne JC Jr, Zech, LA: High density lipoproteins: an overview. In *Report on the High Density Lipoprotein Workshop*, Lippel, K. (ed.), U.S. DHEW NIH Publ. 79-1661, pp. 29-41, 1979.*

12. Brewer HB Jr, Schaefer EJ, Zech LA, Osborne JC JR: Human plasma lipoproteins: structure, function, and metabolism. In *Lipoproteins and Coronary Heart Disease.* (ed.) H. Greten, P.O. Lang, G. Schettler, Verlag G. Witzstrock, pp. 7-16, 1979.*

13. Reinertson JE, Schaefer EJ, Brewer HB Jr, Moutsopoulos H: Sicca syndrome in type V hyperlipoproteinemia. *Arthritis and Rheumatism* 23:114-118, 1980.

14. Brewer HB Jr, Schaefer EJ, Zech LA, Bronzert TJ: Tangier disease. In *Atherosclerosis V, Proceedings of the 4th International Symposium.* B. Schettler, A. Gotto, Jr. (eds.), Springer Verlag, pp. 680-683, 1980.*

15. Schaefer EJ, Zech LA, Schwartz DS, Brewer HB Jr: Coronary heart disease prevalence and other clinical features in familial high density lipoprotein deficiency (Tangier disease). *Ann. Int. Med.* 93:261-266, 1980.

16. Nakaya Y, Schaefer EJ, Brewer HB Jr: Activation of human post heparin lipoprotein lipase by apolipoprotein H (B-2 glycoprotein 1). *Biochem. Biophys. Res. Comm.*, 95:1165-1172, 1980.

17. Ernst ND, Fisher M, Bowden P, Schaefer EJ, Levy RI: Changes in lipids and lipoproteins resulting from a modified fat diet. *Lancet* 2:111-113, 1980.

18. Lipson LC, Bonow RO, Schaefer EJ, Brewer HB Jr, Lindgren FT: Effect of exercise conditioning on plasma high density lipoproteins (HDL) and other lipoproteins. *Atherosclerosis* 37:529-538, 1980.

19. Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TJ, Rubalcaba EA, Brewer HB Jr: Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. *J. Lipid Res.* 22:217-226, 1981.

20. Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr: Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. *Science* 211:584-586, 1981.

21. Anderson DW, Schaefer EJ, Bronzert TJ, Lindgren FT, Forte T, Starzl TB, Niblack GD, Zech LA, Brewer HB Jr: Transport of apolipoprotein A-I and A-II by human thoracic duct lymph. *J. Clin. Invest.* 67:857-866, 1981.

22. Papadopoulos NM, Schaefer EJ, Anderson DW: High density lipoprotein heterogeneity demonstrated by electrophoresis. *Clin. Chem.* 27:197-198, 1981 (letter).

23. Berman MD, Ishak KG, Schaefer EJ, Barnes S, Jones EA: Syndromatic hepatic ductular hypoplasia (arteriohepatic dysplasia): a clinopathologic study of three patients. *Dig. Dis. Sci.* 26:485-497, 1981.

24. Alaupovic P, Schaefer EJ, McConathy WJ, Fesmire JD, Brewer HB Jr: Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). *Metabolism* 30:805-809, 1981.

25. Jahn C, Osborne JC Jr, Schaefer EJ, Brewer HB Jr: In vitro activation of the enzymic activity of hepatic lipase by A-II *FEBS Lett.* 131:366-368, 1981.

26. Schaefer EJ, Levy RI, Ernst ND, Van Sant FD, Brewer HB Jr: The effect of low cholesterol, high polyunsaturated fat, and low fat diets on plasma lipid and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects. *Am. J. Clin. Nutr.* 34:1758-1763, 1981.

27. Corash L, Anderson J, Poindexter B, Schaefer EJ: Platelet function and survival in patients with severe hypercholesterolemia. *Arteriosclerosis* 1:443-448, 1981.

28. Ghiselli G, Schaefer EJ, Gascon P, Brewer HB Jr: Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. *Science* 214:1239-1241, 1981.

29. Papadapoulos NM, Schaefer EJ, Anderson DW. Demonstration of heterogeneity in high density lipoprotein subfraction (letter). *Clin. Chem.* 27:197-198, 1981.

30. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr: Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary artery disease. *Arteriosclerosis* 2:16-26, 1982.

31. Kay LL, Ronan R, Schaefer EJ, Brewer HB Jr: Tangier disease: a structural defect in apolipoprotein A-I. *Proc. Natl. Acad. Sci.* U.S.A. 79:2485-2488, 1982.

32. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK: Plasma lipids in leukemia and lymphoma. *Am. J. Med.* 72:775-782, 1982.

33. Schaefer EJ, Zech LA, Jenkins LL, Aamodt RA, Bronzert TJ, Rubalcaba EA, Lindgren FT, Brewer HB Jr: Human apolipoprotein A-I and A-II metabolism. *J. Lipid Res.* 23:850-862, 1982.

34. Morrow J, Schaefer EJ, Huston DP, Rosen SW: The POEMS syndrome: studies in a patient with IgG kappa monoclonal gammapathy but no polyneuropathy. *Arch. Int. Med.* 142:1231-1234, 1982.

35. Ghiselli G, Schaefer EJ, Zech LA, Gregg RE, Brewer HB Jr: Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. *J. Clin. Invest.* 70:474-477, 1982.

36. Schaefer EJ, Kay L, Zech LA, Lindgren FT, Brewer HB Jr: Tangier disease: high density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-I (apoA-I Tangier). *J. Clin. Invest.* 70:934-945, 1982.

37. Ghiselli G, Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr: Phenotype study of apolipoprotein E isoforms in hyperlipoproteinemic patients. *Lancet* 2:455-457, 1982.

38. Schaefer EJ, Wetzel MG, Bengtsson G, Scow RO, Brewer HB Jr, Olivercrona T: Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. *J. Lipid Res.* 23:1259-1273, 1982.

39. Brewer HB Jr, Schaefer EJ, Osborne JC, Zech LA: Recent advances in the structure, function, and metabolism of plasma

lipoproteins. In *Lipoproteins and Aging*, H. Kaffarnik (ed.), Springer Verlag p1-21, 1982.*

40. Schaefer EJ, Zech LA, Gregg RE, Brewer HB Jr: The metabolism of high density lipoproteins. USA-USSR First Lipoprotein Symposium. *NIH Publication* 83-1966:105-122, 1983.*

41. Jahn CE, Osborne JC, Schaefer EJ, Brewer HB Jr: Apo A-II specific activation of hepatic lipase enzymic activity: identification of a major HDL apoprotein as the activating plasma component in vitro. *European J. Biochem.* 131:25-29, 1983.

42. Zech LA, Schaefer EJ, Jenkins LL, Rubalcaba EA, Bronzert TJ, Aamodt RL, Brewer HB Jr: Metabolism of human apolipoproteins A-I and A-II: compartmental models. *J. Lipid Res.* 24:60-71, 1983.

43. Schaefer EJ: Dietary and drug treatment. pp. 633-637. In Brewer, H.B. Jr., moderator, Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology and treatment. *Ann. Int. Med.* 98(1):623-640, 1983.*

44. Ghiselli G, Schaefer EJ, Light JA, Brewer HB Jr: Apolipoprotein A-I isoforms in human lymph: effect of fat absorption. *J. Lipid Res.* 24:731-736, 1983.

45. Schaefer EJ: High density lipoproteins in health and disease. In Glueck, C.J. *Perspectives in Lipid Disorders.* McGraw-Hill, 1:4-9, 1983.*

46. Schaefer EJ: Disorders of lipoprotein metabolism associated with apolipoprotein deficiencies. Proceedings of the Workshop on Apolipoprotein Quantitation. *NIH Publication* 83-1266:54-70, 1983.*

47. Osborne JC, Brewer HB Jr, Bronzert TJ, Schaefer EJ, Tate RL: Molecular properties of plasma apolipoproteins. Proceedings of the Workshop on Apolipoprotein Quantitation. *NIH Publication* 83-1266:179-199, 1983.*

48. Schaefer EJ, Levy RI: The role of the liver in hyperlipoproteinemia. In *Liver in Metabolic Diseases.* L. Bianchi, W. Gerok, L. Landmann, K. Sickinger, G.A. Stalder, (eds.) MTP Press Limited. pp. 41-47, 1983.*

49. White RW, Schaefer EJ, Papadopoulos NM: The effect of growth hormone administration on lipids and lipoproteins in growth hormone-deficient patients. *Proc. Soc. Exp. Biol. Med.* 173:63-67, 1983.

50. Sweet JB, Callihan MD, Schaefer EJ, Tarpley TM: Tangier disease with oral abnormalities. *Internat. J. of Oral Surgery* 12:110-114, 1983.

51. Schaefer EJ, Woo R, Kibata M, Bjornsen L, Schreibman T: The mobilization of triglyceride but not cholesterol or tocopherol from human adipocytes during weight reduction. *Am. J. Clin. Nutr.* 37:749-754, 1983.

52. Schaefer EJ, Foster DA, Zech LA, Brewer HB Jr, Levy RI: The effect of estrogen administration on plasma lipoprotein metabolism in premenopausal females. *J. Clin. Endocr. Metab.* 57:262-270, 1983.

53. Meng MS, Gregg RE, Schaefer EJ, Hoeg JM, Brewer HB Jr: Presence of two forms of apolipoprotein B in patients with dyslipoproteinemia. *J. Lipid Res.* 24:803-809, 1983.

54. Schaefer EJ, Triche TJ, Zech LA, Stein E, Kemeny MM, Brennan MF, Brewer HB Jr: Massive omental reticuloendothelial cell lipid uptake in Tangier disease following splenectomy. *Am. J. Med.* 75:521-526, 1983.

55. Starzl TE, Chase HP, Ahrens EH, MacNamara DJ, Bilheimer DW, Schaefer EJ, Rey J, Porter KA Porter, Stein E, Francaville A, Benson LN: Portacaval shunt in patients with familial hypercholesterolemia. *Ann. Surgery* 198:273-283, 1983.

56. Zech LA, Schaefer EJ, Osborne JO, Aamodt RL, Brewer HB Jr: High density lipoprotein metabolism. In *Pathophysiology of Plasma Proteins*, (Mariani G., ed.) pp. 333-356, MacMillan, New York, 1983.*

57. Malinow MR, Brown BG, Wissler RW, Stein O, Stein Y, Schwartz SM, Schonfeld G, Schaefer EJ, Thompson GR. Atherosclerosis, regression, arterial wall cell interactions, and atherogenic lipoproteins. *Arteriosclerosis* 3:627-630, 1983.*

58. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK. Fluorescence polarization as a parameter of plasma lipids in patients with hematologic malignancies. *Leuk. Res.* 7:647-654, 1983.

59. Fleischmajer R, Schaefer EJ, Gal AE, Pentchev PG, Tint GS: Normolipemic subcutaneous xanthomatosis. *Am. J. Med.* 75:1065-1070, 1983.

60. Osborne JO, Schaefer EJ, Lee N, Zech L: Molecular properties of radioiodinated apolipoprotein A-I. *J. Biol. Chem.* 259:347-353, 1984.

61. Bieri JG, Hoeg JM, Schaefer EJ, Zech LA, Brewer HB Jr: Vitamin A and vitamin E replacement in abetalipoproteinemia. *Ann. Intern. Med.* 100:235-239, 1984.

62. Schaefer EJ: Premature coronary artery disease: familial lipoprotein disorders entities, mechanism, and recognition. *Primary Cardiology* 10(4):151-180, 1984.*

63. Schaefer EJ: Premature coronary artery disease: familial lipoprotein disorders. Therapy: medical and surgical. *Primary Cardiology* 10(5):71-78, 1984.*

64. Hoeg JM, Demosky SJ, Schaefer EJ, Starzl TE, Brewer HB Jr: Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects. *J. Clin. Invest.* 73:429-436, 1984.

65. Sprecher DS, Schaefer EJ, Kent K, Gregg RE, Zech LA, Hoeg JM, McManus B, Roberts D, Brewer HB Jr: Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. *Am. J. Cardiol.* 54:20-30, 1984.

66. Schaefer EJ: The clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. *Arteriosclerosis* 4:303-322, 1984.*

67. Newman RP, Schaefer EJ, Thomas CB, Oldfield E: Abetalipoproteinemia and metastatic spinal cord glioblastoma. *Arch. Neurol.* 41:554-556, 1984.

68. Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr: Apolipoprotein E metabolism in normolipoproteinemic human subjects. *J. Lipid Res.* 25:1167-1176, 1984.

69. Cogan DG, Rodrigues M, Chu FC, Schaefer EJ: Ocular clinico-pathology in abetalipoproteinemia. *Arch. Opthal.* 91:991-998, 1984.

70. Ginns EI, Barranger JA, McClean SW, Sliva C, Young R, Schaefer EJ, Goodman SI, McCabe RB. A juvenile form of glycerol kinase deficiency with episodic vomiting, acidemia, and stupor. *J. Pediatrics* 5:736-739, 1984.

71. Schaefer EJ, Levy RI: *Disorders of lipid transport. Current Diagnosis,* R. Conn (ed.) W.B. Saunders Co., 7th Edition, p. 762-770, 1985.*

72. Hoeg JM, Demosky SJ, Gregg RE, Schaefer EJ, Brewer HB Jr: Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans. *Science* 227:759-761, 1985.

73. Bojanovski D, Gregg RE, Ghiselli G, Schaefer EJ, Zech LA, Light JA, Brewer HB Jr: Human apolipoprotein A-I isoprotein metabolism: proapoA-I conversion to mature apoA-I. *J. Lipid Res.* 26:185-193, 1985.

74. Hoeg JM, Schaefer EJ, Romano CA, Bou E, Pikus AM, Zech LA, Bailey KR, Gregg RE, Wilson PWF, Sprecher DL, Grimes AM, Sebring NG, Ayres EJ, Jahn CE, Brewer HB Jr: Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. *Clin. Pharm. and Therapeutics* 36:555-565, 1985.

75. Sprecher DL, Hoeg JM, Schaefer EJ, Zech LA, Gregg RE, Lakatos E, Brewer HB Jr: The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. *Metabolism* 34:294-299, 1985.

76. Hoeg JM, Demosky SJ Jr, Schaefer EJ, Starzl TE, Porter KA, Brewer HB Jr: The effect of portacaval shunt on hepatic lipoprotein

metabolism in familial hypercholesterolemia. *J. Surg. Res.* 39:369-377, 1985.

77. Schaefer EJ, Levy RI: The pathogenesis and management of lipoprotein disorders. *N. Eng. J. Med.* 312:1300-1310, 1985.*

78. Libby P, Miao P, Ordovas J, Schaefer EJ: Lipoproteins increase growth of mitogen stimulated arterial smooth muscle cells. *J. Cell Physiol.* 24:1-8, 1985.

79. Schaefer EJ, Ordovas JM, Law S, Ghiselli G, Kashyap ML, Srivastava LS, Heaton WH, Albers JJ, Connor WE, Lemeshev Y, Segrest J, Brewer HB Jr: Familial apolipoprotein A-I and C-III deficiency, variant II. *J. Lipid Res.* 26:1089-1101, 1985.

80. Jahn CE, Schaefer EJ, Taam L, Hoofnagel J, Jones EA, Brewer HB Jr: Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. *Gastroenterology* 89:1266-1278, 1985.

81. Wilson PWF, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr: Estimation of VLDL cholesterol in hyperlipidemia. *Clin. Chem. Acta.* 151:285-291, 1985.

82. Zannis V, Ordovas JM, Claradas C, Cole FS, Forbes G, Schaefer EJ: mRNA and apolipoprotein synthesis abnormalities in peripheral blood monocyte-macrophages in familial apolipoprotein E deficiency. *J. Biol. Chem.* 260:12891-12894, 1985.

83. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, Wilson PW, Karathanasis SK: Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. *N. Engl. J. Med.* 314:671-677, 1986.

84. Schaefer EJ, Rees, DM, Siguel EN: Nutrition, lipoproteins and atherosclerosis. *Clinical Nutrition* 5:99-ll, 1986.*

85. Schaefer EJ: Lipoprotein metabolism and lipid disorders. *Masters in Cardiology.* 3:14-24, 1986.*

86. Schaefer EJ, Ordovas JM: Metabolism of the apolipoproteins A-I, A-II, and A-IV. In *Methods in Enzymology,* Plasma Lipoproteins, Part B: Characterization, Cell Biology and Metabolism (J. Segrest, J. Albers, eds.). Academic Press. 129:420-442, 1986.*

87. Triau JE, Arbetter J, Schaefer EJ: Impaired hepatocyte binding, uptake and degradation of glucosylated low density lipoproteins. *Biochim. Biophys. Acta* 877:359-365, 1986.

88. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr: Abnormal in vivo metabolism of apolipoprotein E4 in humans. *J. Clin. Invest* 78:815-821, 1986.

89. Schaefer EJ: Lipid lowering agents other than anion exchange resins acting in the gastrointestinal tract. In J. Shepherd, R.I. Levy (eds.) *Pharmacologic Control of Hyperlipidemia.* J.R. Prous Science Publishers, Barcelona, pp. 119-132, 1986.*

90. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Lindgren FT, Brewer HB Jr: Familial apolipoprotein E deficiency. *J. Clin Invest.* 78:1206-1219, 1986.

91. Schaefer EJ, McNamara JR, Mitri C, Ordovas JM: Genetic high density lipoprotein deficiency states. *Atherosclerosis VII, Proceedings of the Seventh International Symposium on Atherosclerosis,* Excerpta Medica, Amsterdam, pp. 183-186, 1986.*

92. Schaefer EJ, McNamara JR, Mitri C, Ordovas JM: Genetic high density lipoprotein deficiency and atherosclerosis. Angel A., Frohlich J., (eds.) Lipoprotein Deficiency Syndromes. *Adv. Exp. Biol. Med.* 201:1-15, 1986.*

93. Ellis JK, Russell RM, Makrauer FL, Schaefer EJ: Increased risk of vitamin A toxicity in severe hypertriglyceridemia. *Ann Intern Med.* 105:877-879, 1986.

94. Hughes T, Sasak V, Ordovas JM, Forte T, Lamon-Fava S, Schaefer EJ: A novel cell line (Caco-2) for the study of intestinal lipoprotein synthesis. *J. Biol. Chem.* 262:3762-3767, 1987.

95. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. *Clin. Chim.*

*Acta* 166:1-8, 1987.

96. Ordovas JM, Litwack-Klein LE, Schaefer MM, Wilson PWF, Schaefer EJ: Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. *J. Lipid Res.* 28:371-380, 1987.

97. Lamon-Fava S, Ordovas JM, Mandel G, Forte TM, Goodman RH, Schaefer EJ: Secretion of apolipoprotein A-I in lipoprotein particles following transfection of the human apolipoprotein A-I gene into 3T3 cells. *J. Biol. Chem.* 262:8944-8947, 1987.

98. Farber HN, Arbetter J, Schaefer EJ, Hill SP, Dallal G, Grimaldi R, Hill NS: Acute metabolic effects of an endurance triathlon. *Ann Sports Med.* 32:131-138, 1987.

99. Schaefer EJ: Diagnosis and management of ocular abnormalities in abetalipoproteinemia in Research in Retinitis Pigmentosa, E. Zrenner, H. Krastel, H. H. Goebel, (eds.) *Adv. in Biosciences.* 62:579-581, 1987.*

100. Woods M, Schaefer EJ, Morrill A, Goldin BR, Longcope C, Dwyer JD, Gorbach SL: Effects of menstrual cycle phase on plasma lipids. *J. Clin. Endocr. Metab.* 65:321-323, 1987.

101. Ordovas JM, Peterson JP, Santaniello P, Cohn J, Wilson PWF, Schaefer EJ: Enzyme linked immunosorbent assay for human plasma apolipoprotein B. *J. Lipid Res.* 28:1216-1224, 1987.

102. Siguel EN, Chee KW, Gong J, Schaefer EJ: Criteria for plasma essential fatty acid deficiency as assessed by capillary column gas liquid chromatography. *Clin. Chem.* 33:1869-1873, 1987.

103. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ: Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. *Arteriosclerosis* 7:483-490, 1987.

104. Prioli RP, Ordovas JM, Rosenberg I, Schaefer EJ, Pereira MEA. Similarity of cruzin, an inhibitor of Trypanosoma cruzi neuraminidase, to high-density lipoprotein. *Science* 238:1417-1419, 1987.

105. Cohn JS, Schaefer EJ. Sample lipolysis for quantification of apolipoprotein B. *Clin. Chem.* 33:338-339, 1987 (letter).

106. Samuel P, Chin B, Schoenfeld BH, Schaefer EJ, Gonasun LM: Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension. *Br. J. Clin. Pharm.* 24:(Suppl.1)63S-64S, 1987.

107. Schaefer EJ, Rifkin RD, Genest J: Diagnosis and management of lipid disorders. *Cardiovascular Reviews and Reports* 8(11):19-22, 1987.*

108. Schaefer EJ: When and how to treat the dyslipidemias. *Hospital Practice* 23 (1):69-80, 83-84, 1988.*

109. Hughes T, Ordovas JM, Schaefer EJ. Regulation of apolipoprotein B synthesis and secretion by Caco-2 cells: lack of fatty acid effects and control by intracellular calcium ion. *J Biol. Chem.* 263:3425-3431, 1988.

110. McNamara JR, Campos H, Ordovas JM, Wilson PWF. Gradient gel electrophoretic analysis of low density lipoproteins. *Am. Biotech. Lab.* 6(1):1-4, 1988.*

111. Rosenberg IH, Schaefer EJ: Dietary saturated fat and cholesterol. *N. Eng. J. Med.* 318:1270-1271, 1988 (editorial).*

112. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ: Postprandial plasma lipoprotein changes in human subjects of different ages. *J. Lipid. Res.* 29:469-478, 1988.

113. Genest J, Corbett H, McNamara JR, Schaefer MM, Salem DN, Schaefer EJ: Effect of hospitalization on high density lipoprotein cholesterol in patients undergoing elective angiography. *Am. J. Cardiol.* 61:998-1000, 1988.

114. Schaefer EJ, McNamara JR, Ordovas JM: Lipoprotein Abnormalities in Premature Coronary Artery Disease. In *Atherosclerosis Reviews,* R.I. Levy, (ed.) 17:21-27, 1988.*

115. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ: Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. *J. Lipid Res.* 29:925-936, 1988.

116. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. *J. Clin. Endocr. Metab.* 67:30-35, 1988.

117. Schaefer EJ, McNamara JR, Genest J, Ordovas JM: Clinical significance of hypertriglyceridemia. *Sem. Thrombosis and Hemostasis* 14:143-148, 1988.*

118. Schaefer EJ, McNamara JR, Genest J, Ordovas JM: Genetics and abnormalities of plasma lipoproteins. *Clin. Chem.* 34(8):B9-B12.*

119. Genest J, Ordovas J, Robbins A, King DC, Frossard PM, Schaefer EJ: Two new apoB gene polymorphisms:RsI and Rs2 *Nucleic Acids Research* 16:8746, 1988.

120. Genest J, Ordovas JM, Robbins AH, King DC, Frossard PM, Schaefer EJ: Two new apoB gene polymorphisms: Rs3 and Rs4. *Nucleic Acids Research* 16:8747, 1988.

121. Schaefer EJ: Sleep abnormalities in patients on lovastatin. *N. Engl. J. Med.* 319:1222, 1988 (letter).

122. Triau JE, Meydani SN, Schaefer EJ: Oxidized low density lipoproteins stimulate prostacyclin production by human vascular endothelial cells. *Arteriosclerosis* 8:810-818, 1988.

123. Cohn JS, McNamara JR, Schaefer EJ: Lipoprotein concentrations in the plasma of human subjects as measured in the fed and fasted states. *Clin. Chem.* 34:2456-2459, 1988.

124. Samuel P, Kirkendall W, Schaefer EJ, Chin B, Schoenfeld BH, Gonasun LM, Lieberman S: Effects of isradipine, a new calcium channel antagonist, versus hydrochlorthiazide on serum lipids and apolipoproteins in patients with systemic hypertension. *Am. J. Cardiol.* 62:1068-1071, 1988.

125. Ordovas J, Schaefer EJ: Coronary artery disease, lipid disorders, and genetic polymorphisms. *Ann. Biol. Clin.* 46:24-29,1988.*

126. The Expert Panel. Report of the National Cholesterol Education Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. *Arch. Intern. Med.* 148: 36-69, 1988.*

127. Lamon-Fava S, Fisher EC, Nelson ME, Evans WE, Miller JS, Ordovas JM, Schaefer EJ: Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins. *J. Clin. Endocr. Metab.* 68:17-21, 1989.

128. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonneman G, Van Der Meer JWM, Cannon JG, Klempner M, Schaefer EJ, Wolff SM, Dinarello CA: Dietary n-3 polyunsaturated fatty acids suppress synthesis of interleukin-1 and tumor necrosis factor. *N. Eng. J. Med.* 320:265-271, 1989.

129. Schaefer EJ, Moussa PB, Wilson PWF, McGee D, Dallal G, Castelli WP: Plasma lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: Results from the Framingham Heart Study. *Metabolism* 38:293-296, 1989.

130. Dallal GE, Choi E, Jacques P, Schaefer EJ and Jacob RA: Ascorbic acid, HDL cholesterol, and apolipoprotein A-I in an Elderly Chinese population in Boston. *J. Amer. Coll. Nutr.* 8:69-74, 1989.

131. Cohn JS, McNamara JR, Krasinski SD, Russell RM, Schaefer EJ: Role of triglyceride rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. *Metabolism* 38:484-490, 1989.

132. McNamara JR, Adolfsen J, Campos H, Ordovas JM, Albers JJ, Usher D, Schaefer EJ: Screening for lipoprotein (a) elevations in plasma and assessment of size heterogeneity using gradient gel electrophoresis. *J. Lipid Res.* 30:747-755, 1989.

133. Siguel E, Schaefer EJ: Aging and nutritional requirements of essential fatty acids in J. Beare Rogers in *Dietary Fat Requirements in Health and Disease* p. 1653-1689, Amer. Oil Chemists Society, Champaign, Il, 1989.*

134. Schaefer EJ, McNamara JR, Genest JJ, Ordovas JM: Genetic high density lipoprotein deficiency. in N.E. Miller, (ed.) High Density Lipoproteins and Atherosclerosis II. *Excerpta Medica,* Amsterdam, 1989; pp.29-36.*

135. Meydani M, Cohn JS, Macauley JB, McNamara JR, Blumberg JB, Schaefer EJ: Postprandial changes in the plasma concentration of alpha and beta-tocopherol in human subjects fed a fat rich meal supplemented with fat soluble vitamins. *J. Nutr.* 119:1252-1258, 1989.

136. Breslow JL, Deeb S, Lalouel JM, Le Boeuf R, Schaefer EJ, Tyroler HA, Wilson PWF, Young S: Workshop II. Genetic susceptibility to atherosclerosis. In: AHA Conference Report on Cholesterol, A.M. Gotto Jr., (ed.) *Circulation* 80:724-728, 1989.*

137. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ: Familial apolipoprotein A-I, C-III, and A-IV deficiency with marked high density lipoprotein deficiency and premature atherosclerosis due to a deletion of the apolipoprotein A-I, C-III, and A-IV gene complex. *J. Biol. Chem.* 264:16339-16342, 1989.

138. Lamon-Fava S, McNamara JR, Farber HW, Hill NS, Schaefer EJ: Acute changes in lipid, lipoprotein, apolipoprotein and low density lipoprotein particle size after an endurance triathlon. *Metabolism* 38:921-925, 1989.

139. Gorbach SL, Schaefer EJ, Woods M, Longcope C, Dwyer JT, Goldin BR, Morrill-Labrode A, Dallal G: Plasma lipids and endogenous sex hormones in healthy young women. J. Clin. Endocr. *Metabolism* 38:1077-1081, 1989.

140. Schaefer EJ: Hyperlipoproteinemia In: Conn's Current Therapy, Rakel R. E., (ed.) W.B. Saunders Co., Philadelphia, PA, pp. 516-525, 1990.*

141. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ: Calculated values for low density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. *Clin. Chem.* 36:36-42, 1990.

142. Kaufman HW, McNamara JR, Anderson KM, Wilson PWF, Schaefer EJ: How reliably can compact chemistry analyzers measure lipids? *JAMA* 263:1245-1249, 1990.

143. Schaefer EJ: The Hyperlipoproteinemias and other lipoprotein disorders in *Principles and Practice of Endocrinology and Metabolism,* K. L. Becker, (ed.) J.B. Lippincott, Philadelphia, pp. 1229-1241, 1990.*

144. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ: The measurement of very low density lipoprotein and low density lipoprotein apoB-100 and high density lipoprotein A-I synthesis in human subjects using deuterated leucine: effect of fasting and feeding. *J. Clin. Invest.* 85:804-811, 1990.

145. Choi SK, McGrandy RB, Dallal GE, Russell RM, Jacob RA, Schaefer EJ, Sadowski JA: The prevalence of cardiovascular risk factors among elderly Chinese Americans. *Arch. Intern. Med.* 150:413,-418, 1990.

146. Krasinski SD, Cohn JS, Schaefer EJ, Russell RM: Post-prandial plasma retinyl ester response is greater in older subjects compared with younger subjects. *J. Clin. Invest.* 85:883-892, 1990.

147. Nicolosi RJ, Stucchi AF, Kowala MC, Hennessy LK, Hegsted DM, Schaefer EJ: Effect of dietary fat saturation and cholesterol on low density lipoprotein composition and metabolism. I. In vivo studies of receptor and non-receptor mediated catabolism of LDL in Cebus monkeys. *Arteriosclerosis* 10:119-128, 1990.

148. Genest JJ, McNamara JR, Ordovas JM, Martin-Munley S, Jenner JL, Millar JS, Salem DN, Schaefer EJ: Effect of elective hospitalization on plasma lipoprotein cholesterol and apolipoproteins A-I, B, and Lp(a). *Am. J. Cardiol.* 65:677-679, 1990.

149. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ: Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally-derived chylomicrons and their remnants. *Metabolism* 39:357-365, 1990.

150. Ordovas JM, Civeira F, Genest J, Schaefer EJ: Genetic high density lipoprotein deficiency states. In: Biotechnology of Dyslipidemias: Applications in Diagnosis and Control. (C. Lenfant, et al., eds), Raven Press, New York, pp. 261-273, 1990.*

151. Schaefer EJ: High Density Lipoproteins and Coronary Heart Disease. Gower Medical Publishing, New York, pp. 1-38, 1990.*

152. Genest JM, Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, Wilson PWF, Masharani U, Frossard PM, Schaefer EJ: DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. *Atherosclerosis* 82:7-17, 1990.

153. Campos H, Wilson PWF, Jimenez D, McNamara JR, Ordovas JM, Schaefer EJ: Differences in apolipoproteins and low density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: Results from the Framingham Study. *Metabolism* 39:1033-1038, 1990.

154. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR: Plasma homocyst(e)ine levels in men with premature coronary artery disease. *J. Am. Coll. Cardiol.* 16:1114-1119, 1990.

155. Lichtenstein AH, Cohn JS, Hachey DLK, Millar JS, Ordovas JM, Schaefer EJ: Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B kinetics. *J. Lipid Res.* 31:1693-1701, 1990.

156. Chee KM, Gong JX, Rees DM, Meydani M, Ausman L, Johnson J, Siguel EN, Schaefer EJ: Fatty acid content of marine oil capsules. *Lipids* 25:523-528, 1990.

157. Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W Jr, Stein EA: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. *Atherosclerosis* 85:81-89, 1990.

158. Dupont J, White PJ, Carpenter MP, Schaefer EJ, Meydani SN, Elson CE, Woods M, Gorbach SL: Food Uses and Health Effects of Corn Oil. *Journal of the American College of Nutrition* 9(5):438-470, 1990.*

159. Schaefer EJ: Hyperlipoproteinemia in: Conn's Current Therapy 1991. Rakel R.E., (ed.), W.B. Saunders Co., Philadelphia pp. 515-522, 1991.*

160. Wardell MR, Rall Jr SC, Schaefer EJ, Kane JP, Weisgraber KH: Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity. *J. Lipid Res.* 32:521-528, 1991.

161. Ordovas JM, Civeira F, Genest J, Robbins AH, Meade T, Pocovi M, Frossard PM, Masharani U, Wilson PWF, Salem DN, Ward RH, Schaefer EJ: Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus: Relationships with lipids, apolipoproteins, and coronary artery disease. *Atherosclerosis* 87:75-86, 1991.

162. Genest JJ, McNamara JR, Salem DN, Schaefer EJ: Prevalence of risk factors in men with premature coronary artery disease. *Am. J. Cardiol.* 67:1185-1189, 1991.

163. Genest J, Jenner JL, McNamara JR, Ordovas JM, Silberman SR, Wilson PWF, Schaefer EJ: Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. *Am J Cardiol* 67:1039-1045, 1991.

164. Campos H, Bailey SM, Gussak LS, Siles X, Ordovas JM, Schaefer EJ: Relationships of body habitus, fitness levels and cardiovascular risk factors including lipoproteins and apolipoproteins in a rural and urban Costa Rican population. *Arteriosclerosis* 11:1077-1088, 1991.

165. Campos H, Willet WC, Peterson RM, Siles X, Bailey SM, Wilson PWF, Posner BM, Ordovas JM, Schaefer EJ: Nutrient intake comparisons between Framingham and rural and urban Puriscal, Costa Rica: associations with lipoproteins, apolipoproteins, and LDL particle size. *Arteriosclerosis* 11:1089-1099, 1991.

166. Shapiro AC, SN Meydani, M Meydani, F Morrow, JR McNamara, EJ Schaefer, S Endres, CA Dinarello: The effect of fish oil supplementation on plasma alpha tocopherol, retinol, lipid, and lipoprotein levels in normolipidemic subjects. *Nutr. Res.* 11:539-548, 1991.

167. Meydani M, Natiello F, Goldin B, Free N, Woods M, Schaefer EJ, Blumberg JB, Gorbach SL: Effect of long term fish oil supplementation on vitamin E status and lipid peroxidation in women. *J. Nutr.* 121:484-491, 1991.

168. Schaefer EJ: Diagnosis and Management of Lipid Disorders In: *Methods for Clinical Laboratory Measurements of Lipids and Lipoprotein Risk Factors*, Rifai N., Warnick W. R., (eds) AACC Press pp. 1-16, 1991.*

169. Schaefer EJ: Diagnosis and Management of Lipoprotein Disorders. In: *Drug Treatment of Hyperlipidemia* Rifkin B., Lenfant C., (eds.) M. Dekker pp. 17-52, 1991.*

170. Farber HW, Schaefer EJ, Franey R, Grimaldi R, Hill, NS: The endurance triathlon: metabolic changes after each event and during recovery. *Medicine and Science in Sports and Exercise* 23(8):959-965, 1991.

171. Genest JJ Jr, McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, Malinow MR: Prevalence of familial hyperhomocysteinemia in men with premature coronary artery disease. *Arteriosclerosis and Thrombosis* 11:1129-1136, 1991.

172. Meydani SN, Lichtenstein AH, White PS, Goodnight SH, Elson CE, Woods M, Gorbach SL, Schaefer EJ: Food use and health effects of soybean and sunflower oils. *J. Am. Coll. Nutr.* 10:406-428, 1991.*

173. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PWF, Schaefer EJ: Plasma apolipoproteins (a), A-I, A-II, B, E, and C-III containing particles in men with premature coronary artery disease. *Atherosclerosis* 90:149-157, 1991.

174. Stucchi AF, Hennessy LK, Vespa DB, Weiner EJ, Osada J, Ordovas JM, Schaefer EJ, Nicolosi RJ: Effect of corn and coconut oil-containing diets with and without cholesterol on high density lipoprotein apoprotein A-I metabolism and hepatic apoprotein A-I mRNA levels in Cebus monkeys. *Arteriosclerosis and Thrombosis* 11:1719-1729, 1991.

175. Schaefer EJ: Diagnosis and Treatment of Lipid Disorders. *Endocrinology and Metabolism American College of Physicians MKSAP IX* Herschman J., (ed.), Philadelphia Part A, book 4, pp. 160-166, 1991.*

176. Lamon-Fava S, Jimenez D, Christian JC, Fabsitz RR, Reed T, Carmelli D, Castelli, WP, Ordovas JM, Wilson PWF, Schaefer EJ: The NHLBI Twin Study: heritability of apolipoprotein A-I, B and low density lipoprotein subclasses and concordance for lipoprotein (a). *Atherosclerosis* 91:97-106, 1991.

177. Campos H, Siles X, Vives M, Ordovas JM, Mata L, Schaefer EJ: Prevalence of cardiovascular risk factors in rural and urban Puriscal, Costa Rica. *Circulation* 85:648-658, 1992.

178. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner J, Ordovas JM, Wilson PWF, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. *Arteriosclerosis and Thrombosis* 12:187-195, 1992.

179. Civeira F, Genest J, Pocovi M, Salem DN, Herbert PN, Wilson PWF, Schaefer EJ, Ordovas, JM: The MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. *Atherosclerosis* 92:165-176, 1992.

180. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Millar JS, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ: Prevalence of lipoprotein cholesterol and apolipoprotein A-I, B and Lp(a) abnormalities in men with premature coronary artery disease. *J. Am. Coll. Cardiol.* 19:792-802, 1992.

181. Posner BM, Martin-Munley SS, Smigelski C, Cupples LA, Cobb JL, Schaefer E, Miller DR, D'Agostino RB: Comparison of techniques for estimating nutrient intake: the Framingham Study. *Epidemiology* 3:171-177, 1992.

182. Hennessy LK, Osada J, Ordovas JM, Nicolosi RJ, Brousseau ME, Schaefer EJ: Effects of dietary fatty acids and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B and E and LDL receptor mRNA levels in Cebus monkeys. *J Lipid Res* 33:351-360;1992.

183. Schaefer EJ: Lipids In: *Nutritional Status of the Elderly: The Boston Study* Hartz, S. C., Russell, R. M., Rosenberg, I. H., (eds.) Smith-Gordon Co., Ltd., London. pp. 65-74, 1992.*

184. Genest JJ, Martin-Munley S, McNamara JR, Ordovas JM, Jenner J, Meyers R, Wilson PWF, Schaefer EJ: Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation* 85:2025-2033, 1992.

185. Nicolosi RJ, Schaefer EJ: Pathobiology of hypercholesterolemia and atherosclerosis: Genetic and environmental determinants of elevated lipoprotein levels. In: *Prevention of Coronary Heart Disease* Ockene IS, Ockene JK (eds). Little, Brown and Company, Boston, pp. 69-102, 1992.*

186. Lichtenstein AH, Hachey DL, Millar JS, Jenner JL, Booth L, Ordovas JM, Schaefer EJ: Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-$^2H_3$] leucine. *J. Lipid Res.* 33:907-914, 1992.

187. Gong J, Rosner B, Rees DG, Berson EL, Weigel-DeFranco, Schaefer EJ: Plasma docosahexaenoic acid levels in various genetic forms of Retinitis Pigmentosa. *Investigative Opthalmology and Visual Science* 33:2596-2602, 1992.

188. Granfone A, Campos H, McNamara JR, Schaefer MM, Ordovas JM, Schaefer EJ: Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in dyslipidemic postmenopausal women. *Metabolism* 41:1193-1198, 1992.

189. Schaefer EJ: The hyperlipoproteinemias and other lipoprotein disorders. In: *Vascular Medicine*, Loscalzo, J., Creager, M. A., and Dzau, V. J., (eds). Little Brown, Boston pp. 575-594, 1992.*

190. Schaefer EJ, Ordovas JM. Diagnosis and management of high density lipoprotein deficiency states. *High Density Lipoproteins and Atherosclerosis III* (N.E. Miller and A.R. Tall, eds). Elsevier Science Publishers, Amsterdam, pp. 235-251, 1992.*

191. McNamara JR, Jenner JL, Li Z, Wilson PWF, Schaefer EJ: Change in low density lipoprotein particle size is associated with change in plasma triglyceride concentration. *Arteriosclerosis and Thrombosis* 12:1284-1290, 1992.

192. Campos H, Blijlevens E, McNamara JR, Ordvoas JM, Wilson PWF, Schaefer EJ: LDL particle size distribution: results from the Framingham Offspring Study. *Arteriosclerosis and Thrombosis* 12:1410-1419, 1992.

193. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ: Hydrogenation impairs the hypolipidemic effect of corn oil in humans. *Arteriosclerosis and Thrombosis* 13:154-161, 1993.

194. Expert Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) *JAMA* 269;3015-3023, 1993.*

195. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ: Effects of age, gender, and menopausal status on plasma lipoprotein (a) levels: The Framingham Offspring Study. *Circulation* 87:135-1141, 1993.

196. Meydani SN, Lichtenstein AH, Cornwall S, Meydani M, Goldin BR, Rasmussen H, Dinarello CA, Schaefer EJ: Immunologic effects of National Cholesterol Panel Step 2 diets with and without fish derived on three fatty acid enrichment *J. Clin. Invest.* 92:105-113, 1993.

197. Reisher SR, Hughes TE, Ordovas JM, Schaefer EJ, Feinstein SI: Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2. *Proc. Natl. Acad. Sci. USA* 90:5757-5761, 1993.

198. Schaefer EJ, Genest JJ, Ordovas JM, Salem DN, Wilson, PWF: Familial lipoprotein disorders and premature coronary artery disease. *Current Opinion in Lipidology* 4:288-298, 1993.*

199. Schaefer EJ, New recommendations for the diagnosis and treatment of plasma lipid abnormalities. *Nutrition Reviews*, 51:246-252, 1993.*

200. Lyu L-C, Schaefer EJ: Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. *Arteriosclerosis and Thrombosis* 13:1429-1440, 1993.

201. Lichtenstein AH, Carrasco W, Jenner JL, Ausman L, Ordovas JM, Schaefer EJ: Effects of canola, corn, olive, and rice bran oil on fasting and post-prandial lipoproteins in humans as part of a National Cholesterol Education Program Step 2 diet. *Arteriosclerosis and Thrombosis* 13:1533-1542, 1993.

202. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ: The contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins to post-prandial increases in plasma triglycerides and retinyl esters. *J. Lipid Res.* 34:2033-

2040, 1993.

203. Genest JJ Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. *Arteriosclerosis and Thrombosis* 13:1728-1737, 1993.

204. Chait A, Brunzell JD, Denke MA, Eisenberg D, Ernst ND, Franklin FA, Ginsberg H, Kotchen TA, Kuller L, Mullis RM, Nichaman MZ, Nicolosi RJ, Schaefer EJ, Stone NJ, Weidman WH. Rationale of the Diet Heart Statement of the American Heart Association. Report of the Nutrition Committee. *Circulation* 88:3008-3029;1993.*

205. Osada J, Pocovi M, Nicolosi RJ, Schaefer EJ, Ordovas JM. Nucleotide sequences of the *Macaca fascicularis* apolipoprotein C-III and A-IV genes. *Biochim Biophys Acta Gene Struct Expression* 1172:335-339, 1993.

206. Osada J, Garces C, Sastre J, Schaefer EJ, Ordovas JM. Molecular cloning and sequence of the cynomolgus monkey apolipoprotein A-II gene. *Biochim Biophys Acta Gene Struct Expression* 1172:340-342, 1993.

207. Lamon-Fava S, Jenner JL, Jacques PF, Schaefer EJ: Effects of dietary intakes on plasma lipids, lipoproteins, and apolipoproteins in free-living elderly men and women. *Am. J. Clin. Nutr.* 59:32-41, 1994.

208. Schaefer EJ, Lamon-Fava S, Jenner JL, Ordovas JM, Davis CE, Lippel K, Levy RI: Lipoprotein(a) levels predict coronary heart disease in the lipid research clinics coronary prevention trial. *JAMA* 271:999-1003, 1994.

209. Schaefer EJ: Familial lipoprotein disorders and premature coronary artery disease. In: Lipid Disorders D. Hunninghake (ed), Medical Clinics of North Amercia 78(1) pp. 21-39, 1994.*

210. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ: Hypercholesterolemic effect of dietary cholesterol in diets enriched in polyunsaturated and saturated fat. *Atherosclerosis and Thrombosis* 14:168-175, 1994.

211. Ferretti A, Meydani SN, Lichtenstein AH, Flanagan FP, Schaefer EJ. Prostaglandin E metabolite excretion in normolipidemic subjects is lowered by a moderate reduction of n-6/n-3 polyunsaturate ratio and total fat intake. *Nutrition Research*, Vol 14 No. 2 pp. 185-193, 1994.

212. Lichtenstein AH, Carrasco W, Jenner JL, Ausman L, Ordovas JM, Schaefer EJ. Rice bran oil consumption and plasma lipid levels in moderately hypercholesterolemic humans. *Arteriosclerosis and Thrombosis* 14:549-556, 1994.

213. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. *JAMA* 271:999-1003, 1994.

214. Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest JJ Jr, Wilson PWF, Schaefer EJ. Lipoprotein (a) and coronary heart disease. *Chemistry and Physics of Lipids* Vol. 67/68: 389-398, 1994.

215. McNamara JR, Huang C, Massov T, Teng-Leary E, Warnick GR, Rubins HB, Robins SJ, Schaefer EJ. Modification of the Dextran-$Mg^{2+}$ HDL cholesterol precipitation method for use with previously frozen plasma. *Clin Chem.* 40/2:233-239, 1994.

216. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein (a) in plasma by assaying cholesterol in lectin bound plasma fraction. *Clin Chem* 40:400-403, 1994.

217. Jones PJH, Lichtenstein AH, Schaefer EJ, Namchuk GL. Effect of dietary fat selection on plasma cholesterol synthesis in older moderately hypercholesterolemic subjects. *Arteriosclerosis and Thrombosis* 14:542-548, 1994.

218. Jones PJH, Lichtenstein AH, Schaefer EJ. Interaction of dietary fat type and cholesterol level on cholesterol synthesis measured using deuterium incorporation. *J Lipid Res.* 35:1093-1101; 1994.

219. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF, Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. *J. Lipid Res.* 35:871-882, 1994.

220. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PWF: Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. *J. Lipid Res.* 35:779-792, 1994.

221. Serfaty-Lacrosniere C, Lanzberg A, Civeira F, Isaia P, Berg J, Janus ED, Smith MP, Pritchard PH, Frohlich J, Lees RS, Ordovas JM, Schaefer EJ: Homozygous Tangier disease and cardiovascular disease *Atherosclerosis* 107:85-98, 1994.

222. Brousseau ME, Ordovas JM, Nicolosi RJ, Schaefer EJ: Effects of dietary fat saturation on plasma lipoproteins(a) and hepatic apolipoprotein(a) mRNA concentrations in cynomolgus monkeys. *Atherosclerosis* 106:109-118, 1994.

223. Mata P, Ordovas JM, Lopez-Miranda J, Lichtenstein AH, Clevidence B, Judd JT, Denke MA, Schaefer EJ. Apolipoprotein A-IV phenotype affects diet induced plasma low density lipoprotein cholesterol lowering. *Arteriosclerosis and Thrombosis* 14:884-891, 1994.

224. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PWF. Apolipoprotein E phenotype affects plasma lipoprotein levels in a gender and menopausal status dependent manner. Results from the Framingham Offspring Study. *Arteriosclerosis and Thrombosis* 14:1105-1113, 1994.

225. Schaefer EJ, McNamara JR. Chemistry: routine diagnostic testing for ApoA-I, Apo-B, Lp(a), and LDL cholesterol in clinical laboratories *Clin Laboratory Science* 7:205-208; 1994.*

226. Schaefer EJ. Commentary. Apolipoproteins and coronary heart disease. *Eur. J. Clin. Invest.* 24:441-443; 1994.*

227. Li Z, McNamara JR, Ordovas JM, Schaefer EJ. Analysis of high density lipoproteins by a modified gradient gel electrophoresis method. *J. Lipid Res.* 35:1698-1711; 1994.

228. Lyu LC, Shieh MJ, Posner BM, Ordovas JM, Dwyer JT, Lichtenstein AH, Cupples LA, Dallal GE, Wilson PWF, Schaefer EJ: Relationship between dietary intake, lipoproteins, and apolipoproteins in Taipei and Framingham. *Am. J. Clin. Nutr.* 60:765-774; 1994.

229. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, Schaefer EJ: Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. *J. Lipid Res.* 35:1965-75; 1994.

230. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ: Short term consumption of a low-fat diet beneficially affects plasma lipid concentrations only when accompanied by weight loss. *Arteriosclerosis and Thrombosis* 14:1751-1760; 1994.

231. Ahn, Y-S, Smith D, Schaefer EJ, Ordovas JM. Dietary fat saturation affects apolipoprotein gene expression and high density lipoprotein size distribution in Golden Syrian hamsters. *Journal of Nutrition* 124:2147-2155; 1994.

232. Cheung MC, Lichtenstein AH, Schaefer EJ. The effects of a diet restricted in saturated fat and cholesterol on the composition of apolipoprotein A-I containing particles in the fasting and fed state. *Am J Clin Nutr* 60:911-918; 1994.

233. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA* 272:1666-1671; 1994.

234. Lopez-Miranda J, Kam N, Osada J, Rodriguez C, Fernandez P, Contois J, Schaefer EJ, Ordovas JM. Effect of fat feeding on human intestinal apolipoprotein B mRNA levels and editing. In: *Biochemical and Biophysical Research Communications* 1214:143-147; 1994.

235. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. *Circulation* 90:1688-1695; 1994.

236. Lyu LC, Posner BM, Shieh MJ, Lichtenstein AH, Cupples LA, Dwyer JT, Wilson PWF, Schaefer EJ. Cross-cultural comparisons

between Taipei Chinese and Framingham Americans: dietary intakes, blood lipids, and apolipoproteins. *Asia Pacific J Clin N* 3:119-125;1994.

237. Lyu LC, Shieh M-J, Bailey SM, Dallal GE, Carrasco WI, Ordovas JM, Lichtenstein AH, Schaefer EJ. Relationship of body m distribution with cardiovascular risk factors in healthy Chinese. *Ann Epidemiol* 4:434-444;1994.

238. Schaefer EJ, Genest JJ, Ordovas JM, Salem DN, Wilson PWF. Familial lipoprotein disorders and premature coronary art disease. *Atherosclerosis* 108:S41-S54;1994.*

239. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenb IH. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. *N Engl J Med* 332:286-2 1995.

240. Jacques PF, Sulsky SI, Perrone GE, Jenner J, Schaefer EJ. Effect of vitamin C supplementation on lipoprotein choleste: apolipoprotein, and triglyceride concentrations. *Ann Epidemiol* 5:52-59;1995.

241. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ: Immunoseparation method for measuring lo density lipoprotein cholesterol directly from serum evaluated. *Clin. Chem.* 41:232-240; 1995.

242. Brousseau ME, Ordovas J, Osada J, Fasulo J, Robins S, Nicolosi R, Schaefer EJ: Dietary monounsaturated and polyunsatura fatty acids are comparable in their effects on hepatic apolipoprotein mRNA abundance and liver lipid concentrations wl substituted for saturated fatty acids in cynomolgus monkeys. *J Nutrition* 125:425-436; 1995.

243. Otto J, Ordovas JM, Smith D, VanDongen D, Nicolosi RJ, Schaefer EJ. Lovastatin inhibits diet induced atherosclerosis in I Golden Syrian hamsters. *Atherosclerosis* 114:19-28; 1995.

244. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ. Effect of apolipoprotein E and A phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. *Atherosclerosis* 113:157-166;19

245. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Ordovas JM. Lipoproteins, nutrition, aging, and atherosclerosis. *J Clin Nutr* 61:726S-740S;1995.*

246. Clevidence BA, Reichman ME, Judd JT, Muesing RA, Schatzkin A, Schaefer EJ, Li Z, Jenner J, Brown CC, Sunkin M, Campl WS, Taylor PR. Effects of alcohol consumption on lipoproteins of premenopausal women. *Arterioscler Thromb Vasc I* 15:179-184;1995.

247. Brousseau ME, Schaefer EJ, Stucchi AF, Osada J, Vespa DB, Ordovas JM, Nicolosi RJ. Diets enriched in unsaturated fatty ac enhance apolipoprotein A-I catabolism but do not affect either its production or hepatic mRNA abundance in cynomol monkeys. *Atherosclerosis* 115:107-119;1995.

248. Schaefer EJ, Lamon-Fava S, Spiegelman D, Dwyer JT, Lichtenstein AH, McNamara JR, Goldin BR, Woods MN, Mon Labrode A, Hertzmark E, Longcope C, Gorbach SL. Changes in plasma lipoprotein concentrations and composition in respo to a low fat, high fiber diet are associated with changes in serum estrogen concentrations in premenopausal women *Metabol* 44:749-756; 1995.

249. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ. Impact of age on the metabolisn VLDL, IDL, and LDL apolipoprotein B-100. *J Lipid Res* 36:1155-1167;1995.

250. Schaefer EJ, Robins SJ, Patton GM, Sandberg MA, Weigel-DiFranco CA, Rosner B, Berson EL. Red blood cell membr phosphatidylethanolamine fatty acid content in various forms of retinitis pigmentosa. *J Lipid Res* 36:1427-1433;1995.

251. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Rasmussen H, McNamara JR, Ordovas JM. Efficacy ( National Cholesterol Education Program Step 2 Diet in normolipidemic and hyperlipidemic middle aged and elderly men women. *Arterioscler Thromb & Vasc Biol* 15:1079-1085;1995.

252. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Schaefer MM, Rasmussen H, Ordovas JM. Body weight and l

density lipoprotein cholesterol changes after consumption of a low fat ad libitum diet. *JAMA* 274:1450-1455;1995.

253. Welty FK, Ordovas JM, Schaefer EJ, Wilson PWF, Young SG. Identification and molecular analysis of two apoB gene mutati causing low plasma cholesterol levels. *Circulation* 92:2036-2040;1995.

254. Myers RH, Schaefer EJ, Wilson PWF, D'Agostino R, Bachman DL, Ordovas JM, Au R, Cobb JL, Wolf PA. Apolipoprotei allele 4 is associated with dementia in the Framingham Study. In: *Research Advances in Alzheimer's Disease and Rela Disorders*. J.W. Wiley and Sons, Iqbal K, Mortimer JA, Winblad B, Wishlewski HM, pp 63-70;1995.

255. Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determin plasma lipid response to dietary intervention. *Atherosclerosis* 118 Suppl. S11-S27;1995.*

256. Robins SJ, Fasulo J, Patton GM, Schaefer EJ, Smith DE, Ordovas JM. Gender differences in the development of hyperlipidei and atherosclerosis in hybrid hamsters. *Metabolism* 44:1326-1331;1995.

257. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Goldin BR, Rasmussen H, McNamara JR, Ordovas JM. Effe of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plas lipoproteins in middle-aged and elderly subjects. *Am J Clin Nutr* 63:234-241;1996.

258. Cuchel M, Schwab US, Jones PJH, Vogel S, Lammi-Keefe C, Li Z, Ordovas J, McNamara JR, Schaefer EJ, Lichtenstein A Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low-density lipoprotei oxidation in moderately hypercholesterolemic individuals. *Metabolism* 45:241-247;1996.

259. Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ. Effects of diet and exercise on qualitative and quantitat measures of LDL and its susceptibility to oxidation. *Arterio Thromb & Vasc Biol* 16:201-207;1996.

260. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a commercially available immunoturbidometric assay: results from the Framingham Offspring Study. Clin Ch *Clin Chem* 42:(4)507-514;1996.

261. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein E determined with a commercially available immunoturbidometric assay: results from the Framingham Offspring Study. *Clin Ch* 42:(4)515-523;1996.

262. Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, Schaefer EJ, Wilson AF, Wilson, PWF, Vasan RS, My RH, Levy D. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventrici mass. *NEJM* 334:1023-1028;1996.

263. Myers RH, Schaefer EJ, Wilson PWF, D'Agostino RD, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNı KA, Beiser A, Wolf PA. Apolipoprotein E4 association with dementia in a population based study *Neurology* 46:673-677;19

264. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plas lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. *JAMA* 276:544-548;199

265. McNamara JR, Small DM, Li Z, Schaefer EJ. Differences in LDL subspecies involve alterations in lipid composition conformational changes in apolipoprotein B. *J Lipid Res* 37:1924-1935;1996.

266. Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PWF, Schaefer EJ. Effects of gender and menopai status on plasma lipoprotein subspecies and particle sizes. *J Lipid Res* 37:1886-1896;1996.

267. McNamara JR, Warnick GR, Leary ET, Wittles E, Nelson FE, Pearl MF, Schaefer EJ. Multi-center evaluation of a pati administered test for blood cholesterol measurement. *Preventive Med* 25:583-592;1996.

268. Contois JH, McNamara JR, Vogel S, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipopro (a) as determined with a commercially available immunoturbidometric assay: results from the Framingham Offspring Study. ( *Chim Acta* 253:21-35;1996.

269. Craig SB, Bandini LG, Lichtenstein AH, Schaefer EJ, Dietz WH. The impact of physical activity on lipids, lipoproteins, and blo pressure in preadolescent girls. *Pediatrics* 98:389-395;1996.

270. Siegel RD, Cupples A, Schaefer EJ, Wilson PWF. Lipoproteins, apolipoproteins, and low density lipoprotein size among diabet in the Framingham Offspring Study. *Metabolism* 45:1267-1272;1996.

271. Schaefer EJ, Lamon Fava S, Cole T, Sprecher DL, Cilla DD Jr, Balagtas CC, Rowan JP, Black DM. Effects of regular a extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HI cholesterol levels. *Atherosclerosis* 127:113-122;1996.

272. Lahoz C, Osgood D, Wilson PWF, Schaefer EJ, Ordovas JM. Frequency of phenotype discrepancies at the apolipoprotein E lo in a large population study. *Clin Chem* 42:1817-1823;1996.

273. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analys *Arterioscl Thromb & Vasc Biol* 16:1250-1255;1996.

274. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart risk factors in men and women. T Framingham Offspring Study. *Arterioscl Thromb & Vasc Biol* 16:1509-1515;1996.

275. Selhub J, Jacques PF, Boston AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Rush D, Schaefer Rosenberg IH. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in Framingham Study Population. *J Nutr* 126:1258S-1265S;1996.

276. Schaefer EJ, Lamon-Fava S, Ausman LM, Ordovas JM, Clevidence BA, Judd JT, Goldin BR, Woods M, Gorbach S, Lichtenst AH. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. *Am J C Nutr* 65:823-830;1997.

277. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD. Absence of selectin delays fatty streak formation in mice. *J Clin Invest* 99:1037-1043;1997.

278. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Ordovas JM, and Schaefer EJ. Decreased production and increa catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. *Arterioscler Thromb Vasc Biol* 17:8 888;1997.

279. Tilly-Kiesi M, Lichtenstein AH, Ordovas JM, Dolnikowski GG, Malmstrom R, Taskinen MR, and Schaefer EJ. Subjects w apoA-I ($Lys_{107}$[illegible]0) exhibit enhanced fractional catabolic rate of apoA-I in Lp(AI) and apoA-II in Lp(AI with AII). *Arteriosc Thromb Vasc Biol* 17:873-880;1997.

280. Schaefer EJ. Effects of dietary fatty acids on lipoproteins and cardiovascular disease risk: summary. *Am J Clin Nutr* 65 (Sup 1655S-1656S; 1997.*

281. Farrer LA, Cupples LA, Kukull WA, Volicer L, Wells JM, Kurz A, Green RC, Chui H, Duara R, Auerbach SA, Larsen Lautenschlager N, Wolf PA, D'Agostino RD, Ordovas JM, Schaefer EJ, Growden JH, Haines JL. Risk of Alzheimer's diseas associated with parental age among apolipoprotein E ε4 heterozygotes. *Alzheimer's Research* 3:83-91;1997.

282. Nelson GJ, Schmidt PC, Bartolini G, Kelley DS, Phinney SD, Kyle D, Silberman S, Schaefer EJ. The effects of diet arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in hum *Lipids* 32:427-433;1997.

283. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Ordovas JM, and Schaefer EJ. Production of apolipoprotein B-6 apolipoprotein B-67/B-100 heterozygotes: technical problems associated with leucine contamination in stable isotope studie *Lipid Res* 38:1535-1543;1997.

284. Cuchel M, Schaefer EJ, Millar JS, Jones PJH, Dolnikowski GG, Vergani C, and Lichtenstein AH. Lovastatin decreases de n cholesterol synthesis and LDL apoB-100 production rates in combined-hyperlipidemic males. *Arterioscler Thromb Vasc I*

1997;17:1910-1917.

285. Davidson MH, Maki KC, Kalkowski J, Schaefer EJ, Torri SA, and Drennan KB. Effects of docosahexaenoic acid on se lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. *J Am Coll* 1997;16(3):236-243.

286. Campos H, Lopez-Miranda J, Rodriguez C, Albajar M, Schaefer EJ, and Ordovas JM. Urbanization elicits a more atherog lipoprotein profile in carriers of the apolipoprotein A-IV-2 allele than in A-IV-1 homozygotes. *Arterioscler Thromb Vasc* 1997;17:1074-1081.

287. Vogel S, Contois JH, Tucker KL, Wilson PWF, Schaefer EJ, and Lammi-Keefe CJ. Plasma retinol and plasma and lipopro tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. *Am J Clin* 1997;66:950-958.

288. Ellison RC, Moore LL, Proctor MH, Nguyen UDT, Schaefer EJ, and Stare FJ. Effect of response to a low-fat diet am adolescent males on their adult blood cholesterol levels. *Preventive Med* 1997;26:686-693.

289. Schaefer EJ and McNamara JR. Overview of the Diagnosis and Treatment of Lipid Disorders. Chap. 2. In: Handbool Lipoprotein Testing. Rifai N, Warnick GR, and Dominiczak MH, Eds. *AACC Press* 1997;25-47.*

290. Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, Wilson PWF, Eisman JA, Holick MF. The *Bsm*I vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intak bone mineral density. *J Bone Miner Res* 1997;12:1049-1057.

291. Smith D, Botet JP, Cantuti-Castelvetri I, Schaefer EJ, Ordovas JM. Influence of age, diet, and laboratory caging on lipid prc among FIB hamsters. *Nutr Res* Res 10:1569-1575;1997.

292. Ehrenborg E, Clee SM, Pimstone SN, Reymer PWA, Hoogendijk CF, Davis HJ, Bissada N, Miao L, Gagne SE, Greenberg Henry R, Henderson H, Ordovas JM, Schaefer EJ, Kastelein JTP, Kotze MJ, Hayden MR. Ethnic variation and in vivo effect the -93 Ig promoter variant in the lipoprotein lipase gene. *Arterioscler Thromb Vasc Biol* 17:2672-2678;1997.

293. Tilly-Kiesi M, Lichtenstein AH, Joven J, Vilella E, Cheung MC, Carrasco WV, Ordovas JM, Dolnikowski G, Schaefer Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. *Arterios Thromb Vasc Biol* 17:3513-3518;1997.

294. Tall A, Welch C, Applebaum-Bowden D, Wassef M, and the Working Group. Interaction of diet and genes in atherogenesis re of an NHLBI Working Group. *Arterioscler Thromb Vasc Biol* 17:3326-3331;1997.*

295. Jones, PJH, Ausman LM, Croll DH, Feng JY, Schaefer EJ, and Lichtenstein AH. Validation of deuterium incorporation aga sterol balance for measurement of human cholesterol biosynthesis. *J Lipid Res* 39:1111-1117;1998.

296. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ. Plasma lipoproteins as carrier phylloquinone (vitamin $K_1$) in humans. *Am J Clin Nutr* 67:1226-1331;1998.

297. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant lipoprotein cholesterol triglyceride reference ranges from the Framingham Heart Study. *Clin Chem* 44(6):1224-1232;1998.

298. Pitman WA, Osgood DP, Smith D, Schaefer EJ, Ordovas JM. The effects of diet and lovastatin on regression of fatty str lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in F1B hamst *Atherosclerosis* 138:43-52;1998.

299. Jones PJH, Ausman LM, Croll DH, Feng JY, Schaefer EJ, and Lichtenstein AH. Validation of deuterium incorporation aga sterol balance for measurement of human cholesterol biosynthesis. *J Lipid Res*39:1111-1117;1998.

300. Meydani SN, Meydani M, Blumberg JB, Leka LS, Pedrosa M, Diamond R, Schaefer EJ. Assessment of the safety supplementation with different amounts of vitamin E in healthy older adults. *Am J Clin Nutr* 63:311-318;1998.

301. Schwab US, Sarkkinen ES, Lichtenstein AH, Li Z, Ordovas JM, Schaefer EJ, Uusitupa MIJ. The effect of quality and amour dietary fat on the susceptibility of low density lipoprotein to oxidation in subjects with impaired glucose tolerance. *Eur J Clin I* 52:452-458;1998.

302. Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Proposal of a multicompartmental model for use in study of apolipoprotein E metabolism. *Metabolism* 47:(8) 922-928;1998.

303. Schaefer EJ and Brousseau ME. Diet, lipoproteins, and coronary heart disease. *Lipid Disorders.* In: Endocrinology Metabolism Clinics of North America 27:711-732;1998.*

304. Schaefer EJ, Brousseau ME, McNamara JR, Cohn JS, Lichtenstein AH, Genest JJr, Seman LJ, Lamon-Fava S, Ordovas Diagnosis and management of lipoprotein disorders: a review and update. Part I: Lipoprotein metabolism, familial lipopro disorders, and the rationale for treatment of lipid disorders. *Nutr in Clin Care* 1:71-79;1998.

305. Judd JT, Baer DJ, Clevidence BA, Muesing RA, Chen SC, Weststrate JA, Meijer GW, Wittes J, Lichtenstein AH, Vilella-Bacl Schaefer EJ. Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular disease factors in normolipemic adults fed controlled diets. *Am J Clin Nutr* 68:768-777;1998.

306. Schwab US, Vogel S, Lammi-Keefe CJ, Ordovas JM, Schaefer EJ, Li Z, Ausman LM, Gualtieri L, Goldin BR, Furr Lichtenstein AH. Varying dietary fat type of reduced-fat diets has little effect on the susceptibility of LDL to oxida modification in moderately hypercholesterolemic subjects. *J Nutr* 128:1703-1709;1998.

307. Schaefer EJ. Recognition and management of patients with lipoprotein disorders. In *Primary Cardiology* Goldman L, Braun\ E, ed., W.B. Saunders, p.445-467;1998.*

308. Ordovas JM, Cupples LA, Wilson PWF, Lahoz C, Levy D, Otvos JD, McNamara JR, Gagne E, Hayden M, Schaefer Advances in cardiovascular risk prediction: new biochemical and genetic markers. In *Atherosclerosis XI* Excerpta Me International Congress Series 1155:425-431;1998.*

309. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, Myers RH, Levy D. Evidence for association genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women ir Framingham Heart Study. *Circulation* 97:1766-1772;1998.

310. Lichtenstein AH, Kennedy E, Barrier P, Danford D, Ernst ND, Grundy SM, Leveille GA, VanHorn L, Williams CL, Booth Dietary fat consumption and health. *Nutrition Reviews* 56(5):S3-S28;1998.

311. Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PWF, Schaefer EJ. Frequency of apoB and apoE gene mutations as ca of hypobetalipoproteinemia in the Framingham Offspring Population. *Arterio Thromb Vasc Biol* 18:1745-1751;1998.

312. Seman LJ, McNamara JR, Schaefer EJ. Lipoprotein(a), homocysteine, and remnant-like particles: emerging risk factors. ( *Opin Cardiol* 1999;14:186-191.

313. Tucker KL, Chen H, Vogel S, Wilson PWF, Schaefer EJ, Lammi-Keefe CJ. Carotenoid intakes, assessed by dietary questionn are associated with plasma carotenoid concentrations in an elderly population. *J Nutr* 1999;129:438-445.

314. Velez-Carrasco W, Lichtenstein AH, Welty FK, Li Z, Lamon-Fava S, Dolnikowski GG, Schaefer EJ. Dietary restrictio saturated fat and cholesterol decreases HDL apoA-I secretion. *Arterioscler Thromb Vasc Biol* 1999;19:918-924.

315. Larson I, Hoffmann MM, Ordovas JM, Schaefer EJ, Marz W, Kreuzer J. The Lipoprotein lipase *Hin*dIII polymorph Association with total cholesterol and LDL cholesterol, but not with HDL and triglycerides in 342 females. *Clin Chem* 45:(7) 968;1999.

316. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PWF, Castelli WP, Ordovas JM, Schaefer Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. *Clin Chem* 45:(7)1039-1046;1999

317. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on se

lipoprotein cholesterol levels. *NEJM* 340(25):1933-1940;1999.

318. Ordovas JM, Schaefer EJ. Genes, variation of cholesterol and fat intake, and serum lipids. *Current Opin Lipid* 10:15-22;19

319. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipopro cholesterol. *N Engl J Med* 341:410-418;1999.

320. Handelman GJ, Nightingale ZD, Lichtenstein AH, Schaefer EJ, Blumberg JB. Lutein and zeaxanthin concentrations in pla after dietary supplementation with egg yolk. *Am J Clin Nutr* 70:247-251;1999.

321. Couture P, Otvos JD, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in cholesterol 7α-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offsp Study. *J Lipid Res* 40:1883-1889;1999.

322. Velez-Carrasco W, Lichtenstein AH, Barrett PHR, Sun Z, Dolnikowski GG, Welty FK, Schaefer EJ. Human apolipoprotein kinetics within triglyceride-rich lipoproteins and high density lipoproteins. *J Lipid Res* 40:1695-1700;1999.

323. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and Apo B- kinetics with stable isotopes. *Arterioscler Thromb Vasc Biol* 1999;19:2966;2974.

324. Mascioli EA, McLennan CE, Schaefer EJ, Lichtenstein AH, Hoy C-E, Christensen MS, Bistrian BR. Lipidemic effects o interesterified mixture of butter, medium-chain triacylglycerol and safflower oils. *Lipids* 34,889-894;1999.

325. Lamon-Fava S, Ordovas JM, Schaefer EJ. Estrogen increases apolipoprotein (Apo) A-I secretion in Hep G2 cells by modula transcription of the Apo A-I gene promoter. *Arterioscler Thromb Vasc Biol* 1999;19:2960-2965.

326. Aguilar CA, Talavera G, Ordovas JM, Barriguete JA, Guillen LE, Leco ME, Pedro-Botet J, Gonzalez-Barranco J, Gomez-Perez FJ, Rull JA. The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle. Atherosclerosis 1999;142:409-414.

327. Ordovas JM, Schaefer EJ. Treatment of dyslipidemia: genetic interactions with diet and drug therapy. Curr Atheroscler F 1999;1:16-23.

328. Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagne SE, Larson MG, Schaefer EJ, Boer JM, Gerd C, Hayden MR. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet 1999;56:297-305.

329. McNamara JR, Seman LJ, Schaefer EJ. The laboratory's role in identifying lipid and lipoprotein risk factors for CHD. M Med Lab Obs 1999;31:24-28,30-36,51.

330. Couture P, Otvos JD, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM. Absence of association between genetic variat in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in The Framingham Offsprin Study. Atherosclerosis 148:337-344,2000.

331. Larson IA, Ordovas JM, DeLuca C, Barnard JR, Feussner G, Schaefer EJ. Association of apolipoprotein (Apo)E genotype with plasma apo E levels. *Atherosclerosis* 148:327-335;2000.

332. Velez-Carrasco W, Lichtenstein AH, Li Z, Dolnikowski GG, Lamon-Fava S, Welty FK, Schaefer EJ. Apolipoprotein A-I and A-II kinetic parameters as assessed by endogenous labeling with [$^2H_3$] leucine in middle-aged and elderly men and women. *Arterioscler Thromb Vasc Biol* 20:801-806;2000.

333. Couture P, Otvos JD, Cupples LA, Lahoz C, Wilson PWF, Schaefer EJ, Ordovas JM. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Stud *Arterioscler Thromb Vasc Biol* 20:815-822;2000.

334. Schwab US, Ausman LM, Vogel S, Li Z, Lammi-Keefe CJ, Goldin BR, Ordovas JM, Schaefer EJ, Lichtenstein AH. Dieta cholesterol increases the susceptibility of low density lipoprotein to oxidative modification. *Atherosclerosis* 149:83-90;20(

335. Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasel McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr., Gu JZ. Novel mutation the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. *J Lipid Res* 41:433-441;2000.

336. Schaefer EJ, Augustin JL, Schaefer MM, Rasmussen H, Ordovas JM, Dallal GE, Dwyer JT. Lack of efficacy of a food-frequency questionnaire in assessing dietary macronutrient intakes in subjects consuming diets of known composition. Ar Clin Nutr 2000;71:746-751.

337. El-Swefy S, Schaefer EJ, Seman LJ, vanDongen D, Sevanian A, Smith DE, Ordovas JM, El-Sweidy M, Meydani M. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamster *Atherosclerosis* 149:277-286;2000.

338. Schaefer EJ and Seman LJ. The diagnosis and management of lipoprotein disorders. In Medical Management of Diabete Mellitus. Leahy JL, Clark NG, Cefalu WT (Eds). Marcel Dekker, Inc., NY. 499-526.*

339. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PWF, Schaefer EJ. Association of cholesteryl ester transfer protein - *Taq*IB polymorphism with variations in lipoprotein subclasses and coron heart disease risk. The Framingham Study. *Arterioscler Thromb Vasc Biol* 2000;20:1323-1329.

340. Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PWF, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. *Am J Clin Nutr* 71:1201-1208;2000.

341. Ordovas JM, Schaefer EJ. Genetic determinants of plasma lipid response to dietary intervention: the role of the *APOA1/C3/A4* gene cluster and the *APOE* gene. *British J Nutr* 83:S127-S136;2000.*

342. Marsh JB, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr Opin Lipidol 11:261-266;2000.*

343. Wityk RJ, Kittner SJ, Jenner JL, Hebel JR, Epstein A, Wozniak MA, Stolley PD, Stern BJ, Sloan MA, Price TR, McCarte RJ, Macko RF, Johnson CT, Earley CJ, Buehholz DW, Schaefer EJ. Lipoprotein(a) and the risk of ischemic stroke in wom Atherosclerosis 150:381-388,2000.

344. Welty FK, Lichtenstein AH, Barrett PHR, Jenner JL, Dolnikowski GG, Schaefer EJ. Effects of apoE genotype on apoB-48 and apoB-100 kinetics with stable isotopes in humans. Arterio Thromb Vasc Biol 20:1807-1810;2000.

345. Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman MW. Cellular cholesterol effl in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res 41:1125-1135;2000.

346. Sun Z, Larson IA, Ordovas JM, Barnard JR, Schaefer EJ. Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations. Atherosclerosis 151:381-388;2000.

347. Jenner JL, Jacques PF, Seman LJ, Schaefer EJ. Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations. Atherosclerosis 151:541-544;2000.

348. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of apoA-I containing HDL subpopulations in patients with coronary heart disease. *Arterioscler Thromb Vasc Biol* 2000;20:2670-26

349. Schaefer EJ, Brousseau, ME. Benefits of reducing low-density lipoprotein cholesterol concentrations to <100 mg/dl. *Preventive Cardiol* 2000;2:136-139.

350. Brousseau ME, Schaefer EJ. Diet and coronary heart disease: clinical trials. Curr Athero Reports 2000;2:487-493.

351. Meigs JB, Ordovas JM, Cupples LA, Singer DE, Nathan DM, Schaefer EJ, Wilson PW. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. Diabetes Care 2000;23:669-6

352. Shearman AM, Ordovas JM, Cupples LA, Schaefer EJ, Harmon MD, Shao Y, Keen JD, DeStefano AL, Joost O, Wilson P Housman DE, Myers RH. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3-qter: a genome-w scan in the Framingham study. Hum Mol Genet 2000;9:1315-1320.

353. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. *Atherosclerosis* 2001;154:229-236.

354. Millar JS, Lichtenstein AH, Ordovas JM, Dolnikowski GG, Schaefer EJ. Human triglyeride-rich lipoprotein apoE kinetic and its relationship to LDL apo B-100 metabolism. Atherosclerosis 155:477-485;2001.

355. Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, Ehnholm C, Frohlich J, Schaef EJ. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res 42:597-604;2001.

356. Schaefer EJ, Augustin JL, McNamara JR, Seman LJ, Bourdet KL, Meydani MM, Holay S. Lipid lowering and weight reduction by home-delivered dietary modification in coronary heart disease patients taking statins. Am J Cardiol 87:1000-1003;2001.

357. Lahoz C, Schaefer EJ, Cupples LA, Wilson PWF, Levy D, Osgood D, Parpos S, Pedro-Botet J, Daly JA, Ordovas JM. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154:529-537;2001

358. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high-density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 156:217-225,2001.

359. Sun Z, Lichtenstein AH, Dolnikowski GG, Welty FK, Schaefer EJ. Human apolipoprotein A-IV metabolism within triglyceride-rich lipoproteins and plasma. Atherosclerosis 156:363-372;2001.

360. Maki KC, Davidson MH, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, Chen S, McNamara JR, Gebhart BW, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step 1 diet. Am J Clin Nutr 74:33-43;2001.

361. Lyu LC, Yeh CY, Lichtenstein AH, Li Z, Ordovas JM, Schaefer EJ. Association of sex, adiposity, and diet with HDL subclasses in middle aged Chinese. Am J Clin Nutr 74:64-71;2001.

362. Saltzman E, Das SK, Lichtenstein AH, Dallal GE, Corrales A, Schaefer EJ, Greenberg EJ, Roberts SB. An oat-containing hypo caloric diet reduces blood pressure and improves lipid profile beyond effects of weight loss in men and women. J Nu 131:1465-1470;2001.

363. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88:270-274;2001.

364. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PWF, Lahoz C, Cucinotta D, Couture P, Mallory T, Schaefer EJ, Ordovas JM. Association of the Sst-1 polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham Offspring Study. Atherosclerosis 158:173-82,2001.

365. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM. Apolipoprotein E genotyp affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158:183-94,2001.

366. Sun Z, Welty FK, Dolnikowski GG, Lichtenstein AH, Schaefer EJ. Effects of a National Cholesterol Education Program S II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma. Am J Clin Nutr 2001;74:3 14.

367. Davidson MH, Maki KC, Umporowicz DM, Ingram KA, Dicklin MR, Schaefer E, Lane RW, McNamara JR, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. Safety and tolerability of esterified phytosterols administered in reduced spread and salad dressing to healthy adult men and women. J Am Coll Nutr 20:(4)307-319,2001.

368. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman Wexler LF, Rubins HB, for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 2001;285:1585-91.

369. Schaefer EJ, Brousseau ME, Diffenderfer MR, Cohn JS, Welty FK, O'Connor J, Dolnikowski GG, Wang J, Hegele RA, Jones PJ. Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis 2001;159:231-236.

370. Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, Augustin JL, Seman LJ, Rubenstein JL. Compari of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 2001;88:1129-1133.

371. Galluzzi JR, Cupples LA, Otvos JD, Wilson PWF, Schaefer EJ, Ordovas JM. Association of the A/T54 polymorphism in intestinal fatty acid binding protein with variations in plasma lipids in the Framingham Offspring Study. Atherosclerosis 159:417-424,2001.

372. Corella D, Tucker K, Lahoz C, Coltell O, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM. Alcohol drinking determi the effect of the apoE locus on LDL cholesterol in men: the Framingham Offspring Study. Am J Clin Nutr 2001;73:736-7

373. Brousseau ME, Bodzioch M, Schaefer EJ, Goldkamp AL, Kielar D, Probst M, Ordovas JM, Aslanidas C, Lackner K, Rub HB, Collins D, Robins SJ, Wilson PWF, Schmitz G. Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis 154:607-611,2001.

374. Ordovas JM, Corella D, Cupples LA, Demissie S, Kelleher A, Coltell O, Wilson PWF, Schaefer EJ, Tucker K. Polyunsaturated fatty acids modulate the effects of the apoA-I, 6-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner. The Framingham Study. Am J Clin Nutr 75:38-46,2002.

375. Schaefer EJ. E.V. McCollum Award Lecture: Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002;75:191-212

376. Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach M, Jauhiainen M, McGladdery S, Erkkila AT, Ehnholm C, Frohl J, Schaefer EJ. Efficacy of a therapeutic lifestyle change/step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res 2002;43:264-273.

377. Sung NH, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, rela to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res 2002,43:445-452.

378. Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach M, Jauhiainen M, McGladdery S, Erkkila AT, Ehnholm C, Frohl J, Schaefer EJ. Efficacy of a therapeutic lifestyle change/step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res 2002;43:264-273.

379. Sung NH, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, rela to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Re 2002;43:445-452.

380. Batista MC, Schaefer EJ. Diagnosis and Management of Lipoprotein Abnormalities. Nutr Clin Care 2002;5:115-123.

381. Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PWF. Elevated remnant-like partic cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002;25:989-994.

382. Lamon-Fava S, Schaefer EJ, Garuti R, Salen G, Calandra S. Two novel mutations in the sterol 27-hydroxylase gene causi

cerebrotendinous xanthomatosis. Clin Genet 2002;61:185-191.

383. Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, Schaefer EJ. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet 2002;61:176-184.

384. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162:227-244.

385. Brousseau ME, O'Connor JJ, Ordovas JM, Collins D, Otvos JD, Massov T, McNamara JR, Rubins HB, Robins SJ, Schaefer EJ. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease endpoints in men with HDL deficiency. Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002;22:1148-1154.

386. Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr Athero Reports 2002,4:343-349.

387. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubenstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361-369,2002.

388. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002,90:689-696.

389. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubenstein JJ, Schaefer EJ. Effects of atorvastatin on HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002;43:1701-1707.

390. Gleason JA, Bourdet KL, Koehn K, Holay S, Schaefer EJ. Cardiovascular risk reduction and dietary compliance with a home-delivered diet and lifestyle modification program. J Am Diet Assoc 2002;102:1445-1451.

391. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, Ausman LM. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol 2002;22:1852-1858.

392. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. For the VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease. Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.

393. Bermudez OI, Velez-Carrasco W, Schaefer EJ, Tucker KL. Dietary and plasma lipid, lipoprotein, and apolipoprotein profiles among elderly Hispanics and non-Hispanics and their association with diabetes. Am J Clin Nutr 2002;76:1214-1221.

394. Schaefer EJ. Importance of dietary management and practical patient counseling – US perspective. Atherosclerosis Suppl 3,2002;17-22.

395. Lamon-Fava S, Posfai B, Schaefer EJ. Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women. Am J Cardiol 91:252-254;2003.

396. Brousseau ME, Schaefer EJ. Structure and mechanisms of action of HMG-CoA reductase inhibitors. G. Schmitz, M. Torzewski (eds). In: Milestones in Drug Therapy. Pp 19-34, 2003.

397. Hays NP, Bathalon GP, Meydani SN, Leka LS, Lipman R, Roubenoff R, Schaefer EJ, Roberts SB. Metabolic aging and predicted longevity: results of a cross-sectional study in post-menopausal women. Aging Clin Exp Res 2002;14(6):465-473.

398. Matthan NR, Giovanni A, Schaefer EJ, Brown BG, Lichtenstein AH. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res 2003;44:800-806.

399. Asztalos BF, Schaefer EJ. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003;91(suppl):12E-17E.

400. Asztalos BF, Schaefer EJ. HDL in atherosclerosis: actor or bystander? Atherosclerosis Supplements 4 (2003)21-29.

401. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-852.

402. Kakko S, Kelloniemi J, von Rohr P, Hoeschele I, Tamminen M, Brousseau ME, Kesaniemi YA, Savolainen MJ. ATP-binding cassette transporter A1 locus is not a major determinant of HDL C levels in a population at high risk for coronary heart disease. Atherosclerosis 2003;166:285-290.

ABSTRACTS

1. Schaefer EJ, Blum CB, Levy RI, Goebel RH, Brewer HB Jr, Berman M.: High density lipoprotein metabolism in Tangier disease. *Circulation* 54:27-II, 1976.
2. Corash L, Schaefer EJ, Poindexter E, Anderson J: Platelet function in familial hypercholesterolemia. *Circulation* 54:117-II, 1976.
3. Schreibman PH, Schaefer EJ, Kibata M, Woo R: Changes in adipocyte cholesterol and triglyceride content during weight reduction. *Circulation* 54:165-II, 1976.
4. Schaefer EJ, Levy RI, Jenkins LL, Brewer HB Jr: The effect of estrogen administration on human lipoprotein metabolism. Sixth International Symposium on Drugs Affecting Lipid Metabolism. In D. Kritchevsky, R. Paoletti, W.L. Holmes (eds.) Drugs, Lipid Metabolism, and Atherosclerosis, Plenum Press, *Adv. Exp. Med.* 109:408, 1978.
5. Schaefer EJ, and Brewer HB Jr: Tangier disease: a defect in the conversion of chylomicrons to high density lipoproteins. *Clin. Res.* 26:532A, 1978.
6. Schaefer EJ, and Brewer HB Jr: High density lipoprotein apolipoprotein metabolism. *Am. Oil Chemist Soc.* (HDL Symposium, St. Louis), pp. 64, 1978.
7. Zech LA, Schaefer EJ, Brewer HB Jr: Metabolism of plasma apolipoproteins A-I and A-II in man. *Circulation* 58:Suppl. 2,II-40, 1978.
8. Schwartz DE, Liotta L, Schaefer EJ, Brewer HB Jr: Localization of apolipoproteins A-I, A-II, and B in normal, Tangier, and abetalipoproteinemia intestinal mucosa. *Circulation* 58:Suppl.2,II-90, 1978.
9. Schaefer EJ, Zech LA, Anderson DW, Bronzert TJ, Lindgren FT, Brewer HB Jr: The metabolism of high density lipoprotein constituents in Tangier disease. *Clin. Res.* 27:376A, 1979.
10. Anderson DW, Schaefer EJ, Forte T, Niblack GD, Brewer HB Jr: Evidence for recirculation of apolipoproteins A-I and A-II between plasma and human thoracic duct lymph. *Clin. Res.* 27:362A, 1979.
11. Schaefer EJ, and Brewer HB Jr: The HDL-triglyceride connection, factors regulating HDL cholesterol levels. *Am. J. Cardiology* 43:409, 1979.
12. Lipson LC, Bonow RO, Schaefer EJ, Brewer HB Jr, Lindgren FT, Epstein SE: Effects of exercise on human plasma lipoproteins. *Am. J. Cardiology* 43:409, 1979.
13. Schaefer EJ, Zech LA, Bronzert TJ, Brewer HB Jr: Apolipoprotein metabolism in abetalipoproteinemia. *Circulation* 60:II-118, 1979.
14. Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr: Apolipoprotein E metabolism in normal subjects and patients with type III hyperlipoproteinemia. *Clin. Res.* 28:394A, 1980.
15. Gregg RE, Schaefer EJ, Zech LA, Brewer HB Jr: Lipoprotein distribution of radioiodinated apoE in type III and type V apolipoprotein E. *Circulation* 62:III-43, 1980.
16. Schaefer EJ, Levy RI, Ernst NC, Brewer HB Jr: Effects of cholesterol lowering diets on lipoprotein cholerterol levels. *Circulation* 62:III-227, 1980.
17. Schaefer, EJ, Heaton WH, Brewer HB Jr: Plasma apolipoprotein A-I absence associated with coronary artery disease. *Arteriosclerosis* 1:395A, 1981.
18. Ghiselli G, Schaefer EJ, Brewer HB Jr: Type III hyperlipoproteinemia associated with plasma apolipoprotein E deficiency. *Arteriosclerosis* 1:377A, 1981.
19. Jahn C, Osborne JO Jr, Schaefer EJ, Brewer HB Jr: Activation of the enzymic activity of hepatic lipase by apoA-II. *Arteriosclerosis* 1:381, 1981.
20. Summerfield JA, Vergalla J, Schaefer EJ, Kay L, Brewer HB Jr: The molecular basis of Tangier disease: a structurally abnormal apolipoprotein A-I mediates hypercatabolism of lipoprotein by hepatocytes and an accumulation of cholesterol in Kuppfer cells. *Hepatology* 1:552, 1981.
21. Ghiselli G, Summerfield JA, Schaefer EJ, Sirtori C, Jones EA, Brewer HB Jr: Abnormal catabolism of apolipoprotein A-I Milano. *Clin. Res.* 30:291A, 1982.
22. Ghiselli G, Schaefer EJ, Zech LA, Gregg RE, Brewer HB Jr: Increased prevalence of apolipoprotein E4 in type V

hyperlipoproteinemia. *Clin. Res.* 30:291A, 1982.
23. Gregg RE, Zech LA, Schaefer EJ, Ronan R, Brewer HB Jr: Increased production and delayed catabolism of apolipoprotein E: a dual defect in apo E metabolism in type III hyperlipoproteinemia. *Clin. Res.* 30:481A, 1982.
24. Schaefer EJ, Kay LL, Summerfield JA, Jones EA, Brewer HB Jr: Tangier disease: high density lipoprotein deficiency due to defective metabolism of an abnormal apo A-I (apoA-I Tangier). *Clin. Res.* 30:529A, 1982.
25. Jahn CE, Schaefer EJ, Hoofnagle JH, Jones EA, Brewer HB Jr: Lipoprotein abnormalities in primary biliary cirrhosis due to hepatic lipase inhibition. *Clin. Res.* 30:496A, 1982.
26. Hoeg JM, Demosky SJ, Schaefer EJ, Brewer HB Jr: Of binding of low density lipoproteins (LDL) to human hepatic membranes of normal and homozygous type IIA hyper-lipoproteinemic subjects. *Clin. Res.* 30:193a, 1982.
27. Schaefer EJ, Zech LA, Ghiselli G, Brewer HB Jr: ApoB-48 metabolism: retarded catabolism due to apo E deficiency. *Circulation* 66:II-161, 1982.
28. Gregg RE, Ronan R, Zech LA, Ghiselli G, Schaefer EJ, Brewer HB Jr: Abnormal metabolism of apolipoprotein E4. *Circulation* 66:II-161, 1982.
29. Hoeg JM, Demosky SJ, Schaefer EJ, Starzl TE, Brewer HB Jr: Familial hypercholesterolemia: defective hepatic LDL receptor binding with accumulation of hepatic cholesterol and cholesteryl ester. *Arteriosclerosis* 2:421a, 1982.
30. Sprecher DL, Schaefer EJ, Gregg RE, Zech LA, Brewer HB Jr: Homozygous familial hypercholesterolemia: review of the NIH experience. *Arteriosclerosis* 2:425a, 1982.
31. Zech LA, Gregg RE, Albers JJ, Schaefer EJ, Brewer HB Jr: Increased catabolism of apoA-I and apoE in LCAT deficiency. *Arteriosclerosis* 2:426a, 1982.
32. Ghiselli G, Schaefer EJ, Zech LA, Light JA, Brewer HB Jr: Apolipoprotein A-I polymorphism in human lymph, effect of fat feeding. *Arteriosclerosis* 2:439a,.
33. Sprecher DL, Hoeg JM, Schaefer EJ, Brewer HB Jr: Correlation of LDL receptor activity and clinical course in patients with homozygous familial hypercholesterolemia. *Clin. Res.* 31:292a, 1983.
34. Sprecher DL, Schaefer EJ, Gregg RE, Wilson P, Brewer HB Jr: Apolipoprotein A-I, C-II, and A-I/C-II ratio: new parameters correlating with coronary artery disease. *Clin. Res.* 31:219a, 1983.
35. Ghiselli G, Schaefer EJ, Law S, Light JA, Brewer HB Jr: Plasma catabolism of human proapoA-I (apoA-I2): evidence that apoA-I isoproteins A-I4 and A-I5 are the major catabolic products of proapoA-I in plasma. *Clin. Res.* 31:500a, 1983.
36. Schaefer EJ, Riggs P, Jenkins LL, Gregg RE, Zech LA, Brewer HB Jr: Synergistic effect of dietary cholesterol and fat in alteration of low density lipoproteins. *Clin. Res.* 31:466a, 1983.
37. Hoeg JM, Demosky SJ, Schaefer EJ, Starzl TE, Brewer HB Jr: The effect of portacaval shunt on hepatic lipid and lipoprotein metabolism in familial hypercholesterolemia. *Clin. Res.* 31:492a, 1983.
38. Hoeg JM, Schaefer EJ, Gregg RE, Zech LA, Jahn C, Brewer HB Jr: The safety and efficacy of neomycin in the treatment of type II hyperlipoproteinemia. *Clin. Res.* 31:248a, 1983.
39. Santaniello P, Ordovas JM, Sasak V, Schaefer EJ: Enzyme linked immunosorbent assay for plasma apolipoprotein B utilizing polyclonal and monoclonal antibodies. *J. Am. Coll. Nutr.* 3:44, 1984.
40. Ordovas JM, Litwack-Klein L, Schaefer EJ: Relationship of genetic apolipoprotein E polymorphism to plasma lipids. *J. Am. Coll. Nutr.* 3:44, 1984.
41. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Siguel EN, Castelli WP: Coronary artery disease risk factors in healthy octogenarians: Framingham Heart Study. *J. Am. Coll. Nutr.* 3:44, 1984.
42. Sasak V, Ordovas JM, Schaefer EJ: A novel cell line for human intestinal apolipoprotein synthesis. *J. Am. Coll. Nutr.* 3:23, 1984.
43. Siguel EN, Blumberg JB, Russell RM, Schaefer EJ: Diagnosis of essential fatty acid deficiency using high sensitivity capillary column gas liquid chromatography. *J. Am. Coll. Nutr.* 3:145, 1984.
44. Farber HN, Hill NS, Hill SP, Arbetter J, Grimaldi R, Schaefer EJA Acute metabolic effects of an endurance triathlon. *Clin. Res.* 33:250a, 1985.
45. Schaefer EJ, McNamara JR, Krasinski SD, Russell RM: Postprandial alterations in plasma lipoproteins and retinyl esters. *Clin. Res.* 33:277a, 1985.
46. Meydani M, Macauley JB, Blumberg JB, McNamara JR, Schaefer EJ: Postprandial alterations in lipoprotein alpha-tocopherol. *Am. J. Clin. Nutr.* 41:869, 1985.
47. Triau JE, Arbetter J, Schaefer EJ: Impaired hepatocyte binding and degradation of glucosylated low density lipoproteins. *Fed. Proc.* 44:753, 1985.
48. McNamara JR, Salem D, Schaefer EJ: Prevalence of lipoprotein abnormalities in coronary artery disease patients. *Clin. Chem.* 31:947, 1985.
49. McNamara JR, Schaefer EJ: Automated enzymatic lipid analyses with CDC standardization. *Clin. Chem.* 31:947, 1985.
50. Schaefer EJ, Peterson J, Santaniello P, Wilson PWF, Ordovas JM: Enzyme linked immunosorbent assay (ELISA) for plasma apolipoprotein B and apolipoprotein B-100 utilizing polyclonal and monoclonal antibodies. *Arteriosclerosis* 5:496a, 1985.
51. Ordovas JM, Sasak V, Schaefer EJ: Human intestinal apolipoprotein synthesis in vitro. *Arteriosclerosis* 5:532a, 1985.

52. Ordovas JM, Schaefer EJ, Salem D, Glueck CJ, Vergani C, Wilson PWF, Karathanasis SK: Apolipoprotein A-I gene polymorphism associated with familial hypoalphalipoproteinemia and premature coronary artery disease. *Arteriosclerosis* 5:505a, 1985.
53. Zannis V, Ordovas JM, Claradas C, Schaefer EJ: ApoE mRNA and protein synthesis abnormalities in a patient with familial plasma apoE deficiency. *Arteriosclerosis* 5:503a, 1985.
54. Triau JE, Meydani SN, Meydani M, Libby P, Schaefer EJ: Oxidized low density lipoproteins stimulate prostacyclin (PGI2) production by adult vascular endothelial cells. *Fed. Proc.* 45:347, 1985.
55. Schaefer EJ, Ordovas JM, Cohn S, Wilson PWF: Apolipoprotein E isoforms in the Framingham Offspring Study: significance of variant alleles. *Arteriosclerosis* 6:545a, 1986.
56. Schaefer EJ, McNamara JR, Ordovas JM, Campos H, Peterson J, Albers JJ, Wilson PWF: Lipoprotein abnormalities in coronary artery disease patients. *Arteriosclerosis* 6:549a, 1986.
57. Ordovas JM, Mandel G, Goodman RH, Schaefer EJ: Production of apoA-I in HDL following transfection of the human apoA-I gene into 3T3 cells. *Arteriosclerosis* 6:553a, 1986.
58. McNamara JR, Campos H, Ordovas JM, Schaefer EJ, Albers JJ: Identification of lipoprotein (a) by gradient gel electrophoresis: relationship to coronary artery disease. *Clin. Chem.* 33:897, 1987.
59. Hennessy LK, Arrigo DA, Nicolosi RJ, Schaefer EJ: Dietary effects on LDL particle size in cebus monkeys. *Arteriosclerosis* 7:534a, 1987.
60. Cohn JS, McNamara JR, Cohn SD, Krasinski SD, Ordovas JM, Russell RM, Schaefer EJ: Postprandial plasma triglyceride peaks once, twice or three times in subjects fed a fat-rich meal. *Arteriosclerosis* 7:534a, 1987.
61. Hughes TE, Ordovas JM, Schaefer EJ: Apolipoprotein B and A-I Synthesis and secretion: modification by alterations in intracellular calcium. *Arteriosclerosis* 7:493a, 1987.
62. Zech LA, Schaefer EJ: Model for absorption and catabolism of plasma triglyceride in response to an oval fat challenge. *Arteriosclerosis* 7:535a, 1987.
63. Schaefer EJ, McNamara JR, Genest J, Schaefer MM, Wilson PWF, Albers JJ, Ordovas JM: LDL particle size lipoproteins, and apolipoproteins in premature coronary artery disease: confounding effects of beta blockers. *Arteriosclerosis* 7:535a, 1987.
64. Schaefer EJ, Cohn SD, Schaefer MM, Ordovas JM, Wilson PWF: Factors affecting apolipoproteins A-I and B: results from the Framingham Offspring Study. *Circulation* 78:II-226, 1988.
65. Ordovas JM, King DC, Bisgaier CL, Schaefer EJ: Familial apolipoprotein A-I, C-III, and A-IV deficiency due to deletion of a gene complex. *Circulation* 78:II-389, 1988.
66. Genest JJ, Ordovas JM, McNamara JR, Salem DN, Frossard P, Wilson PWF, Schaefer EJ: DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. *Arteriosclerosis* 8:613a, 1988.
67. Pitman WA, Gordon PR, Lamon-Fava S, Ordovas JM, Schaefer EJ: Regulation of intestinal lipid and apoB Secretion by phosphoinositol and Ca++. *Arteriosclerosis* 8:568a, 1988.
68. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ: The measurement of VLDL and LDL apoB-100 synthesis in humans using deuterated leucine:effect of feeding and fasting. *Circulation* 78:II-193, 1988.
69. Hennessy LK, Schaefer EJ, Nicolosi RJ: Saturated Fat Effects on LDL Subclass Metabolism. *Circulation* 78:II-571, 1988.
70. Hughes TE, Ordovas JM, Schaefer EJ: ApoA-I gene expression during enterocytic differentiation. *Arteriosclerosis*, 8:566a, 1988.
71. Lamon-Fava S, Campos H, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ: Effect of menstrual status on plasma lipid and apolipoprotein levels. Proc. Eighth International Sympos. *Atherosclerosis,* p. 154, 1988.
72. Nicolosi R, Kowala M, Karge W, Kuo P, Loscalzo J, Schaefer EJ: Diet effects on low density lipoprotein metabolism in monkeys. Proc. Eighth International Sympos. *Atherosclerosis*, p. 661, 1988.
73. Ordovas JM, King DC, Schaefer EJ: Familial apolipoprotein A-I and C-III deficiency is due to a deletion of the apolipoprotein A-I, C-III, A-IV gene complex. Proc. Eighth International Sympos. *Atherosclerosis*, p. 691, 1988.
74. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ: The measurement of apoB-100 and apoA-I synthesis in humans using stable isotopes. Proc. Eighth International Sympos. *Atherosclerosis*, p. 154, 1988.
75. Genest J, Ordovas JM, McNamara JR, Salem DN, Frossard P, Wilson PWF, Schaefer EJ: DNA polymorphisms of the apoB gene in patients with premature coronary artery disease and in an elderly population free of disease. Proc. Eighth International Sympos. *Atherosclerosis*, p. 297, 1988.
76. Genest JJ, Martin-Munley S, McNamara JR, Salem D, Schaefer EJ: Frequency of genetic dyslipidemia in patients with premature coronary artery disease. *Circulation* 80:II-180, 1989.
77. Osada J, Hennessy L, Ordovas JM, Stucchi A, Nicolosi R, Schaefer EJ: Effects of dietary fats and cholesterol on hepatic apolipoprotein mRNA levels. *Circulation* 80:II-621, 1989.
78. Cohn JS, Millar JS, Cohn SD, Johnson EJ, Milne RW, Marcel YL, Russell RM, Schaefer EJ: The contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to post-prandial increases in plasma triglyceride and retinyl esters. *Arteriosclerosis* 9:728a, 1989.
79. Lichtenstein AH, Cohn JS, Hachey DL, Millar JS, Jenner JL, Schaefer EJ: The measurement of apolipoprotein synthesis by the

constant infusion of three dueterated amino acids. *Arteriosclerosis* 9:749a, 1989.

80. Schaefer EJ, Blijleven E, McNamara JR, Campos H, Genest JJ, Wilson PWF: Factors affecting LDL subclasses and relationship to premature coronary artery disease. *Arteriosclerosis* 9:761a, 1989.
81. Campos H, Granfone A, McNamara JR, Ordovas JM, Wilson PWF, Schaefer EJ: Effects of estrogen on plasma lipoproteins and apolipoproteins (apo) A-I and B in normal and dyslipidemic women. *Circulation* 80:II-207, 1989.
82. Lamon-Fava S, Jimenez D, Christian JC, Reed T, Fabsitz RR, Ordovas JM, Wilson PWF, Schaefer EJ: Heritability of apoA-I, apoB, lipoprotein (a), and low density lipoprotein subclasses. *Circulation* 80:II-408, 1989.
83. Genest JJ, Bard JM, Fruchart JC, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ: Plasma Apolipoproteins (a), A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. *Circulation* 1990;82:III-2467.
84. Osada J, Ordovas JM, Stucchi A, Nicolosi RJ, Schaefer EJ: LDL response to an atherogenic diet is related to hepatic apolipoprotein A-IV gene expression in Cynomolgus monkeys. *Arteriosclerosis* 1990;10:881a.
85. Rodriguez CR, Ordovas JM, Genest JJ, Schaefer EJ: Familial Lp(a) excess: association with specific low molecular weight apo(a) isoforms. *Arteriosclerosis* 1990;10:848a.
86. Ordovas JM, Osada J, Hennessy LK, Stucchi AF, Nicolosi RJ, Loscalzo J, Schaefer EJ: Dietary saturated fatty acids and cholesterol regulate LDL receptor mediated catabolism by decreasing both LDL receptor gene expression and membrane fluidity. *Arteriosclerosis* 1990;10:882a.
87. Genest JJ, McNamara JR, Upson B, Salem D, Schaefer EJ, Malinow MR: Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. *Circulation* 1990;82:III-517.
88. Hachey DL, Lichtenstein AH, Millar JS, Ordovas JM, Schaefer EJ: Primed constant [5,5,5-2H3] leucine infusion in the fed state: greater maximal enrichment of apoB-100 than apoB-48 within triglyceride-rich lipoproteins. *Circulation* 82:III-475, 1990.
89. Lichtenstein AH, Millar J, McNamara JR, Ordovas JM, Schaefer EJ: Long term lipoprotein response to the NCEP Step 2 diet enriched in n-3 fatty acids. *Circulation* 1990;82:III-475.
90. Meydani SN, Lichtenstein AH, Cornwall S, Dinarello CA, Schaefer EJ: Effect of NCEP step 2 diet enriched in n-3 fatty acid on the immune response. *Arteriosclerosis* 1990;82:III-475.
91. Campos H, Posner BM, Ordovas JM, Wilson PWF, Schaefer EJ: Dietary intake and plasma lipoproteins, apolipoproteins and LDL particle size in Costa Ricans and Framingham Offspring Study participants. *Circulation* 1990;92:III-477.
92. Campos H, Genest JJ, McNamara JR, Ordovas JM, Wilson PWF, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. *Circulation* 1990;82:III-349.
93. Schaefer EJ, Millar JS, Hachey DL, Jenner J, McNamara JR, Ordovas JM, Lichtenstein AH: Effect of an NCEP Step 2 diet rich in n-3 fatty acids on apolipoprotein B kinetics. *FASEB J* 1991;5:A-1070.
94. Lichtenstein AH, Millar JS, McNamara JR, Jenner JL, Rasmussen H, Ordovas JM, Schaefer EJ: Effect of long term consumption of an NCEP Step 2 diet on fasting and fed plasma lipoprotein concentrations. *FASEB J* 1991;5:A-1070.
95. Stucchi A, Hennessy L, Vespa D, Osada J, Ordovas J, Schaefer EJ, Nicolosi R. Effects of dietary fat saturation and cholesterol on HDL apoA-I metabolism and hepatic apoA-I mRNA levels. *FASEB J.* 1991;5:A711.
96. Ordovas JM, Osada J, Hennessy LK, Stucchi AF, Nicolosi RJ, Loscalzo J, Schaefer EJ: Cellular fluidity is the predominant factor by which dietary fat affects LDL receptor mediated catabolism. *Arteriosclerosis and Thrombosis* 11:1604a, 1991.
97. Meydani SN, Lichtenstein AH, Cornwall S, Dinarello CA, Rasmussen H, Schaefer EJ: Immunological effects of NCEP-Step 2 diets: effects of n3 fatty acids. *Arteriosclerosis and Thrombosis* 11:16.
98. Jones PJH, Lichtenstein AH, Leitch CA, Schaefer EJ: Differences in cholesterol kinetics in humans fed corn oil versus olive oil. *Arteriosclerosis and Thrombosis* 11:1602a, 1991.
99. Lichtenstein AH, Ausman L, Jenner JL, Carrasco W, Schaefer EJ: Effect of the consumption of rice bran, corn, canola, and olive oil on plasma lipids and apolipoprotein concentrations in humans. *Arteriosclerosis and Thrombosis* 11:1603a, 1991.
100. Seman L, Rodriguez C, Ordovas JM, Genest J Jr, Schaefer EJ: Apolipoprotein (a) isoforms are inherited in an autosomal co-dominant pattern. *Arteriosclerosis and Thrombosis* 11:1526a, 1991.
101. Schaefer, EJ, Cheung, M, Hachey DL, Lichtenstein, AH: Apolipoprotein A-I and A-II metabolism in HDL subpopulations. *Arteriosclerosis and Thrombosis* 11:1408a, 1991.
102. Lichtenstein AH, Ausman L, Jenner JL, Carrasco W, Schaefer, EJ: Effect of Substituting Hydrogenated For Unhydrogenated Corn Oil on Plasma Lipid and Apoliprotein Concentrations in Humans. *Circulation* 86:I-406, 1992.
103. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd, JT, Denke MA, Grundy SM, Schaefer EJ: Effect of apoliprotein E isoforms on the LDL cholesterol response to an NCEP Step 2 diet. *Circulation* 86:I-406, 1992.
104. Mata P, Ordovas JM, Lopez-Miranda J, Lichtenstein AH, Clevidence B, Judd JT, Denke MA, Grundy SM, Schaefer EJ: Variation at the apoliprotein A-IV gene locus affects plasma LDL cholesterol response to an NCEP Step 2 Diet. *Circulation* 86:I-405, 1992.
105. Campos H, Blijlevens E, McNamara J, Ordovas JM, Posner BM, Wilson PW, Castelli P, Schaefer EJ: Low Density Lipoprotein Particle Size Distribution in the Framingham Offspring Cycle: Relation to Plasma Lipoproteins and Dietary Fat Intake. *Circulation* 86:I-811, 1992.
106. McNamara JR, Li Z, Wilson PWF, Schaefer EJ: Change in LDL Particle Size is Associated with Change in Plasma Triglyceride

Concentration. *Circulation* 86:I-811, 1992.
107. Brousseau ME, Stucchi AF, Vespa DB, Schaefer EJ, Nicolosi RJ: Comparative Effects of Diets Enriched in Saturated, Monounsaturated, and Polyunsaturated Fats on Lipoprotein Metabolism. *Circulation* 86:I-746, 1992.
108. Schaefer EJ, Jenner JL, Ordovas JM, O'Grady HK, Davis CE, Lippel K: Elevated Lipoprotein (a) Levels Predict CHD Incidence in the Prospective Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT). *Circulation* 86:I-812, 1992.
109. Wilson PWF, Larson MG, Ordovas JM, Schaefer EJ: Apolipoprotein E isoforms and CHD prevalence in the Framingham Offspring Study. *Circulation* 86:I-810, 1992.
110. Wilson PWF, Schaefer EJ, Larson MG. The 1993 national cholesterol guidelines and coronary prediction. The Framingham Heart Study. *Circulation* 88:I-14; 1993.
111. McNamara JR, Small DM, Schaefer EJ. Differences in LDL subspecies involve conformational changes in apoB. *Circulation* 88:I-133; 1993.
112. Li Z, McNamara JR, Fruchart JC, Ordovas JM, Schaefer EJ. Effects of gender and menopause on lipoprotein subspecies. *Circulation* 88:I-221; 1993.
113. Brousseau ME, Ordovas JM, Nicolosi RJ, Schaefer EJ. A diet enriched in monounsaturated fatty acids lowers plasma lipoprotein (a) concentrations by a different mechanism than does a diet enriched in polyunsaturated fatty acids. *Circulation* 88:I-456; 1993.
114. Lichtenstein AH, Ausman LM, Jenner J, Carrasco W, Schaefer EJ. Effect of low and very low fat diets on plasma lipid and lipoprotein concentrations in moderately hypercholesterolemic subjects during weight maintenance and weight loss. *Circulation* 88:I-455; 1993.
115. Cheung MC, Lichtenstein AH, Schaefer EJ: Effects of a diet restricted in saturated fatty acids and cholesterol on the composition of apolipoprotein A-I-containing lipoprotein particles in the fasting and fed states. *Am. J. Clin. Nutr.* 60:911-918; 1994.
116. Brousseau ME, Ordovas JM, Osada J, Fasulo J, Robins SJ, Nicolosi RJ, Schaefer EJ. Dietary monounsaturated and polyunsaturated fats are comparable in the effects on hepatic lipid and apolipoprotein mRNA content. *Circulation* 90:I-235; 1994.
117. Lamon-Fava S, Schaefer EJ, Lichtenstein AH, McNamara JR, Spiegelman D, Dwyer JT, Goldin BR, Woods MN, Gorbach SL. A low fat, high fiber diet induces changes in plasma lipid levels that are associated with changes in estrogen levels in premenopausal women. *Circulation* 90:I-235; 1994.
118. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantitation of serum lipoprotein (a) cholesterol levels in population studies. *Circulation* 90:I-504; 1994.
119. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriquez C, Park JS, Cole TG, Schaefer EJ. Effect of apolipoprotein E and A-IV isoforms on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. *Circulation* 90:I-666, 1994.
120. Jacques PF, Sulsky SI, Perrone GE, Jenner J, Schaefer EJ. Effect of vitamin C supplementation on lipoprotein cholesterol, apolipoprotein, and triglyceride concentrations. *Ann Epidemiol* 5:52-59; 1995.
121. Mendoza I, Struetjen A, Siedenburg A, Valdez C, Mazariegos M, Solomons NW, Carrasco W, Schaefer EJ, Schaefer M. Cardiovascular risk factors in communities of Guatemala: comparison with Framingham, MA residents. FASEB J 9:A178, 1995.
122. Contois JH, Lammi-Keefe CJ, Tucker K, Wilson PWF, Rush D, Schaefer EJ. Diet in relation to plasma lipids, lipoproteins, and apolipoproteins in elderly subjects with and without coronary heart disease. FASEB J 9:A470, 1995.
123. Li Z, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Change in HDL particle size is associated with change in plasma triglyceride, HDL cholesterol, and LDL particle size. FASEB J 9:A472, 1995.
124. Jones PJH, Lichtenstein AH, Cuchel M, Schaefer EJ. Lovastatin depresses human cholesterol synthesis and production rates in hypercholesterolemic subjects. FASEB J 9:A574, 1995.
125. Lichtenstein AH, Schaefer EJ. Response to dietary modification is similar in normocholesterolemic and hypercholesterolemic subjects. FASEB J 9:A575, 1995.
126. Larsen E, Smith D, Schaefer EJ, Ordovas JM. Vitamin E supplementation does not prevent diet induced aortic foam cell formation in male Golden Syrian hamsters. FASEB J 9:A578, 1995.
127. Clevidence BA, Judd JT, Schaefer EJ, McNamara JR, Muesing RA, Wittes J, Sunkin ME. Plasma lipoprotein (a) levels in subjects consuming trans fatty acids. FASEB J 9:A579, 1995.
128. Vogel S, Lichtenstein AH, Schaefer EJ, Lammi-Keefe CJ. Effects of dietary fatty acids on plasma alpha tocopherol concentrations in human subjects. FASEB J 9:A579, 1995.
129. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Schaefer MM, Rasmussen H, Ordovas JM. Consumption of an ad libitum low fat diet promotes weight loss and low density lipoprotein lowering in middle aged and elderly men and women with moderate hypercholesterolemia. FASEB J 9:A978, 1995.
130. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Clevidence BA, Judd JT, Goldin BR, Ordovas JM. Efficacy of National Cholesterol Education Program Step 2 diets. Circulation 92:I-95, 1995.
131. Campos H, Lopez-Miranda F, Rodriguez C, Albajar M, Schaefer EJ, Ordovas JM. Reduced HDL cholesterol and small LDL particle size in subjects with the apolipoprotein A-IV-1 phenotype living in an urban versus rural area. Circulation 92:I-156, 1995.
132. Meydani SN, Leka LS, Schaefer EJ, Lichtenstein AH. Immunologic effects of low fat diets with and without weight loss. Circulation 94:I-96, 1996.

133. Schaefer EJ, Lichtenstein AH, Welty FK, Barrett PHR, Lamon-Fava S, McNamara JR, Ordovas JM. Metabolic basis of variability in low density lipoprotein (LDL) lowering in response to diet. Circulation 94:I-96, 1996.
134. Lichtenstein AH, Ausman LM, McNamara JR, Schaefer EJ. Trans and saturated fatty acid content of dietary fat affects plasma lipid and lipoprotein concentrations. Circulation 94:I-97, 1996.
135. Ordovas JM, Lopez de Yela A, Lahoz C, DeLuca C, Osgood D, McNamara JR, Silberman SR, Wilson PWF, Schaefer EJ. Distribution of apoE in plasma lipoproteins is a major determinant of triglyceride, HDL cholesterol, and LDL particle size in the Framingham Offspring Study. Circulation 94:I-93, 1996.
136. Cendoroglo M, Lahoz C, McNamara JR, Levy D, Schaefer EJ, Ordovas JM. The apoA-IV (360:Gln:His) mutation is a genetic determinant of LDL particle size in the Framingham Offspring Study: interaction with smoking and alcohol. Circulation 94:I-93, 1996.
137. McNamara JR, Shah PK, Nelson SM, Nakajima K, Wilson PWF, Schaefer EJ. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls. Circulation 94:I-94, 1996.
138. Gagne SE, Pimstone SN, Larson MG, Schaefer EJ, Wilson PWF, Ordovas JM, Hayden MR. Effects of lipoprotein lipase gene mutations on plasma lipids: The Framingham Offspring Study. Circulation 94:I-273, 1996.
139. Ordovas JM, Dobiasova M, Cendoroglo M, Lahoz C, Wilson PWF, Frohlich J, Schaefer EJ. Cholesterol ester transfer protein and cholesterol esterification rates are modulated by the 360:Glutamine/histidine polymorphism in the apolipoprotein A-IV gene locus. Circulation 94:I-275, 1996.
140. Li Z, Otvos JD, Carrasco WV, Lichtenstein AH, McNamara JR, Ordovas JM, Schaefer EJ. Effects of gender on lipoprotein subspecies response to a National Cholesterol Education Program Step 2 diet. *Circulation* 96:1-34;1997.
141. Carrasco WV, Lichtenstein AH, Welty FK, Lamon-Fava S, Dolnikowski GG, Schaefer EJ. Effects of a Step 2 diet on HDL apolipoprotein A-I catabolism and secretion in postmenopausal females and older males. *Circulation* 96:1-34;1997.
142. Jenner JL, Seman LJ, Millar JS, Lichtenstein AH, Welty FK, Dolnikowski GG, Schaefer EJ. The differential metabolism of the apo(a) and apoB-100 components of the lipoprotein(a) particle: a stable isotope study in humans. *Circulation* 96:1-228;1997.
143. Seman LJ, DeLuca C, Ordovas JM, Wilson PWF, Cupples LA, Schaefer EJ. Lipoprotein(a) cholesterol compared with sinking pre beta lipoprotein and associated relative risk of heart disease in the Framingham Heart Study. *Circulation* 96:I-304;1997.
144. Ordovas JM, Gagne E, McNamara JR, Shah PK, Wilson PWF, Cupples LA, Hayden MR, Schaefer EJ. Effect of the Ser 447 Stop mutation on the lipoprotein lipase gene locus on plasma triglyceride-rich lipoprotein remnants. *Circulation* 96:I-336;1997.
145. Wilson PWF, Ordovas JM, Silberschatz H, D'Agostino RB, Schaefer EJ. Efficacy of LDL and HDL vs apoB and apoAI-I in the prediction of incident coronary disease: the Framingham Offspring Study. *Circulation* 96:I-337;1997.
146. Welty FK, Lichtenstein AH, Barrett PHR, Ordovas JM, Schaefer EJ. Apolipoprotein B-48 and VLDL and LDL apoB-100 kinetics in normal humans using stable isotope studies. *Circulation* 96:I-413;1997.
147. Lichtenstein AH, Ausman LM, Vilella-Bach M, Schaefer EJ. Hydrogenated vegetable oil results in higher lipoprotein levels than the naturally occurring oil and lower lipoprotein levels than butter. *Circulation* 96:I-480;1997.
148. Schaefer EJ, Welty FK, Barrett PHR, Dolnikowski GG, Jenner JL, Lichtenstein AH. Effects of an NCEP Step 2 diet on apolipoprotein B-48 and B-100 metabolism in humans. *Circulation* 98:I-193;1998.
149. Saltzman E, Das SK, Greenberg AS, Dallal GE, Schaefer EJ, Roberts SB, Lichtenstein AH. Effects of a hypocaloric diet containing oats on blood pressure and cholesterol concentrations. *Circulation* 98:I-193;1998.
150. Welty FK, Lichtenstein AH, Dolnikowski GG, Barrett PHR, Schaefer EJ. Effects of apolipoprotein E genotype on apoB-48 and apoB-100 metabolism. *Circulation* 98:I-239;1998.
151. Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. ApoE and apoB-100 kinetics in triglyceride-rich lipoproteins and their role in LDL production. *Circulation* 98:I-305;1998.
152. Couture P, Cupples AL, Schaefer EJ. Association of the -480T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profile: the Framingham Offspring Study. *Circulation* 98:I-533;1998.
153. Tangney C, Schaefer EJ, Rosenson RS. Changes in plasma viscosity following a fast food breakfast meal in hyperlipidemic adults. *Circulation* 98:I-534;1998.
154. McNamara JR, Shah PK, Tayler TD, Schaefer EJ. Postprandial response of remnant-like particles in coronary heart disease patients and controls. *Circulation* I-584;1998.
155. Ordovas JM, McNamara JR, Otvos JD, Wilson PWF, Cupples AL, Osgood D, Schaefer EJ. Association between apoE alleles, remnant lipoproteins, and VLDL subclass phenotypes in the Framingham Offspring Study. *Circulation* I-790;1998.
156. Lichtenstein AH, Ausman LM, Nelson SM, Schaefer EJ. Dietary palm oil has an adverse effect on serum lipid and lipoprotein levels in moderately hyperlipidemic subjects. *Circulation* I-584;1998.
157. Ordovas JM, Otvos JD, Martinez A, Najeri G, Wilson PWF, Cupples AL, McNamara JR, Schaefer EJ. Association of a common variant of the CETP gene (Taq1B) with lipoprotein subfractions: the Framingham Offspring Study. *Circulation* I-738;1998.
158. Maki KC, Davidson MH, Umponowics D, Schaefer EJ, Decklin MR, Ingram KA, Chen S, Gebhart B, Franke WC. Lipid responses to plant sterol-enriched reduced fat spreads incorporated into a step 1 diet. *Circulation* 100:1-115;1999.
159. Elam MB, Schaefer EJ, McNamara JR, Robins SR, Collins D, Graney MJ, Rubins HB. Fasting and postprandial remnant-like

particles as predictors of cardiovascular events in the VA HDL Intervention Trial (VA HIT). *Circulation* 100:I-472,1999.
160. Lichtenstein AH, Welty, FK, Millar JS, Jenner JL, Dolnikowski G, Schaefer EJ. Fish consumption decreases TRL apoB-48 and apoB-100 production rates. *Circulation* 100:I-659,1999.
161. Russo G, Cupples LA, Otvos JD, Wilson PWF, Kelleher AL, Schaefer EJ, Couture P, Ordovas JM. The S2 allele at the apoCIII gene locus is associated with lipid profiles that are atherogenic but that differ by gender. *Circulation* 100:I-740,1999.
162. Couture, P, Otvos JD, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM. Association of the A-278C polymorphism in the cholesterol 7 □hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. *Circulation* 100:I-740,1999.
163. Rosenson RS, Tangney CC, Schaefer EJ. Comparative HMG CoA Reductase Inhibitor (CHRIS) substudy on fibrinogen. *Circulation* 100:I-825,1999.
164. Ordovas JM, Vargas C, Santos A, Taylor TD, Daly JA, Augustin J, Seman LJ, McNamara JR, Schaefer EJ. The G/A promoter polymorphism at the apoA-I gene locus predicts individual variability in fasting and postprandial responses to the HMG CoA reductase inhibitor atorvastatin. *Circulation* 100:I-239,1999.
165. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Postprandial response to diets enriched in hydrogenated fats or butter. Circulation 102:II-380;2000.
166. Russo GT, Cupples LA, Otvos JD, Wilson PWF, Reaven P, Schaefer EJ, Ordovas JM. The paraoxonase (PON) 192R allele may be a protective CHD risk factor in women: the Framingham Offspring Study. Circulation 102:II-276;2000.
167. Schaefer EJ, McNamara JR, Selhub JM, Bostom AG, Collins D, Rubins HB, Robins SR. Gemfibrozil raised homocysteine concentrations in VA HIT. Circulation 102:II-847;2000.
168. Asztalos BF, KV Horvath, S Demissie, AL Cupples, D Collins, SJ Robins, EJ Schaefer. ApoA-I alpha-1 HDL is a strong independent predictor of CHD in Framingham and VA-HIT. Circulation 108:IV-730,2003.
169. Brousseau ME, ES Tai, D Collins, JJ O'Connor, JM Ordovas, HB Rubins, ST Robins, EJ Schaefer. A common variant in the peroxisome proliferator-activated receptor alpha gene is associated with decreased risk for new coronary events in diabetic and insulin-resistant subjects in VA-HIT. Circulation 108:IV-772,2003.
170. Otvos JD, W Cromwell, I Shalaurova, EJ Schaefer. LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome: Results from the Framingham Offspring Study. Circulation 108:IV-740,2003.
171. Jeyarajah EJ, DS Freedman, JD Otvos, EJ Schaefer. Age and gender differences in lipoprotein subclasses in the Framingham Offspring Study help explain the sex differential in CHD. Circulation 108:IV-730,2003.
172. Schaefer EJ, DJ Kyle, V Bongard, K Tucker, A Beiser, PW Wilson, PA Wolf. Plasma phosphatidyl-choline (PC) docosahexaenoic acid, fish intake, and risk of dementia. Circulation 108:IV-753,2003.
173. Dansinger ML, JL Gleason, W Li, HP Selker, EJ Schaefer. One year effectiveness of the Atkins, Ornish, Weight Watchers, and Zone diets. Circulation 108:IV-784,2003.
174. Matthan NR, SM Jalbert, GS Dolnikowski, FK Welty, HP Barrett, EJ Schaefer, AH Lichtenstein. Dietary hydrogenated fat decreases LDL apoB-100 catabolism and enhances HDL apoA-I catabolism in hypercholesterolemic women. Circulation 108:IV-784,2003.

**University Service**

| | |
|---|---|
| 1983-1992 | Annual lectures in Tufts University School of Nutrition; Nutritional Biochemistry Course. |
| 1984-1991 | Annual lecture in Tufts University School of Dental Medicine; Nutrition and Prevention Course. |
| 1984-present | Annual lectures in Tufts University School of Medicine; Pharmacology course. |
| 1985-1986 | Member, Search Committee for Chairman of Biochemistry. |
| 1985-present | Member, Promotions Committee, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. |
| 1985-1989 | Member, Clinical Appointments and Promotions Committee, Tufts University School of Medicine. |
| 1992 | Course Director, Nutrition and Aging, student elective. |
| 1993-present | Annual lecturer in Tufts University School of Medicine; Nutrition Course. |
| 1993-present | Course Director, Clinical Nutrition and Aging, student elective. |

**Post-Doctoral Fellows, Visiting Scientists and Current Positions**

Richard E. Gregg, M.D. 1977-79. Director of Lipid Metabolism Laboratory, Squibb, Inc., NJ, formerly Senior Investigator, NHLBI, National Institutes of Health, Bethesda, MD. (NIH)
David W. Anderson, Ph.D. M.D. 1978-80. Staff Physician, Armed Forces Institute of Pathology, Washington, D.C. (NIH)
Giancarlo Ghiselli, Ph.D. 1980-82. Associate Professor, Temple University School of Medicine, Philadelphia, PA (NIH)
Dennis Sprecher, M.D. 1980-82. Professor of Medicine, Chief, Preventive Cardiology, Cleveland Clinic, Case Western Reserve University, Cleveland, OH. (NIH)
Vodek Sasak, Ph.D. 1983-1985, Assistant Professor of Medicine, Beth Israel Hospital, Boston, MA
Jose M. Ordovas, Ph.D. 1982-85, Sr. Scientist, Professor of Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA.
Eduardo N. Siguel, M.D., Ph.D., 1983-1986. Assistant Professor of Medicine, Boston University School of Medicine.
Stefania L. Fava, M.D. 1984-1989, Scientist II, Assistant Professor of Nutrition, USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA.
Jeffrey S. Cohn, Ph.D. 1985-1988, Staff Scientist, Clinical Research Institute of Montreal, Canada
Lola Jimenez, M.D. 1986-1987, Assistant Professor, Dept. of Obstetrics and Gynecology, University of Zaragoza, Spain.
Jacques Genest, M.D. 1986-1990. Staff Scientist, Associate Professor, Chief, Cardiovascular Genetics Laboratory, Clinical Research Institute of Montreal, Canada.
Kew M. Chee, Ph.D. 1986-1987, Professor of Animal Science, Korea National University, Seoul.
Fernando Civeira, M.D. 1987-1989, Professor of Medicine, University of Zaragoza, Spain.
Jesus Osada, Ph.D. 1988-1990, Professor of Biochemistry, University of Zaragoza, Spain.
Nathan Kam, M.D. 1989-1990. Department of Medicine, Gastroenterology, Kaiser Hospital, Hayward, CA.
Howard N. Newman, Ph.D. 1988-1989. Professor, Ohio State University School of Medicine.
Carmen Rodriguez, Ph.D. 1989-1991. Assistant Professor of Biochemistry, University of Tannanarive, Canary Islands, Spain.
Pedro Mata, M.D. 1990-1991. Associate Professor of Medicine, University of Madrid, Spain.
Jose Lopez Miranda, M.D. 1990-1992. Associate Professor of Medicine, University of Cordoba School of Medicine, Cordoba, Spain.
Jens Otto, M.D. 1991-1993. Staff Cardiologist, Division of Cardiology, Rothenburg/Lahn, Germany.
Pascal LaGroua, Ph.D. 1991-1992. Private industry, Paris, France.
Leo Seman, M.D., Ph.D. 1990-2000. Staff Scientist, Bayer Corporation, West Haven, CT
Francine Welty, M.D., Ph.D. 1991-1996, Associate Professor of Medicine, Harvard Medical School, New England Deaconness Hospital, Scientist II, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.
Marina Cuchel, M.D. 1992-1993. Research Associate, Dept. of Medicine, University of Pennsylvania, Philadelphia, PA.
Ricardo Chirino, M.D., 1993-1994. Assistant Professor of Medicine, University of Las Palmas, Spain
Ursula Schwab, Ph.D., 1994-1995. Research Associate, University of Kuopio, Finland.
Carlos Lahoz, M.D., 1994-1996. Assistant Professor of Medicine, University of Madrid, Spain.
Marju Tilly-Kiesi, M.D., 1995-1996. Associate Professor of Medicine, University of Helsinki, Finland.
Maysa Cendoroglo, M.D., 1995-1997. Assistant Professor of Medicine, Division of Gerontology, National University, Sao Paolo, Brasil.
Rafael Carmena, M.D., 1996-1997, Assistant Professor of Dermatology, Valencia, Spain.
Juan Pedro Botet, M.D., 1996-1997, Associate Professor of Medicine, Barcelona, Spain.
Marita Ostos, Ph.D., 1996-1997, Assistant Professor of Medicine, Zaragoza, Spain.
Patrick Couture, M.D., Ph.D., 1997-1999, Assistant Professor of Medicine, Laval University, Quebec.
Julian Marsh, M.D., 1998-1999, Senior Scientist, Atherosclerosis Research Laboratory, Tufts University.
Sander Robins, M.D., 1998-1999, Professor of Medicine, Boston University.

Giusseppina Russo, M.D., Ph.D., 1998-1999, Assistant Professor of Medicine, University of Messina, Italy.
Eyshong Tai, M.D., 1999-2001. Assistant Professor of Medicine, University Hospital, Singapore
Chorthip Nartsupha, M.D., 2001-2004.
Marcello Batista, M.D., 2001-2003.
Ann McDermott, Ph.D., 2002-2004
Kouji Kajinami, M.D., 2002-2003, Associate Professor of Medicine, University of Kanazawa, Japan
Vanina Bongard, M.D., 2003-2004, Assistant Professor of Epidemiology, University of Toulouse, France

**Graduate Students** (Ph.D. Candidates, Subsequent or Current Positions).

| | | |
|---|---|---|
| Jean Eric Triau | 1983-1987 | Post-doctoral fellowship, Rockefeller University, NY. Received Ph.D. 1987; (Advisor, E.J. Schaefer) |
| Thomas Hughes | 1984-1987 | Staff Scientist, Sandoz Research Institute, Received Ph.D. 1988 (Advisor, E.J. Schaefer) |
| Lori Hennessy | 1985-1988 | Research Scientist, University of California, San Francisco, Cardiovascular Research Institute, Received Ph.D. 1989 (Advisor, E.J. Schaefer) |
| Hannia Campos | 1986-1989 | Assistant Professor, Harvard School of Public Health, Boston. Received Ph.D. 1990; (Advisor, E.J. Schaefer) |
| Young Shin Ahn | 1989-1993 | Assistant Professor, University of Seoul, Korea, Received Ph.D. 1993; (Advisor J.M. Ordovas) |
| Margaret Brousseau | 1989-1993 | Scientist II, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University; Received Ph.D. 1993. (Advisor, E.J. Schaefer) |
| Li Ching Lyu | 1989-1993 | Associate Professor, Taiwan Normal University, Taipei, Taiwan Received Ph.D. 1993; (Advisor, E.J. Schaefer) |
| John Millar | 1989-1994 | Research Scientist, Univ. of Pennsylvania, Philadelphia, PA. Received Ph.D. 1995; (Advisor A.H. Lichtenstein) |
| John Contois | 1990-1994 | Staff Scientist, Bayer Corp., West Haven, CT Received Ph.D. 1995, U. of Connecticut, Hartford, CT (Advisors, C. Lammi-Keefe, E.J. Schaefer) |
| Wendy Pitman | 1986-1988<br>1994-1996 | Research Associate, Jackson Laboratories, Bar Harbor, ME Received Ph.D. 1996; (Advisor J.M. Ordovas) |
| William Karge | 1992-1995 | Major, US Army, Research Laboratories, Natick, MA Received Ph.D. 1996; (Advisor J.M. Ordovas) |
| Zhengling Li | 1990-1997 | Research Associate, Joslin Diabetes Center, Harvard Medical School, Beth Israel-Deaconness Med.Ctr., Boston, MA Received Ph.D. 1997; (Advisor, E.J. Schaefer) |
| Silke Vogel | 1991-1997 | Research Associate, Dept of Pediatrics, Columbia-Presbyterian Medical Ctr., NY, NY; Ph.D. U. Connecticut; Received Ph.D. 1997; (Advisor, C. Lammi-Keefe) |
| Jennifer Jenner | 1990-1998 | Research Associate, US Army Research Laboratories, Natick, MA Received Ph.D. 1998; (Advisor, E.J. Schaefer) |
| Sahar El Swefy | 1995-1997 | Assistant Professor, University of Zagazig, Egypt; (Advisors E.J. Schaefer, L.Seman, M. El Sweidy); Received Ph.D. 1997. |
| Elaine Larsen | 1991-1999 | Research Associate, Albany Medical Center; Received Ph.D. 1999; (Advisor J.M. Ordovas) |
| Wanda Carrasco | 1992-1998 | Research Associate, Rockefeller University, NY, NY; Received Ph.D. 1998; (Advisor E.J. Schaefer) |
| Ilona Larsen | 1994-1999 | Ph.D., University of Giessen, Germany; Received Ph.D. 1999; (Advisors H. Daniel, E.J. Schaefer) |
| Zhiyong Sun | 1994-1999 | Research Scientist, Archer Daniel Midlands, Decatur, IL. Received Ph.D. 1999; (Advisor, E.J. Schaefer) |
| Doreen Osgood | 1994-2000 | Research Scientist, Division of Endocrinology, RI Hospital, |

| | | |
|---|---|---|
| | | Providence, RI. |
| | | Received Ph.D. 2000; (Advisor J.M. Ordovas) |
| Jennifer Galluzi | 1995-2001 | Research Scientist, CT. |
| | | Received Ph.D. 2001; (Advisor J.M. Ordovas) |
| Suzanne Dorfman | 1998-2004 | (Advisor A.H. Lichtenstein) |

**Endocrinology Fellows with Lipid Clinic Training Rotation**

| | | |
|---|---|---|
| Elise Rodman, M.D. | 1983-1984; | Practice, Woburn, MA |
| James Goldman, M.D. | 1983-1984; | Practice, Lexington, MA |
| Charles O'Neill, M.D. | 1984-1985; | Emory University School of Med./Hosp./Atlanta, GA |
| Marc Hellerstein, M.D. | 1984-1985; | San Francisco General Hospital, UCSF |
| Antonio Granfone, M.D. | 1985-1986; | Massachusetts General Hospital Practice Group |
| George Chao, M.D. | 1986-1986; | Practice, Modesto, CA |
| Eric Dyess, M.D. | 1987-1988; | Practice, Jackson, Mississippi |
| Glenn Stall, M.D. | 1987-1988; | Practice, Boston, MA |
| Christine McLaughlin, M.D. | 1988 | Practice, Lexington, MA |
| Deborah Riester, M.D. | 1989 | Practice, Framingham, MA |
| Nicholas Sauter, M.D. | 1989 | Practice, Boston, MA |
| Abby Landzberg, M.D. | 1990 | Practice, Boston, MA |
| Leo Seman, M.D. | 1990-1993; | Scientist, Bayer Corporation |
| Maria Vargas, M.D. | 1991-1992; | Practice, Dothan, AL |
| Katya Divari, M.D. | 1992-1993; | Practice, Worcester, MA |
| Boris Stevinin, M.D. | 1993-1994; | Practice, New York |
| Margaret Flynn, M.D. | 1993-1994; | Practice, Boston, MA |
| Richard Siegel, M.D. | 1994-1995; | Endocrine, NEMC |
| Linda Schloepfer, M.D. | 1994-1995; | Practice, Greenwich, CT |
| Sol Jacobs, M.D. | 1995-1996; | Practice, Boston |
| Richard Warshaw, M.D. | 1995-1996; | Practice, Boston, MA |
| Prashant Nadkarni, M.D. | 1996-1997; | Practice, Calcutta, India |
| Linda Margeloff, M.D. | 1997-1998; | Practice, MA |
| Sorin Hersovici, M.D. | 1997-1998; | Practice, CT |
| Sumati Srivatsa, M.D. | 1998-1999; | Practice, MA |
| Anastasios Pittas, M.D. | 1998-1999; | Endocrine, NEMC |
| Sunita Schurgin, M.D. | 2000-2001; | Endocrine, NEMC |
| Florence Solages, M.D. | 2000-2001; | Endocrine, NEMC |
| Radhika Hariharan, M.D. | 2001-2002; | Endocrine, NEMC |
| Nandini Joseph, M.D. | 2001-2002; | Endocrine, NEMC |
| Chorthip Nartsupha, M.D. | 2002-2003; | Endocrine, NEMC |
| Rula Goussous, M.D. | 2002-2003; | Endocrine, NEMC |
| Lisa Neff, M.D. | 2003-2004; | Endocrine, NEMC |
| Colleen Digman, M.D. | 2003-2004; | Endocrine, NEMC |

**Medical Students on Research Rotations**

| | |
|---|---|
| Pierre Moussa | 1984 |
| Carol Mitri | 1984-1985 |
| Wayne deTorres | 1985-1986 |
| Helen Corbett | 1986-1987 |
| Vivian Cheung | 1990-1992 |
| Janine Arnold | 1993 |
| Jens Lohrmann | 1997 |
| Jan Wagner | 1998 |
| Frauke Otto | 1999 |

**Students on Research Rotations**

| | |
|---|---|
| Danique Van Dongen | Summers, 1991-1995 |
| Paul Wong | Summers, 1992, 1993 |
| Eliot Berkowitz | Summer, 1994 |
| Brendan Hayes | Summer, 1995 |
| Jan Hollihn | Summer, 1995 |
| Monique Verner | Summer, 1996 |
| Leo Yin | Summer, 1996 |
| John O'Connor | Summer, 1997 |
| Jacob Taylor | Summers, 1997-1999 |
| Nick Donin | Summer, 1998 |
| Peter Schaefer | Summer, 1998 |
| Robert Higgins | Summer, 1998 |
| Robert Lopez | Summer, 1998 |
| Alex Garcia | Summer, 1998 |
| Isaih Kacyvenski | Summer, 1999 |
| Josh Belcyk | Summer, 1999 |
| Allison Connolly | Summer, 2000 |
| Brandon Kramer | Summer, 2000 |
| Nat Reimers | Summer, 2001 |
| Jamail Soriano | Summer, 2001 |
| Kimberly Morgan | Summer, 2001 |
| Ann Conlin | Summer, 2002 |
| Sigi Asztalos | Summers, 2002, 2003 |
| Peter Schaefer | Summer, 2003 |

**Technicians and Subsequent Positions**

| | |
|---|---|
| Judith R. McNamara | 1982-present |
| Lois Litwack Klein | 1984-1986, student, Tufts University School of Nutrition |
| Allison Robins | 1984-1986, student, Tufts University School of Veterinary Medicine |
| Sandra Craig | 1984-1987, student, University of Massachusetts, Lowell, physical therapy |
| Diane Cassidy | 1985-1989, employee, Serono Corporation |
| Steven Johnson | 1985-1989, student, University of Missouri School of Osteopathic Medicine |
| John Millar | 1985-1989, student, Tufts University School of Nutrition |
| Jennifer Jenner | 1987-1990, student, Tufts University School of Nutrition |
| John Contois | 1987-1990, student, University of Connecticut Nutrition Program |
| Erling Blijlevens | 1989-1992, private industry, The Netherlands |
| Kari Wojtanik | 1992-1995, student, Biochemistry Dept., Tufts University School of Medicine |
| Wanda Carrasco | 1990-1992, student, Tufts University School of Nutrition |
| Doreen Osgood | 1992-1997, student, Tufts University School of Nutrition |
| Tatyana Massov | 1993-present |
| Carol Lum | 1993-1995, private industry |
| Tracy Thomas | 1993-1996, study coordinator, Massachusetts General Hospital |
| Scott Dunlop | 1993-1995, private industry |
| Carl Deluca | 1995-1998, graduate student, Columbia University, Department of Nutrition |
| Susan Jalbert | 1996-present |
| Paulesh Shah | 1996-1998, medical student, Boston University School of Medicine |
| Jennifer Daly | 1996-1997, medical student, Tufts University School of Medicine |
| Tim Tayler | 1996-1998, graduate student, MIT School of Neuroscience |
| Montserrat Villela | 1996-1997, graduate student, University of Illinois, Urbana/Champaign |
| Danique Van Dongen | 1996-1999, medical student, Cornell Medical School |
| Richard Lirio | 1997-1999, pre-medical student, Harvard University |
| Alison Kelleher | 1998-2000, graduate student, University of New Hampshire |
| Margaret Diffenderfer | 1998-present |

| | |
|---|---|
| Allison Goldkamp | 1998-2000, medical student, Dartmouth Medical School |
| Kati Horvath | 1999-present |
| John O'Connor | 1998-present, medical student, New York Medical College |
| Kourosh Hashemi-Zonouz | 2000-present |
| Dale Micherone | 2001-2002, medical Student, Dublin, Ireland |
| Rod Ferreira | 2001-2002, technician, Rhode Island Hospital |
| Borbala Posfai | 2001-2003, research scientist, Budapest, Hungary |